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Age-related macular degeneration 
Age-related macular degeneration (AMD) is currently the leading cause of blindness 
among elderly in the Western world, typically affecting individuals 60 years of age and 
older. AMD is characterized by drusen, which are small lipid- and protein-rich deposits 
between the retinal pigment epithelium (RPE) and Bruch’s membrane (see Figure 1 for 
gross anatomy of the eye). In the early stages, AMD presents with drusen and pigmentary 
changes in the RPE, and both the extent of these pigmentary changes and the size of 
the drusen are correlated with the risk of developing late-stage disease1; choroidal 
neovascularization (CNV, or “wet” AMD) and geographic atrophy (GA, or “dry” AMD). CNV 
is characterized by the development of new blood vessels that arise from the choroid 
and grow into the retina. Due to the poor quality of these vessels, they can leak, causing 
hemorrhage and initiating the formation of fibrosis. GA is characterized by atrophy of the 
RPE together with a loss of photoreceptor cells and the choriocapillaris. Both wet and 
dry AMD develop in the macula and therefore affect visual acuity, particularly when the 
fovea becomes involved.
Cornea Lens Macula Retina
Figure 1. Gross anatomy of the eye. Light enters the eye through the cornea and is focused on the retina by 
the lens. The retina is the inner lining of the eye and contains the light-sensitive photoreceptor cells, namely the 
rods and cones. The rods allow vision under low luminance conditions, and the cones provide detailed, color 
vision. The cones are largely concentrated in the central part of the retina known as the macula, with the highest 
concentration of cone cells at the midpoint (the fovea). Photoreceptors convert light energy into an electrical 
signal that is carried by the optic nerve to the brain. The retinal cell layer below the photoreceptors is called 
the retinal pigment epithelium (RPE), which protects against free radicals and absorbs light2. In addition, the RPE 
takes up lipoproteins from the circulation3, releases cholesterol into the inter-photoreceptor matrix4, phagocytes 
membrane lipids from photoreceptors5, and releases lipids back into the circulation6. Age-related macular 
degeneration affects the retina, specifically the RPE located in the macula.




The prevalence of early and late AMD increases with age, reaching up to 25% among 
individuals 80-84 years of age7. Given our aging population, particularly in the Western 
world, the number of individuals with AMD is expected to increase rapidly. Indeed, 
estimates suggest that by the year 2040, the global incidence of AMD could reach 
288 million, including 12.5 million cases of late-stage AMD7. When corrected for age, 
the prevalence of AMD is similar between men and women8,9. Individuals of European 
descent are more susceptible to developing AMD compared to Asians and Africans, with 
a prevalence of 12.3% versus 7.4% and 7.5%, respectively7; this difference in prevalence 
among ethnic groups supports the notion that genetic and/or environmental factors 
contribute to the development of AMD.
In 2005, the first genetic variant related to AMD was identified in the CFH gene (which 
encodes complement factor H)10 using a genome-wide association analysis involving 
96 patients and 50 controls (Figure 2). The following year, a variant in the ARMS2-HTRA1 
locus was discovered11. This locus (see Figure 2) is located between the ARMS2 (Age-
Related Maculopathy Susceptibility 2) and HTRA1 (HtrA Serine Peptidase 1) genes. 
Subsequent studies involving larger sample sizes revealed additional variants associated 
with AMD. For example, a large genome-wide association study (GWAS; see Figure 2) 
identified a set of 52 independent loci associated with AMD12, to which an additional 12 
loci were added by the largest and most recent GWAS13. Studies involving thousands of 
patients and subjects not only revealed common variants with small effect sizes, but also 
revealed relatively rare variants with large effect sizes. Together, the genetic variants 
identified to date are estimated to explain more than half of the genetic heritability of 
AMD12. Since a large percentage of this heritability remains unexplained, the search 
continues for additional variants associated with AMD, using a variety of techniques such 
as exome sequencing and whole-genome sequencing. 
Risk factors and protective factors
Environmental risk factors for AMD have been the subject of extensive research; after 
age, smoking is the second-most important risk factor for developing AMD, with a 2-3-
fold higher risk of AMD among smokers compared to non-smokers17,18. Even former 
smokers who quit still have a small but significant increased risk of AMD. Many other risk 
factors have also been associated with AMD, including atherosclerosis and high body 
mass index18-20; however, the effect size of these factors is relatively small compared 
to smoking, and some studies report conflicting results with respect to these relatively 
small risk factors. 






















Figure 2. Genetic epidemiology. Genome-wide association studies (GWAS) are based on the principle that genetic 
variations related to a disease are more common in affected individuals (patients) than in unaffected individuals 
(controls). Because neighboring loci (i.e., loci located relatively close to each other within the chromosome) are 
inherited together more often than distant loci, genetic markers distributed throughout the genome can be used to 
identify disease-associated loci. This so-called “hypothesis-free” approach can reveal candidate genes associated 
with a given disease. Another hypothesis-free approach is to sequence either the entire exome or the entire 
genome. In whole-exome sequencing, all of the protein-coding sequences (exons) are sequenced. Whole-exome 
and whole-genome sequencing are more time-consuming and costly than GWAS, but are more precise and can 
reveal relatively rare variants that occur at a low frequency within the population. Adapted from14-16.
In addition to factors that increase risk, other factors have been shown to reduce the risk of 
developing AMD, including antioxidants and certain nutrients. For example, studies in the 
late 1980s and early 1990s found that carotenoids—particularly lutein and zeaxanthin—
were associated with a reduced risk of developing AMD21,22. Since then, a large number of 
studies investigated the protective effects of micronutrients, food products, and dietary 
patterns23,24. A large randomized controlled trial revealed that supplementation with high-
dose antioxidants and zinc reduced the risk of developing late-stage AMD by 25%(ref. 25). 
Although nutrition can affect the course of the disease, precisely which diet to follow is 
currently unknown and warrants further study. 




In wet AMD, cells release vascular endothelial growth factor (VEGF) due to hypoxia. This 
causes the formation of new blood vessels with increased permeability. The current 
treatment for wet AMD is intravitreal injections of anti-VEGF compounds. Although this 
treatment often improves visual acuity, over the long term patients with wet AMD remain 
at risk for a substantial decline in visual acuity. In contrast, no treatment is available for 
dry AMD; however, many clinical trials are currently ongoing and focus on inhibitors of 
the complement cascade26,27, neuroprotective agents28, regeneration of the RPE (e.g., 
ClinicalTrials.gov Identifier: NCT02286089), molecules that inhibit the visual cycle29,30, anti-
inflammatory agents (e.g., ClinicalTrials.gov Identifier: NCT02564978), and antioxidants31. 
Although some of these trials have revealed small beneficial effects, further study is 
needed; to date, however, most studies have yielded negative results. Because no 
cure currently exists for AMD, the best approach to retaining good visual acuity lies in 
prevention by living a healthy lifestyle. 
Current perspectives and future directions
AMD is a complex but extremely well-studied disease caused by both genetic and 
environmental factors; however, the pathophysiology remains poorly understood, and 
no cure is currently available. In addition, although relatively small studies in Europe have 
provided snapshots of the prevalence of AMD, an overall picture of the prevalence is 
currently lacking but is essential for eye-care policymakers. Furthermore, developing 
a cure for AMD requires additional knowledge with respect to the pathophysiology and 
progression of AMD, including a better understanding of the role of lipids and nutrition. 
Moreover, although much is known regarding the genetic factors associated with AMD, 
the biological consequences of AMD-related variants are currently unknown, requiring 
in-depth genetic profiling of individuals and an interpretation of the associated risk of 
developing AMD. 
Expanding our knowledge of AMD requires large, harmonized international datasets with 
sufficient statistical power to identify genetic and/or environmental factors with relatively 
small effect sizes. Such a dataset would allow researchers to study a homogenous 
phenotype and obtain precise estimates. The results of these studies will pave the way 
toward developing new therapeutic strategies and will lead to better advice for individual 
patients.
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INTRODUCTION
AIMS OF THIS THESIS
This thesis addresses several questions related to the genetics and epidemiology of 
age-related macular degeneration. In Chapter 2, we examine the frequency of age-
related macular degeneration in Europe and the risk of progression to the other eye. In 
Chapter 3, we investigate how geographic atrophy progresses and whether we can use 
deep learning to make predictions. Chapter 4 examines how genetics drives age-related 
macular degeneration and whether rare gene variants play a role. Lastly, in Chapter 5 
we examine the role of diet and lipid metabolism in age-related macular degeneration.
To answer these questions, we combined several study populations in order to increase 
the generalizability of our results and increase the statistical power to identify relatively 
small effects of environmental factors and/or genetic variants. This approach also 
allowed us to determine the consistency of findings across studies, providing an internal 
validation. Below is a brief description of the various consortia and study populations 
used in this thesis. 
The Rotterdam study32 is a population-based study consisting of three cohorts that started 
in 1990, 2000, and 2006. In this study, nearly 15,000 individuals over the age of 45 were 
recruited in the neighborhood of Ommoord, a suburb of Rotterdam in the Netherlands, 
and re-examined every five years. 
EUGENDA (the European Genetic Database)33 is a case-control database containing 
nearly 5,000 individuals who were recruited at the Ophthalmology Department at the 
Radboud University Medical Center in Nijmegen, the Netherlands, and the Department 
of Ophthalmology at the University Hospital of Cologne, Germany. 
The European Eye Epidemiology (E3) Consortium34 is a collaboration between 31 research 
groups in 13 European countries. This consortium includes a variety of study types, 
including population-based studies, case-control studies, and clinical trials. In total, the 
E3 Consortium contains clinical and imaging data on approximately 170,000 Europeans. 
(http://www.eye-epi.eu/) 
The EYE-RISK Consortium is a collaboration between 14 partners throughout Europe, 
including hospitals, universities, and companies, and is funded by the European Union’s 
Horizon 2020 Research and Innovation Programme. The aim of this consortium is to 
identify risk factors, molecular mechanisms, and new therapies for age-related macular 
degeneration. As part of this collaboration, a database was created containing data from 
approximately 50,000 cases compiled from various studies conducted within the E3 
Consortium. (http://www.eyerisk.eu/) 
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The Three Continent AMD Consortium35 consists of the following four population-based 
studies: the Rotterdam Study in the Netherlands, the Beaver Dam Eye Study in Madison, 
Wisconsin, the Blue Mountain Eye Study in Sydney, Australia, and the Los Angeles 
Latino Eye Study in Los Angeles, California. This consortium, which currently includes a 
cohort of approximately 30,000 individuals, was formed in 2009 in order to investigate 
gene–environment interactions, as well as the incidence and progression of age-related 
macular degeneration.




1. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related 
maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001;42(10):2237-2241.
2. Strauss O. The Retinal Pigment Epithelium. In: Kolb H, Fernandez E, Nelson R, eds. Webvision: 
The Organization of the Retina and Visual System. Salt Lake City (UT): University of Utah Health 
Sciences Center; January 26, 2011.
3. Gordiyenko N, Campos M, Lee JW, Fariss RN, Sztein J, Rodriguez IR. RPE cells internalize low-
density lipoprotein (LDL) and oxidized LDL (oxLDL) in large quantities in vitro and in vivo. Invest 
Ophthalmol Vis Sci. 2004;45(8):2822-2829.
4. Tserentsoodol N, Gordiyenko NV, Pascual I, Lee JW, Fliesler SJ, Rodriguez IR. Intraretinal 
lipid transport is dependent on high density lipoprotein-like particles and class B scavenger 
receptors. Mol Vis. 2006;12:1319-1333.
5. Ryeom SW, Sparrow JR, Silverstein RL. CD36 participates in the phagocytosis of rod outer 
segments by retinal pigment epithelium. J Cell Sci. 1996;109 ( Pt 2):387-395.
6. Li CM, Chung BH, Presley JB, et al. Lipoprotein-like particles and cholesteryl esters in human 
Bruch's membrane: initial characterization. Invest Ophthalmol Vis Sci. 2005;46(7):2576-2586.
7. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and 
disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet 
Glob Health. 2014;2(2):e106-116.
8. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. 
The Blue Mountains Eye Study. Ophthalmology. 1995;102(10):1450-1460.
9. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance 
vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 
2017;5(12):e1221-e1234.
10. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular 
degeneration. Science. 2005;308(5720):385-389.
11. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular 
degeneration. Science. 2006;314(5801):989-992.
12. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related 
macular degeneration highlights contributions of rare and common variants. Nat Genet. 
2016;48(2):134-143.
13. Han X, Gharahkhani P, Mitchell P, Liew G, Hewitt AW, MacGregor S. Genome-wide meta-
analysis identifies novel loci associated with age-related macular degeneration. J Hum Genet. 
2020.
14. PGC lectures: Gene Linkage 2017.
15. Generation G. Genome Wide Association Studies (GWAS). 2015; https://knowgenetics.org/
genome-wide-association-studies-gwas/. Accessed May 2020, 2020.
16. EMBL-EBI. What are genome wide association studies (GWAS)? 2020; https://www.ebi.ac.uk/
training-beta/online/courses/gwas-catalogue-exploring-snp-trait-associations/what-is-
gwas-catalog/what-are-genome-wide-association-studies-gwas/. Accessed June 2020, 
2020.
17. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related 
maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol. 2002;120(10):1357-1363.
150421-colijn-layout.indd   17 17/03/2021   17:41
18
CHAPTER 1
18. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled 
findings from three continents. Ophthalmology. 2001;108(4):697-704.
19. Klein R, Deng Y, Klein BE, et al. Cardiovascular disease, its risk factors and treatment, and 
age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J 
Ophthalmol. 2007;143(3):473-483.
20. Saksens NT, Lechanteur YT, Verbakel SK, et al. Analysis of Risk Alleles and Complement 
Activation Levels in Familial and Non-Familial Age-Related Macular Degeneration. PLoS One. 
2016;11(6):e0144367.
21. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and 
advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA. 
1994;272(18):1413-1420.
22. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO. Factors associated with age-related 
macular degeneration. An analysis of data from the first National Health and Nutrition 
Examination Survey. Am J Epidemiol. 1988;128(4):700-710.
23. Snellen EL, Verbeek AL, Van Den Hoogen GW, Cruysberg JR, Hoyng CB. Neovascular age-
related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand. 
2002;80(4):368-371.
24. Christen WG, Schaumberg DA, Glynn RJ, Buring JE. Dietary omega-3 fatty acid and fish intake 
and incident age-related macular degeneration in women. Arch Ophthalmol. 2011;129(7):921-
929.
25. Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial 
of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related 
macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-
1436.
26. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition 
with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE 
study. Ophthalmology. 2014;121(3):693-701.
27. Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement 
pathway reduces geographic atrophy progression secondary to age-related macular 
degeneration. Sci Transl Med. 2017;9(395).
28. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell 
intraocular implants for treatment of geographic atrophy in age-related macular degeneration. 
Proc Natl Acad Sci U S A. 2011;108(15):6241-6245.
29. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ. Investigation of oral fenretinide for 
treatment of geographic atrophy in age-related macular degeneration. Retina. 2013;33(3):498-
507.
30. Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related 
Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 
2016;854:355-361.
31. Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical 
administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 
2010;51(12):6131-6139.
32. Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam Study: 2018 update on objectives, 
design and main results. Eur J Epidemiol. 2017;32(9):807-850.
150421-colijn-layout.indd   18 17/03/2021   17:41
19
INTRODUCTION
33. Fauser S, Smailhodzic D, Caramoy A, et al. Evaluation of serum lipid concentrations and 
genetic variants at high-density lipoprotein metabolism loci and TIMP3 in age-related macular 
degeneration. Invest Ophthalmol Vis Sci. 2011;52(8):5525-5528.
34. Delcourt C, Korobelnik JF, Buitendijk GH, et al. Ophthalmic epidemiology in Europe: the 
"European Eye Epidemiology" (E3) consortium. Eur J Epidemiol. 2016;31(2):197-210.
35. Klein R, Meuer SM, Myers CE, et al. Harmonizing the classification of age-related macular 
degeneration in the three-continent AMD consortium. Ophthalmic Epidemiol. 2014;21(1):14-23.
150421-colijn-layout.indd   19 17/03/2021   17:41
150421-colijn-layout.indd   20 17/03/2021   17:41
2
BURDEN OF AMD
2.1 Prevalence of Age-Related 
Macular Degeneration in Europe: 
the Past and the Future 
Johanna M. Colijn *, Gabriëlle H.S. Buitendijk*, Elena Prokofyeva, Dalila Alves, Maria L. Cachulo, 
Anthony P. Khawaja, Audrey Cougnard-Grégoire, Bénédicte M.J. Merle, Christina Korb, Maja 
G Erke, Alain Bron, Eleftherios Anastasopoulos, Magda A. Meester-Smoor, Tatiana Segato, 
Stefano Piermarocchi, Paulus T.V.M. de Jong, Johannes R Vingerling, EYE-RISK consortium, 
Fotis Topouzis, Catherine Creuzot-Garcher, Geir Bertelsen, Norbert Pfeiffer, Astrid Fletcher, 
Paul J Foster, Rufino Silva, Jean-Francois Korobelnik, Cécile Delcourt, Caroline C.W. Klaver, 
for the European Eye Epidemiology (E3) Consortium
Published in Ophthalmology. 2017 Dec;124(12):1753-1763. doi: 10.1016/j.ophtha.2017.05.035. 
Epub 2017 Jul 14. PMID: 28712657.
* authors contributed equally
Supplementary material is available at: 
https://www.aaojournal.org/article/S0161-6420(16)32475-7/fulltext#supplementaryMaterial




Purpose: Age-related macular degeneration (AMD) is a frequent complex disorder 
in elderly of European ancestry. Risk profiles and treatment options have changed 
considerably over the years, which may have affected disease prevalence and outcome. 
We determined prevalence of early and late AMD in Europe from 1990 to 2013 using the 
European Eye Epidemiology (E3) consortium, and made projections for the future.
Design: Meta-analysis of prevalence data. 
Participants: 42 080 individuals aged 40 years of age and older participating in 14 
population-based cohorts from 10 countries in Europe.
Methods: AMD was diagnosed based on fundus photographs using the Rotterdam 
Classification. Prevalence of early and late AMD was calculated using random effects 
meta-analysis stratified for age, birth cohort, gender, geographic region, and time period 
of the study. Best-corrected visual acuity (BCVA) was compared between late AMD 
subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV). 
Main outcome measures: Prevalence of early and late AMD, BCVA, and number of AMD 
cases.
Results: Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 
2.1%-5.0%) in those aged 55-59 years to 17.6% [95% CI 13.6%-21.5%] in aged ≥85 years; for 
Late AMD these figures were 0.1% [95% CI 0.04% - 0.3%] and 9.8% [95% CI 6.3%-13.3%], 
respectively. We observed a decreasing prevalence of late AMD after 2006, which 
became most prominent after age 70. Prevalences were similar for gender across all age 
groups except for late AMD in the oldest age category, and a trend was found showing 
a higher prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer ≥80 
year old subjects with CNV were visually impaired (P=0.016). Projections of AMD showed 
an almost doubling of affected persons despite a decreasing prevalence. By 2040, the 
number of individuals in Europe with early AMD will range between 14.9 and 21.5 million, 
for late AMD between 3.9 and 4.8 million. 
Conclusion: We observed a decreasing prevalence of AMD and an improvement in 
visual acuity in CNV occurring over the past 2 decades in Europe. Healthier lifestyles and 
implementation of anti-vascular endothelial growth factor treatment are the most likely 
explanations. Nevertheless, the numbers of affected subjects will increase considerably 
in the next 2 decades. AMD continues to remain a significant public health problem 
among Europeans.




Age-related macular degeneration (AMD) can cause irreversible blindness and is the 
leading cause of visual impairment in the elderly of European ancestry.1 Two stages are 
known for this disease: early AMD, which is characterized by drusen and pigmentary 
changes, and late AMD, which can be distinguished in 2 subtypes; geographic atrophy 
(GA) and choroidal neovascularization (CNV).2 
Worldwide estimates approximated that 30-50 million people are affected by AMD3, 4, and 
these numbers are expected to increase over time because of the aging population.1, 5-9 
Although multiple small studies have assessed the prevalence of AMD and its relation 
to visual decline at various places in Europe10-12, a clear overview for Europe as a whole 
is lacking13. Comprehensive epidemiologic figures on AMD in Europe would help proper 
planning for public health and eye care policy makers.
Recent studies report a decrease in AMD-associated blindness and visual impairment14, 15, 
which are likely to be attributable to improved diagnostic procedures and hence earlier 
diagnosis, and the introduction of anti-vascular endothelial growth factor (anti-VEGF) 
therapy.14-16 Anti-VEGF therapy for CNV was introduced in 2004 and, since 2006, it 
has been widely used for clinical care in Europe.17, 18 However, the impact of anti-
VEGF therapy on general visual function of persons with AMD in Europe has not been 
sufficiently studied.1, 16
In this study, we investigated the prevalence of both early and late AMD in Europe using 
summary data of population-based cohort studies from the European Eye Epidemiology 
(E3) consortium. We analyzed changes in prevalence over time, compared geographic 
regions and studied differences between men and women. Moreover, we analyzed 
the visual acuity of affected individuals before and after the introduction of anti-VEGF 
therapy and predicted the number of persons with AMD by 2040 in Europe.
METHODS
Study Population
Fourteen population-based cohort studies participating in the E3 consortium contributed 
to this analysis. This consortium consists of European studies with epidemiologic data on 
common eye disorders; a detailed description on the included studies has been published 
elsewhere16. For the current analysis, studies with gradable macular fundus photographs 
(n=42 080 participants) and participants aged 40 years and over provided summary data. 
Participants were recruited between 1990 and 2013 from the following countries: Estonia, 
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France, Germany, Greece, Italy, Northern Ireland, Norway, Netherlands, Spain, Portugal19, 
20 and United Kingdom (UK) 16 (Table 1). The composition of AMD in each cohort is shown 
in Figure 1 (available at www.aaojournal.org). The study was performed in accordance 
with the Declaration of Helsinki for research involving human subjects and the good 
epidemiological practice guideline.
Grading of Age-Related Macular Degeneration
Both eyes of each participant were graded and classified separately by experienced 
graders or clinicians, and the most severe AMD grade of the worst eye was used for 
classification of the person. To harmonize classification of AMD, studies were graded or 
reclassified according to the Rotterdam Classification, as previously described.21 Main 
outcomes of this study were early AMD (grade 2 or 3 of the Rotterdam Classification) and 
late AMD (grade 4 of the Rotterdam Classification). Persons with late AMD were stratified 
as GA and CNV or mixed (both GA and CNV present in one person, either both types 
in the same eye, or one type per eye), which is henceforth in this article referred to as 
CNV. The Tromsø Eye Study, the Thessaloniki Eye Study, and the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study had fundus photograph grading 
that could not be converted to match the definition of early AMD of the Rotterdam 
Classification. Therefore, these 3 studies only participated in the late AMD analysis.
Visual Impairment
Visual acuity was measured for each eye separately as best-corrected visual acuity in 2 
categories: ≥0.3 and <0.3. When best-corrected visual acuity differed in the 2 eyes, visual 
acuity of the best eye was used to classify the person. Low vision and blindness were 
defined as visual acuity <0.3 and further referred to as visually impaired. 
Projection of Age-Related Macular Degeneration
The projection of AMD cases in Europe from 2013 to 2040 was calculated using the 
prevalence data for 5-year age categories obtained from the meta-analysis. Two 
different scenarios were used to calculate the projection. In the first scenario, it was 
assumed that the prevalence of both early and late AMD will remain stable until 2040. 
This scenario accounted for changes in population structure only. The second scenario 
followed the trend of decreasing prevalence based on data from the meta-analysis of 
the E3 consortium regarding the period 2006-2013. We calculated the rate of decline, 
with 2013 as the starting point and 2040 as the end point, and made the assumption that 
the rate of decline was decelerating and zero at the end point. For each projected year, 
prevalences were calculated for every 5-year age group, for early AMD from 45 years 
of age and onward and for late AMD 65 years and onward. The projected prevalences 
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were then multiplied by the predicted European population estimates obtained from 
Eurostat for all 28 countries in Europe, and the sum of individuals from all age groups 
was calculated.22 
Statistical Analysis
The crude prevalence of early and late AMD were calculated per study for each 5-year 
age group. A random-effects meta-analysis was performed by weighing the studies 
according to sample size, for early and late AMD separately for 5-year age groups and 
for people aged 70 years and older. In case of reported zero prevalence, the Haldane 
correction was used.23 In case of 100% prevalence, 0.01 was subtracted to prevent 
exclusion from the analysis. This analysis was repeated, stratified for the midpoint year 
of the study recruitment period, before and after the year 2006 and for 10-year birth 
cohorts. Furthermore, it was repeated for gender, and for geographical area in Europe 
based on the United Nations Geoscheme.24 A chi-square test was used to compare time-
trends. 
In addition, a meta-analysis was performed for eyes with visual impairment owing to late 
AMD, and per subtype of late AMD. Subsequently, the analysis was stratified for studies 
conducted before and after 2006, for which the midpoint year of the study recruitment 
period was used. The number of visually impaired people was calculated before and 
after 2006. Meta-analysis was performed with Stata software (release 13, version 13.1; 
StataCorp LP, College Station, TX) using metaprop. Graphical outputs were constructed 
with GraphPad Prism 7 (for Windows; GraphPad Software, La Jolla CA; www.graphpad.
com).
RESULTS
The total study population included in this analysis consisted of 42 080 individuals from 
14 studies with a median age of 65-69 years and a slight female predominance (55.8%). 
The prevalence of all age groups together varied per study between 2.3% and 16.8% 
for early AMD (total N=2703) and between 0.2% and 5.6% for late AMD (total N=664) (Fig 
2A and B available at www.aaojournal.org; to avoid biased estimates only groups larger 
than 30 individuals are shown; this applied only to the Rotterdam Study 3 age category 
≥85 years). Owing to moderate to high heterogeneity (I2 >= 75% in 73 of 141 analyses), 
which was not related to time trends, we applied a random-effects model for each meta-
analysis. This provided a prevalence of early AMD increasing with age from 3.5% (95% 
confidence interval [CI] 2.1%-5.0%) at 55-59 years to 17.6% (95% CI 13.6%-21.5%) in persons 
aged ≥85 (Fig 3A, and Table 2, available at www.aaojournal.org). The prevalence of late 
AMD rose from virtually zero in the youngest age group to 9.8% (95% CI 6.3%-13.3%) for 
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those in the highest age group (Fig 3B). Taking together all people aged ≥70 years, the 
overall prevalence was 13.2% (95%CI 11.2%-15.1%] for early AMD and 3.0% (95%CI 2.2%-
3.9%] for late AMD. We investigated prevalence changes over time by dividing the E3 
consortium into studies conducted before and after 2006. The prevalence of early AMD 
before and after 2006 seemed to rise with age in a similar fashion. For late AMD, a trend 
of decreasing prevalence was observed for the higher age categories after 2006 (Fig 3C 
and D). Even after exclusion of the 2 cohorts (Rotterdam Study [RS]-II and European Eye 
Study [EUREYE]) with the highest prevalences in the highest age category before 2006, 
results remained similar (data not shown).
Figure 3. Meta-analysis of (A) early and (B) late age-related macular degeneration (AMD) in Europe per age 
category for the participating studies. Meta-analysis of the prevalence of (C) early and (D) late AMD before and 
after 2006.
When we analyzed prevalence data as a function of birth cohort, a relatively stable 
prevalence of early AMD was visible across all birth cohorts, whereas a decreasing 
prevalence of late AMD was seen for the more recent birth cohorts (Fig 4A and B). 
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Figure 4. Meta-analysis of early (A) and late (B) age-related macular degeneration in Europe by 10-year birth 
cohorts. 
Gender and Geographic Region
We studied the relation with gender and found no differences in the prevalence of early 
and late AMD between men and women except for the age category of 85 years and 
older for late AMD (Fig 5A and B, available at www.aaojournal.org). This category shows 
a trend for a higher prevalence in women compared to men, although CIs overlap.
To address differential distribution of AMD in Europe, we stratified studies according 
to 3 regions defined by the United Nations.24 In older individuals, we observed a trend 
toward a higher prevalence of early AMD in the North (16% in ≥70 years; 95% CI 14%-17%) 
compared to the West (12%; 95% CI 10%-14%) and South (14%; 95% CI 10%-17%) (Fig 6A, 
available at www.aaojournal.org). Likewise, late AMD had the highest prevalence in the 
North (4.2%, 95% CI 2%-6%) compared to the West (3.1%; 95% CI 2%-4%) and South (3.1%; 
95% CI 2%-4%) (Fig 6B, available at www.aaojournal.org). More detailed analyses showed 
that a frequency difference was only present for CNV (Fig 6C and D, available at www.
aaojournal.org); however, CIs of the regional differences overlapped.
Visual consequences 
As most countries implemented anti-VEGF therapy for CNV from 2006 onward, we 
compared visual impairment from AMD in studies carried out before and after this year. 
Before 2006, 54.2% of eyes with GA were visually impaired, and 79.8% of eyes suffering 
from CNV were visually impaired. From 2006 onward, the proportion of visually impaired 
eyes remained the same for GA (47.6%; P= 0.40), but dropped to 66.2% (P= 0.026) for 
CNV (Fig 7A). This improvement was also observed for the number of bilaterally visually 
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impaired persons; 120 of 345 (34.8%) before 2006 to 75 of 259 (28.9%; P=0.13) after 2006. 
The largest drop was seen for people aged 80 years and older; 85 of 175 (48.6%) before 
2006 to 46 of 132 (34.8%; P=0.016) after 2006 (Fig 7B).
Figure 7. A, Proportion of visually impaired eyes within each subgroup of late age-related macular degeneration 
(AMD). The proportion of visually impaired eyes remained the same for geographic atrophy (47.6%; P = 0.4), but 
dropped to 66.2% (P= 0.026) for choroidal neovascularization after 2006. B, Proportion of persons with late AMD 
with bilateral visual impairment before and after 2006 (P=0.016). *P <0.05. 
Projections of Age-Related Macular Degeneration in Europe for 2040
Assuming that the prevalence of early and late AMD will remain stable over time, an 
increase from 15.0 million in 2013 to 21.5 million for early AMD can be expected by 2040. 
The number of people with late AMD will almost double during this time period, from 2.7 
million in 2013 to 4.8 million in 2040.
Figure 8. Predicted number of persons with age-related macular degeneration (AMD) in years 2013-2040 as a 
function of 2 prevalence scenarios.
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Assuming a more realistic scenario for which E3 historic data and a decelerating slope 
were used, we found that the prevalence of early AMD will first decrease and then slightly 
increase between 2013 and 2040. The model estimated that the number of people with 
early AMD would remain almost the same; from 15.0 million in 2013 to 14.9 in 2040. This 
model also displayed that the number of people with late AMD in Europe will increase 
from 2.7 million in 2013 to 3.9 million by 2040 (Fig 8).
DISCUSSION
Age-Related Macular Degeneration Prevalence and Its Time Trends
Our study provides insight into the prevalence of both early and late AMD in Europe. 
Based on meta-analyzed data from 14 population-based cohort studies included in 
the E3 Consortium, the overall prevalence of early and late AMD was 13.2% and 3.0%, 
respectively, in the age-category ≥70 years. These estimates are comparable to persons 
of European descent living in other continents.3, 25
Our data show a trend toward a slightly decreasing prevalence of AMD in the older age 
categories. It is unlikely that this is explained by differential mortality in AMD patients 
before and after 2006, although studies have shown conflicting results on death as a 
competing risk factor for AMD, and we cannot exclude that this plays a role.26-28 The 
decreasing trend in time has also been observed in the Beaver Dam Eye Study, indicating 
that these trends are not confined to Europe.29 Decreasing rates have also been observed 
for other aging disorders such as cardiovascular disease and dementia30-33, and may 
to be related to improved lifestyle among the elderly34-36; for example, the number of 
smokers declined by 30.5% from 1990 to 2010 in Europe37. Taken together, the decline 
in prevalence suggests that the increases in the number of AMD patients may not be as 
substantial as previous prediction studies suggested38.
Gender and Geographic Regions
Our data showed no difference in the prevalence of early and late AMD with respect 
to gender. In the oldest age category of 85 years and older, women seemed to have a 
higher prevalence of late AMD, but detailed analysis showed that this was mostly owing 
to imprecision of the estimate in men, caused by a lower number of men in this age 
group. (Fig 9, available at www.aaojournal.org). This has also been observed in other 
studies.7,39
As for regional differences, we noticed that the northern region of Europe showed a 
slightly higher prevalence of early and late AMD. This trend was the result of a higher 
prevalence of CNV in the north. Our findings are in concordance with the results 
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previously published by the Tromsø Eye Study40 but are in contrast with other studies 
performed in the north of Europe finding a higher prevalence of GA (EUREYE, Reykjavik 
Eye Study and Oslo Macular Study).41-43 Considering the larger sample size and high 
response rate of the Tromsø Eye Study compared with the other studies, these findings 
might be more legitimate. No consistent differences were observed for the western and 
southern regions of Europe.
Visual Consequences
The proportion of eyes affected by CNV that were visually impaired was reduced after 
the year 2006. Unfortunately, our study lacked actual data on interventions for CNV, but 
it is likely that the reduction is attributable to the use of anti-VEGF injections, which were 
introduced as a therapy for CNV in Europe from 2006 onward.18 This notion is supported 
by findings from clinical trials44, 45 and other studies, which show an up to 2-fold decrease 
in legal blindness due to AMD after 2006.14, 15, 46, 47 The public campaigns that were initiated 
after the introduction of anti-VEGF have undoubtedly contributed to the reduction of 
visual loss, as they made elderly persons more aware of the symptoms and stimulated 
prompt therapy.48, 49
Projections of Age-Related Macular Degeneration in Europe
It is unclear whether the prevalence of AMD will decrease even more in the coming 
years, but an increase is not likely to be expected. Therefore, we projected the estimated 
number of AMD-affected persons until the year 2040 based on 2 different scenarios: 
1 based on stable prevalence and 1 following the trend of declining prevalences. The 
results of the first scenario suggests that the absolute number of persons with late AMD 
will increase by 2.1 million, a 1.5-times increase. A Norwegian study predicted, under the 
assumption of a stable prevalence, the same relative increase of affected subjects, with 
a total of 328 000 cases of late AMD in Scandinavia by 2040.5, 8 A study in the United 
States calculated a 2.2-times increase in absolute numbers and estimated a total number 
of affected subjects to be 3.8 million by 2050.5, 8 Worldwide projections have shown a 
doubling of late AMD and an increase of 9 million cases by 2040.3
The second scenario was based on declining rates, and showed a small increase in the 
number of people with early AMD, from 14 million in 2016 to 14.9 million by 2040, and a 
larger relative increase in the number of people with late AMD, from 2.7 million in 2016 
to 3.9 million by 2040. Considering the declining rates of smoking and implementation of 
healthier diet in elderly persons, the second projection may be more legitimate.




A limitation to this E3 consortium meta-analysis is the heterogeneity across studies 
regarding study design and inclusion criteria. For example, age at inclusion and method 
of recruitment varied between studies. Although in every study AMD was classified 
according to the Rotterdam Classification, studies differed in AMD grading, especially for 
pigmentary changes and drusen size. Given the heterogeneity, we therefore performed 
a random-effects meta-analysis for both early and late AMD. Furthermore, patient 
management and access to healthcare may have differed between study sites, resulting 
in differences in preventative and treatment options.50, 51 
When data collection started in 1990, fundus photography was the gold standard for 
grading AMD. Since 1990, imaging techniques evolved rapidly, greatly improving the 
diagnosis of AMD features with non-invasive techniques such as optical coherence 
tomography, autofluorescence, and near-infrared photographs. In addition, multimodal 
imaging better visualizes edema and subtle changes resulting from CNV, which may not 
be so apparent when the patient was treated with anti-VEGF therapy.52,53 Although macular 
edema due to subretinal neovascularization often coincides with prominent retinal 
changes such as hemorrhages or hard exudates, our data may have underestimated the 
true prevalence of CNV.53 
In summary, this study estimates the prevalence of early and late AMD per age category 
in Europe over the past two decades. Prevalence of both these forms remained stable or 
decreased slightly. Nevertheless, we observed a significant reduction in the proportion 
of visually impaired eyes attributable to CNV after 2006. Unfortunately, due to the aging 
population, the number of people with AMD will increase during the next decades, 
indicating a continuous need to develop comprehensive modalities for prevention and 
treatment of AMD.
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Purpose: To assess the 5-year progression from unilateral to bilateral age-related 
macular degeneration (AMD) and associated risk factors.
Design: Pooled data analyses of three prospective population-based cohorts, the Blue 
Mountains Eye Study, Beaver Dam Eye Study and Rotterdam Study.
Methods: Retinal photography and interview with comprehensive questionnaires were 
conducted at each visit of three studies. AMD was assessed following the modified 
Wisconsin AMD grading protocol. Progression to bilateral any (early and late) or late 
AMD was assessed among participants with unilateral involvement only. Factors 
associated with the progression were assessed using logistic regression models while 
simultaneously adjusting for other significant risk factors. 
Results: In any 5-year duration, 19-28% of unilateral any AMD cases became bilateral 
and 27-68% of unilateral late AMD became bilateral. Factors associated with the 
progression to bilateral involvement of any AMD were age (per year increase, adjusted 
OR 1.07), carrying risk alleles of the complement factor H and age-related maculopathy 
susceptibility 2 genes (compared with none, OR 1.76 for 1 risk allele, and OR 3.34 for 2+ risk 
alleles), smoking (compared with non-smokers, OR 1.64 for past and OR 1.67 for current 
smokers), and the presence of large drusen area or retinal pigmentary abnormalities in 
the first eye. 
Conclusions: One in four to one in five unilateral any AMD cases, and up to one 
in two unilateral late AMD cases, progressed to bilateral in 5 years. Known AMD risk 
factors, including smoking, are significantly associated with the progression to bilateral 
involvement.




Age-related macular degeneration (AMD) is a leading cause of blindness in western 
populations1. While the presence of AMD in one eye can be debilitating, vision loss and 
blindness in both eyes due to bilateral AMD will have severe consequences for the 
affected individuals 2,3. 
Previous studies report the development of late AMD in the second eye to be 20-50% 
over 5-10 years4-9. However, the progression from unilateral early AMD to bilateral early 
or any (early and late) AMD10, and its associated risk factors has been less well described. 
We aimed to report the 5-year progression of unilateral AMD cases to bilateral 
involvement in three population-based cohorts, the Three Continent AMD Consortium 
(3CC). We also aimed to investigate this progression in relation to risk factors and early 
AMD lesion characteristics.
METHODS
Among the 3CC, we included non-Hispanic white, population-based cohort studies 
conducted in Australia, the USA and the Netherlands11,12. Written informed consent was 
obtained from each participant at each visit, in all three studies. All studies adhered to the 
tenets of the Declaration of Helsinki.
Blue Mountains Eye Study
The Blue Mountains Eye Study (BMES) recruited 3654 participants (82.4% of those 
eligible) aged ≥49 years living in two postcode regions west of Sydney between 1992-
199413. Of these participants, 2334, 1952 and 1149 were re-examined after 5, 10 and 15 
years, respectively. Examinations were approved by the University of Sydney and the 
Sydney West Area Health Service Human Research Ethics Committees.
Beaver Dam Eye Study
The Beaver Dam Eye Study (BDES), conducted in Beaver Dam, Wisconsin, examined 
4926 participants (83.2% of those eligible) aged 43-86 years from 1988-199014. Of these 
participants, 3721, 2962, 2375 and 1913 were re-examined after 5, 10, 15, and 20 years, 
respectively. The University of Wisconsin-Madison approved all study visits in conformity 
with federal and state laws and compliance with the Health Insurance Portability and 
Accountability Act.




At baseline (1990-1993), the Rotterdam Study (RS) examined 7983 participants (77.7% 
participation rate) aged 55+ years, of whom 6419 had ophthalmic examinations and 
retinal photography performed15. Of 6419 participants, 4977, 3637 and 2674 were re-
examined at the second (1993-1995), third (1997-1999) and fourth (2002-2004) visits, 
respectively. The mean follow-up period was 10 years. Only data from the first, third and 
fourth visits were used. Examinations were approved by the Medical Ethics Committee 
of the Erasmus Medical Centre and the Ministry of Health, Welfare and Sport of the 
Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies 
Act: Rotterdam Study). 
Retinal photography 
Mydriatic stereoscopic color fundus photographs were taken at each study visit. Zeiss 
fundus cameras (Carl Zeiss, Oberkochen, Germany) were used in the first three visits of 
BMES (FF3) and all visits of BDES (FF4), and 30° stereoscopic color fundus photographs of 
the macula and optic disc, and non-stereoscopic photographs of the other retinal fields of 
both eyes were taken in both studies. Topcon TRV-50VT fundus camera (Topcon Optical 
Co., Tokyo, Japan) was used in the RS during the first visits, and 35° stereoscopic colour 
fundus photographs of the macula were taken. In the fourth visit, the BMES used a Canon 
CF-60 DSi with DS Mark II body (Canon, Tokyo, Japan) to take 40° digital photographs; 
and the RS used a Topcon TRC 50EX fundus camera with Sony DXC-950P digital camera 
(Topcon Optical Co.) to take 35° digital photographs. 
Photographic grading and definitions of AMD 
Retinal photographs of both eyes were initially graded by trained graders of each study 
following the Wisconsin Age-related Maculopathy Grading System (WARMGS)16. All 
late AMD incident cases detected from each study were adjudicated and confirmed 
by the retinal specialists of each study team initially, then cross-checked among chief 
investigators of the three cohorts17. 
A 5-step severity scale for AMD, developed after phenotype harmonization11 was used 
to define AMD severity stage. Levels 10, 20, 30, 40 and 50 corresponded to normal, mild 
early, moderate early, severe early and late AMD (see online supplementary appendix). 
We grouped levels 20-40 as early AMD. Unilateral any AMD was defined if either early 
or late AMD were present in one eye only. Unilateral late AMD was defined as late AMD 
presence in one eye with no late AMD in the fellow eye (regardless of presence of early 
AMD). Bilateral any and late AMD were defined as presence of any and late AMD in both 
eyes, respectively. Progression was defined as the transition from unilateral any or late 
AMD to bilateral. 
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Total drusen area, measured as a proportion of the WARMGS grid, and the presence 
of retinal pigment epithelium (RPE) abnormalities were assessed at first detection of 
unilateral AMD, as prognostic factors for bilateral involvement. Methods used to calculate 
total drusen area differed across studies thus we derived quintiles of drusen area within 
each study to obtain comparable measures. Drusen area was categorized as small, 
intermediate or large, representing participants who had the lowest 20%, the middle 60% 
and the highest 20% of drusen area in each population accordingly.
Assessment of risk factors 
Smoking status was assessed using interviewer-administered questionnaires. In the 
BMES, participants were classified as 'non-smokers' if they answered ‘no’ to smoking 
regularly, 'past smokers' if they quit smoking >1 year prior to the examination, and 'current 
smokers' if they currently smoked or stopped smoking <1 year before the examination. 
In the BDES, participants were classified as 'non-smokers' if they had smoked fewer than 
100 cigarettes in their lifetime, 'past smokers' if they smoked ≥100 cigarettes but had 
stopped smoking before the examination or 'current smokers' if they had not stopped 
smoking18. In the RS, smoking status was defined as never, past or current according to 
participants responses ‘no’, ‘yes, stopped smoking’ and ‘yes, still smoking’, respectively19.
Mean systolic and diastolic blood pressures were taken from an average of two readings, 
except for BMES baseline visit, when one measure was taken. Serum total cholesterol 
levels, high density lipoprotein (HDL) levels and white blood cell count were measured at 
baseline from non-fasting blood samples in the BDES and RS and fasting blood samples 
in the BMES20.
Genotyping methods
We used two major AMD-associated genes to represent AMD genetic susceptibility, the 
complement factor H (CFH; OMIM 134370) and age-related maculopathy susceptibility 2 
(ARMS2; OMIM 611313). Genotyping methods are described in the online supplementary 
appendix17,21,22.
Statistical Analyses
All statistical analyses were performed using SAS V.9.3 (SAS Institute, Cary, North 
Caroline, USA).
Progression to bilateral AMD was assessed using discrete time survival analysis, focusing 
solely on the first 5-year interval since initial detection of unilateral cases. Participants 
were included at first detection of unilateral AMD and assessed for progression to 
bilateral involvement at the subsequent 5-year visit. 
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Progression rates were compared across categories of age, genetic risk levels (carrying 
0, 1 or 2-4 risk alleles of the CFH and ARMS2 combined) and smoking status, by individual 
and pooled study samples, using Mantel-Haenzel χ2 tests for linear trend.
Associations between progression to bilateral involvement and age, sex, smoking 
status, genetic risk, blood pressure, white blood cell count, total cholesterol and HDL 
cholesterol levels were assessed in age-adjusted and multivariable-adjusted logistic 
regression models. Age, drusen area and RPE abnormalities were time-dependent 
variables corresponding to the visit when unilateral AMD was first detected. All other co-
variables were defined at baseline. Final models included age, sex, smoking status, total 
drusen area, presence of RPE abnormalities that remained statistically significant in the 
model. Indicators of study site were included in models using pooled-data. Association 
estimates are presented as adjusted ORs and 95% CIs. 
We obtained a receiver operating characteristic (ROC) curve and area under the ROC 
curve (AUC) to assess how useful the final model might be in predicting progression to 
bilateral any AMD in 5 years. The AUC is a measure of discrimination and, here indicates 
the probability that a person with progression will have a higher predicted value in the 
model than a person without progression.
Due to limited numbers of cases, associations with progression to bilateral late AMD 
were examined using pooled-data only, and associations between early AMD lesion 
characteristics and progression to bilateral late AMD could not be assessed.
RESULTS 
Participants with unilateral any or late AMD from the BMES, BDES and RS were included 
(ages 51+, 44+ and 55+ years, respectively). Among 1490 participants (BMES n=335, BDES 
n=625 and RS n=530) with unilateral any AMD detected at any visit, 94 (28%), 119 (19%) 
and 126 (24%) progressed to bilateral in the corresponding cohorts, respectively. Of 96 
participants (BMES n=25, BDES n=51 and RS n=20) with unilateral late AMD, 17 (68%), 14 
(27%) and 11 (55%) progressed to bilateral in the three cohorts respectively. 
Progression to bilateral any AMD
Table 1 compares baseline characteristics between those who did and did not progress 
in the separate and pooled cohorts. Compared with participants who remained unilateral, 
those who progressed to bilateral were older, and more likely to have 2+ risk alleles from 
combined CFH and ARMS2 genes. 
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Table 2 presents proportions of progression to bilateral any AMD by age, genetic risk 
and smoking status in separate and pooled populations. Progression was associated with 
increasing age and increased risk alleles of the CFH and ARMS2 genes. There was no 
significant crude association between smoking status and progression to bilateral any 
AMD.
Table 3 presents factors associated with progression to bilateral any AMD by individual 
cohorts. After adjustment, age and the presence of ≥2 risk alleles from the two genes 
combined were associated with increased risks of progression across three cohorts, 
while smoking was non-significantly associated with this progression. Large total 
drusen area (highest compared with lowest quintile) contributed significantly to the 
risk of progression in each cohort. The presence of RPE abnormalities was significantly 
associated with increased risk of progression in the BMES and BDES but not the RS.
Table 4 presents factors associated with progression to bilateral any AMD in pooled 
data. Progression was more commonly observed in the BMES compared with the 
BDES. Older age, smoking and carrying ≥1 risk allele from the CFH and ARMS2 were 
significantly associated with an increased risk of progression. Large total drusen area 
and RPE abnormalities also contributed significantly to an increased risk of progression.
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Figure 1 presents the ROC curve for bilateral any AMD using the multivariable-adjusted 
model shown in Table 4. The AUC of this model was 0.79, improved by 0.02 from a model 
without genetic risk categories (0.77) and by 0.11 from an age-sex-adjusted model (0.68).
Supplementary analyses using comprehensive gene-environment risk scores23 found no 
additional improvement to the fully-adjusted model in predicting progression to bilateral 
any AMD (data not shown). There was no meaningful difference in the association 
between these risk factors and progression to bilateral any AMD after inclusion of secular 
trend terms in the model, accounting for different detection timing of the unilateral cases 
(data not shown).
Figure 1. ROC curve indicating the prognostic performance of the model in predicting probabilities of 5-year 
progression from unilateral to bilateral involvement by any age-related macular degeneration. A ROC curve that 
follows the left-hand and top axes of the graph (AUC=1) indicates that the model provides perfect discrimination, 
whereas a diagonal line from the bottom left-hand corner of the graph to the top right-hand corner (AUC=0.5) 
indicates a model with no discriminative value. Sensitivity (the true positive rate) indicates the proportion of 
participants with progression who were correctly identified by the model, whereas 1-specificity (the false positive 
rate) indicates the proportion of participants without progression who were misidentified by the model. AUC, area 
under the ROC curve; ROC, receiver operating characteristic.
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Progression to bilateral late AMD
Compared to participants who remained unilateral late AMD over 5 years, those who 
progressed to bilateral late AMD were older (Table 1). However, there was no significant 
trend for age, smoking or genetic crude associations with this progression in separate or 
pooled cohorts (Table 2). 
After adjustment, progression to bilateral late AMD was more commonly observed in 
the BMES compared to the BDES (Table 4). The presence of ≥2 risk alleles from CFH and 
ARMS2 genes combined was associated with a high risk of progression. Increased serum 
total cholesterol was associated with a decreased risk. 
DISCUSSION
We found that over a 5-year period, about 19%-28% of unilateral any AMD cases 
progressed to bilateral, and 27%- 68% of unilateral late AMD cases progressed to bilateral 
in our three population-based cohorts. In addition to age and AMD genetic risk, smoking 
and early AMD lesion characteristics were associated with increased risk of progression 
from unilateral to bilateral involvement in 5 years.
The BDES population includes a younger age spectrum (age 44+ years) compared with 
the BMES (51+ years) and the RS (55+ years), which may explain why higher proportions 
of progression were observed in the BMES and RS than the BDES.
The 5-year incidence of late AMD in the fellow eye of unilateral late AMD patients enrolled 
in a randomized clinical trial was 26%9 which is similar to that found in the BMES and 
BDES (29% and 22%, respectively) 4,6. In the RS 5-year cumulative incidence of late AMD 
in the fellow eye was 39%8. The rates we report currently are greater as the mean age of 
participants are older than the mean age of the aforementioned samples at baseline, by 
including additional unilateral AMD cases detected at follow-up visits.
In addition to older age and AMD genetic risk, we documented that past or current 
smoking was significantly associated with increased risk of progression to bilateral any 
AMD in pooled analyses. Despite the heterogeneity in definitions, the contribution of 
smoking to the risk of developing any AMD in the second eye was evident when the 
sample size increased. The relatively small numbers of participants with unilateral late 
AMD in each individual population and in pooled data, or the narrow difference in smoking 
rates between participants with unilateral and bilateral late AMD are likely reasons for the 
lack of association of smoking with bilateral late AMD found in this report.
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The inverse association between increased diastolic blood pressure and reduced risk of 
progression to bilateral any AMD is not readily explained. The inverse association between 
increased cholesterol level and reduced risk of progression to bilateral late AMD is not 
yet understood. Although elevated total cholesterol levels were found to be associated 
with a reduced incidence of neovascular AMD in a previous study20, the relationship 
between total cholesterol levels and AMD risk has been largely inconsistent12,24,25.
Increasing severity levels of early AMD lesions in one eye were previously reported to be 
associated with increased incidence of AMD in the fellow eye10. We found drusen area to 
be the strongest predictor for progression to bilateral any AMD within 5 years. 
An AUC of 0.79 and 0.77 for bilateral any AMD suggests that both full model and the 
model without genetic risk categories are satisfactory in distinguishing persons who will 
progress to bilateral involvement from those who will not. Previous studies found minimal 
improvement in AUC after including genetic information in prediction models23,26. Genetic 
testing in clinical practice is not supported by ours or other previous findings27.
We assembled a large number of unilateral any AMD cases from the 3CC. Care has 
been taken to harmonize AMD grading, confirm late AMD cases across three cohorts17, 
and use uniformly the severity scale developed11 in the 3CC. Limitations include small 
numbers of unilateral late AMD cases even after pooling, resulting in low power to 
assess modifiable risk factors. The cohort samples are mostly Caucasians of Northern 
and Western European descent, and the findings may not be applicable to other ethnic 
populations.
In summary, 20-25% of unilateral any AMD cases, and up to 50% of unilateral late AMD 
cases on average, progressed to bilateral in 5 years. Of risk factors associated with 
the progression to bilateral involvement, only smoking is modifiable. The protective 
association between cholesterol level and bilateral late AMD warrant further investigation.
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Purpose: To develop and validate a deep learning model for the automatic segmentation 
of geographic atrophy (GA) using color fundus images (CFIs) and its application to study 
the growth rate of GA.
Design: Prospective, multicenter, natural history study with up to 15 years of follow-up.
Participants: Four hundred nine CFIs of 238 eyes with GA from the Rotterdam Study (RS) 
and Blue Mountain Eye Study (BMES) for model development, and 3589 CFIs of 376 eyes 
from the Age-Related Eye Disease Study (AREDS) for analysis of GA growth rate.
Methods:  A deep learning model based on an ensemble of encoder-decoder 
architectures was implemented and optimized for the segmentation of GA in CFIs. Four 
experienced graders delineated, in consensus, GA in CFIs from the RS and BMES. These 
manual delineations were used to evaluate the segmentation model using 5-fold cross-
validation. The model was applied further to CFIs from the AREDS to study the growth 
rate of GA. Linear regression analysis was used to study associations between structural 
biomarkers at baseline and the GA growth rate. A general estimate of the progression 
of GA area over time was made by combining growth rates of all eyes with GA from the 
AREDS set.
Main Outcome Measures: Automatically segmented GA and GA growth rate.
Results: The model obtained an average Dice coefficient of 0.72 ± 0.26 on the BMES 
and RS set while comparing the automatically segmented GA area to the graders' 
manual delineations. An intraclass correlation coefficient of 0.83 was reached between 
the automatically estimated GA area and the graders' consensus measures. Nine 
automatically calculated structural biomarkers (area, filled area, convex area, convex 
solidity, eccentricity, roundness, foveal involvement, perimeter and circularity) were 
significantly associated with growth rate. Combining all growth rates indicated that GA 
area grows quadratically up to an area of approximately 12 mm², after which growth rate 
stabilizes or decreases.
Conclusion: The deep learning model allowed for fully automatic and robust segmentation 
of GA on CFIs. These segmentations can be used to extract structural characteristics of 
GA that predict its growth rate.




Geographic atrophy (GA) occurs in the advanced stage of age-related macular 
degeneration (AMD). It is characterized by progressive atrophy of the retinal pigment 
epithelium, overlying photoreceptors, and underlying choriocapillaris.1 Areas of GA often 
initially appear extrafoveal, which may result in their causing difficulties in reading or 
dim-light vision.2 Over time, the atrophic area may grow, and when it reaches the fovea, 
visual acuity is severely diminished. Prevalence of GA increases exponentially with age3 
and is highest in people of European ancestry.4 The number of people affected by GA is 
expected to increase further in the near future because of the ageing population.5
Currently, no approved treatment exists to prevent progression of GA.6,7 However, clinical 
trials of several potential therapies are underway.8 For evaluation of these trials, reliable 
anatomic endpoints are required, because visual acuity alone provides insufficient insight 
in the severity of the disease.9 Growth rate of the atrophic area has been suggested 
as an important indicator of disease progression.9-11 However, the speed at which GA 
progresses varies greatly between patients.12-14 Therefore, understanding the patterns 
associated with progression and the variability between patients is important for the 
design and interpretation of clinical trials.
To assess growth rate, accurate delineation of the GA area is required. However, because 
manual delineation can be challenging and time consuming,15,16 automatic segmentation 
could provide a scalable and reproducible alternative. Deep learning has emerged as 
a powerful technique for the automatic analysis of medical images.17 Deep learning 
models require labeled examples (training data) to tune their internal parameters. The 
model then learns to extract features that are important for the segmentation task 
without further need of explicit domain knowledge from experts. It has been successfully 
applied to color fundus images (CFIs) for classification of severity stages in AMD18,19 or 
diabetic retinopathy,20-22 and recently also for the detection of GA.23 Although manually 
labeled examples are still required for training and validation, the model thereafter can 
be applied to large data sets, opening up new possibilities for studies and possibly 
reducing the overall effort that is required from experienced graders.
These automatic methods also have the potential to extract structural characteristics 
of GA efficiently and accurately, as seen in imaging that has been demonstrated to 
correlate with growth rate. For example, multifocal lesions grow faster than unifocal 
lesions,24 and extrafoveal lesions grow faster than foveal lesions.13 Circular lesions have 
been demonstrated to grow at a slower rate than more irregularly shaped lesions.25. 
Baseline lesion area has been consistently associated with future growth, with larger 
lesions growing faster than smaller lesions.11,13,26,27 However, applying a square root 
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transformation to the lesion size may remove this dependency.16,28 Therefore, it has been 
hypothesized that lesions with approximate circular shape grow at a constant radial 
speed, thus leading to a quadratic growth of the area.16,29
Various imaging methods have been used to assess GA. Color fundus imaging has 
been used most widely historically, particularly in large epidemiologic studies.12 More 
recently, fundus autofluorescence (FAF) and optical coherence tomography (OCT) 
have also become popular for the study of GA and GA progression.13,16,27 Several lesion 
characteristics visible with those methods can be linked to progression of GA. For 
example, banded or diffuse perilesional patterns on FAF and structural abnormalities 
at the junctional zone on OCT have been associated with faster GA progression.13,27,30 
Although GA may be detected earlier on FAF images than CFIs,31 good agreement on 
quantification of GA area on CFIs between 2 independent reading centers has been 
demonstrated,11 and progression rates assessed from both FAF images and CFIs are 
highly correlated.13,31 Color fundus imaging has the advantage that it is widely available, 
often over longer periods, making it suitable for the study of long-term progression of 
GA.
Previous work on automatic methods for segmentation of GA focuses mainly on OCT32-34 
or FAF.35 Feeny et al.36 proposed a method based on a random forest classifier in color 
fundus imaging. In contrast, herein we present a model that is based on deep learning. 
The purpose of this study is twofold: (1) to develop and validate a fully automatic model 
for segmentation of GA on CFIs and (2) to demonstrate its usefulness in a longitudinal 
setting for the study of GA progression. The performance of the developed model 
was compared against the work of 4 graders on a challenging dataset to evaluate its 
robustness. Next, the automatically segmented GA areas provided measures of structural 
characteristics related to lesion size, location and morphologic features. We investigated 
the associations between those structural characteristics at baseline and the subsequent 
growth rate of GA. Finally, we combined GA growth rates across patients to obtain an 
estimate of average progression of GA area over time.
METHODS
Data
Data for development and evaluation of the deep learning model for GA segmentation 
were collected from the Blue Mountains Eye Study (BMES)37 and the Rotterdam Study 
(RS) cohorts I, II and III.38 The developed model was applied to CFIs from the Age-Related 
Eye Disease Study (AREDS)11 for the assessment of GA growth rate.
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The BMES is a population study from the Blue Mountains region in Australia that started 
between 1992 and 1994 and included 3654 participants 49 years of age or older. For the 
first 3 visits, 30° macula-centered (field 2) CFIs were obtained with a Zeiss fundus camera 
(Carl Zeiss AG, Oberkochen, Germany). For the fourth visit, 40° macula-centered digital 
CFIs were obtained with a Canon CF-60 DSi with DS Mark II body (Canon, Tokyo, Japan). 
The BMES was approved by the University of Sydney and the Sydney West Area Health 
Service Human Research Ethics Committees.
The RS is a population study from a suburb in Rotterdam, The Netherlands. The RS cohort 
I started in 1990 and included 7983 participants 55 years of age or older. Cohort II started 
in 2000 and included 3011 participants 55 years of age or older. Cohort III started in 2006 
and included 3932 participants 45 years of age or older. The CFIs for the first examinations 
were obtained with a Topcon TRV-50VT (Topcon Optical Company, Tokyo, Japan), and 
those from the last 2 examinations were obtained with a Topcon TRC 50EX and a Sony 
DXC-950P (Sony Electronics Inc., New York, NY) digital camera. All CFIs were 35° and 
macula centered (field 2). The RS was approved by the Medical Ethics Committee of the 
Erasmus Medical Center and by the Netherlands Ministry of Health, Welfare and Sport.
The AREDS is a long-term, multicenter, prospective study of the clinical course of AMD 
and cataract. Starting between 1992 and 1998, 11 clinics in the United States enrolled 4757 
participants between 55 and 80 years of age. Stereoscopic CFIs (30° macula centered) 
were acquired with a Zeiss FF-series camera (Carl Zeiss AG). The AREDS was approved 
by an independent institutional review board at each clinical center.
The follow-up interval for RS and BMES was 5 years. The AREDS had follow-ups at 
6-month intervals, although the typical interval between available CFIs was 1 year. The 
BMES, RS and AREDS all adhered to the tenets of the Declaration of Helsinki, and all 
participants provided informed consent.
A total of 504 CFIs of patients diagnosed with AMD and signs of GA were included from 
the BMES and RS sets. Twenty-six images with mixed signs of AMD (neovascularization, 
bleedings, scars) were excluded to disambiguate overlapping areas. Furthermore, no 
GA was delineated in 43 images because it was either not present or ungradable, and 
26 images were excluded because of poor image quality. The remaining 409 images 
were included for development of the model and evaluation of its performance. This set 
contained 87 images from the BMES (26 participants, 43 eyes) and 322 images from the 
RS (149 participants, 195 eyes). The 409 images represent 315 unique visits (some visits 
had 2 CFIs available).
Images for the study of GA progression were selected from the AREDS set, following the 
grading available from the database of genotype and phenotype 2014 table. Inclusion 
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criteria were presence of GA or central GA, and at least 2 years of follow-up. Images with 
neovascular disease co-occurring with GA were excluded. A total of 3589 images of 376 
eyes were included. Most of these images were stereoscopic, so this accounted for 1826 
unique acquisitions (eye-visit). Pixel-to-millimeter conversion was fixed for all images, 
based on the average distance between fovea and center of the optic disc measured in 
a subset of the images. This distance was assumed to be 4.5mm.39
Delineations of GA area were made by 4 graders (3 of them with more than 20 years 
of experience), using an in-house created software platform for manual annotations 
(https://www.a-eyeresearch.nl/software/ophthalmology_workstation/).40 For the  RS, 
additional multimodal imaging (infrared, FAF, OCT or a combination thereof) was 
available for some of the visits, and the platform allowed images of the same eye (both 
multimodal and longitudinal) to be aligned manually by identifying corresponding 
landmarks. The graders could view images of the same eye simultaneously using 
a synchronized cursor on multiple screens. Geographic atrophy was identified as the 
absence of the retinal pigment epithelium and increased visibility of the choriocapillaris 
on CFIs. Additional evidence from other methods was used whenever available. Areas of 
macular and peripapillary atrophy were delineated as separate classes, but for this study 
only macular GA was used.
Each grader annotated the entire BMES set, whereas the RS set was divided in such a 
way that each grader annotated approximately half of the entire set and every image 
was graded by at least 2 graders. Finally, a consensus grading was made for all images 
in both sets. During the consensus grading, all graders decided together which of the 
individual gradings was most accurate and updated this grading, if necessary, until 
consensus was reached. If 2 CFIs of the same visit were present, both were included 
for model development, and the delineated GA area was propagated from one image 
to the other by using the affine transformation calculated from the manual landmarks. 
For evaluation, only the CFI that was used to make the consensus grading was used. 
Additionally, for external validation of the model, we randomly selected 100 CFIs from 
100 participants in the subset of AREDS images that contain GA (including 32 CFIs with 
co-occurring neovascular lesions). A single grader delineated the GA area in all of these 
images, whereas an additional 2 graders delineated GA in 50 of the 100 selected CFIs.
Deep Learning Model
The proposed deep learning model for GA segmentation consisted of an ensemble of 
several models, each trained with partly overlapping training sets. The network architecture 
(the topology of connections between internal parameters of the deep learning model) 
for each model consisted of a deep encoder-decoder structure with residual blocks and 
shortcut connections, similar to that of De Fauw et al,41 but adapted to work with CFIs. 
150421-colijn-layout.indd   76 17/03/2021   17:41
77
GEOGRAPHIC ATROPHY
This architecture, and its variations, can be characterized by a contracting path in which 
the high-resolution input image is converted to a low-resolution abstract representation, 
followed by an expanding path in which the original resolution is reconstructed. The 
contracting and expanding path are connected by shortcut connections. This approach 
has been shown to be very effective for semantic segmentation in medical imaging for 
which large contextual information is required.17,42
Input to each model was both the original color (RGB) image and a contrast-enhanced 
version of the same image, both resampled to 512x512 pixels. The contrast-enhanced 
image was obtained by subtracting a blurred image from the original image.43 The input 
was transformed through the many layers of artificial neurons in the contracting and 
expanding path and ultimately yielded a new image in which the value of every pixel 
represented a likelihood of being part of an area of GA. A schematic overview of the 
model can be found in Figure 1. More details about the model and the training procedure 
used for this study can be found in the Appendix (available at www.aaojournal.org).
Figure 1. Schematic overview of the model. On the left, the preprocessed input: a 512x512 color image (RGB) 
and a contrast enhanced (CE) version. In the middle, the model, with the downsampling path (orange arrows), 
upsampling path (green arrows), and shortcut connections (gray arrows). The ensemble model combines multiple 
outputs into a single binary image. The geographic atrophy (GA) area in the chosen example is intentionally 
ambiguous to highlight how the ensemble handles differences in predicted GA between the individual models.




For the development and validation of the model, we applied a 5-fold cross-validation 
scheme. Data from BMES and RS were merged into 1 dataset and split randomly at 
patient level into 5 approximately equal folds. In a rotating scheme, 4 folds were used for 
model training and validation (development set), whereas the remaining fold was used for 
performance evaluation (test set). Furthermore, 4 separate models were created within 
each development set. Each model used 3 folds for tuning of the internal parameters 
(training) and 1 for validation. An ensemble of these 4 models was then evaluated on 
the respective test set. The output of the ensemble model was obtained by taking the 
average output of the individual models for every pixel, after correcting for differences in 
sensitivity between models. This procedure is explained in more detail in the Appendix 
(available at www.aaojournal.org). Ultimately, an ensemble of the 20 obtained models (4 
models developed for each of the 5 rounds) constituted the final model. Performance of 
this model was validated on the selection of 100 CFIs from the AREDS set.
The performance of the model and the agreement between graders were assessed using 
the Dice coefficient, which is defined as 2 times the intersection of 2 areas divided by the 
sum of the individual areas. Hence, a value of 0 represents disjoint areas (no overlap), 
whereas a value of 1 represents perfect agreement. Dice coefficients were calculated 
between graders to assess the inter-observer agreement, whereas the areas delineated 
in the consensus grading were used as reference for the model. Note that the consensus 
grading was not independent of the individual gradings, and therefore could not be used 
as a reference to estimate graders' performances. Furthermore, intra-class correlation 
coefficient of the GA area and of the square root of the GA area were used to measure 
agreement between graders and the model.
Geographic Atrophy Growth Rate
The final deep learning model (the ensemble of 20 models) was applied to CFIs from 
AREDS for the analysis of GA progression. It is well documented that GA area increases 
faster for larger lesions. To remove the dependency of baseline lesion size on growth 
rate, many researchers apply a square root transformation to the GA area.28 Similarly, 
we calculated the square root annual growth in millimeters per year for each eye to 
assess progression in the AREDS set.39 This value was obtained from the slope of a linear 
regression through the square root of the GA area for a selected set of timepoints. The 
selected set consisted of all available CFIs within a window of 2 years for which the 
number of available CFIs was highest for the respective eye. The window was limited 
at 2 years because growth rate and lesion characteristics may change over time.25 We 
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calculated the correlation of square root annual growth rate between fellow eyes, and 
compared growth rate between groups using an unpaired t test for unilateral versus 
bilateral cases, unifocal versus multifocal cases, and foveal versus extrafoveal cases.
To identify structural characteristics or features that may be predictive for growth rate, we 
built a linear model based on features that were extracted from the segmented GA area 
at baseline (the first image within the selected window). Candidate features were area, 
perimeter, convex area, filled area, convex solidity (area divided by convex area), filled 
area (area divided by filled area), number of lesions, eccentricity, circularity, roundness 
and foveal involvement. Details on how these features were calculated can be found in 
the Appendix (available at www.aaojournal.org). Associations between individual features 
and square root annual growth rate were calculated using univariate linear regression. 
Because the features were not independent, a multivariate linear model was created to 
investigate further which features best explain variation in square root annual growth rate. 
The multivariate model was built using forward selection by iteratively adding the feature 
that yielded the highest increase in adjusted R² value, until it increased no further. When 
stereoscopic images were available, lesion characteristics were represented by the 
mean of the 2 calculated values. To obtain a more homogeneous set for the prediction 
model, we discarded images in which the relative difference in GA area between the left 
and right stereoscopic image was more than 50%, and included only eyes with at least 2 
years of follow-up images.
Finally, we combined all estimates of GA growth in a single figure. Geographic atrophy 
growth in square millimeters per year (not square root transformed) was estimated as a 
function of GA area, again using a linear regression for each eye through the GA area in a 
window of 2 years. This resulted in an estimate of GA growth (the slope of the regression), 
bounded by a minimum and maximum GA area. The estimated general GA growth for 
a given GA area was then represented by the mean of all growth estimates for which 




The deep learning model reached a Dice coefficient of 0.72 ± 0.26 (n=315), measured in 
cross-validation in the BMES and RS data sets, where each test fold was evaluated by 
the ensemble of 4 models. Dice coefficients between 2 independent graders ranged 
from 0.72 ± 0.26 to 0.82 ± 0.21 (0.78 ± 0.24 on average). See Table 1 for more details. The 
intraclass correlation coefficient between the model and the consensus was 0.83 for GA 
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area and 0.84 for the square root of the GA area. Consistency in those values is visualized 
further in Figure 2 using Bland-Altman plots. The mean value of the differences between 
consensus and model did not differ significantly from 0 on the basis of a 1-sample t test 
for either GA area (P=0.82) or square root GA area (P=0.22). Examples of manually and 
automatically segmented GA areas can be found in Figure 3.
The average Dice coefficient on the AREDS set was 0.66 ± 0.27 (n=50) for the model, 
compared with 0.73 ± 0.24 (grader 1) and 0.73 ± 0.27 (grader 2). The intraclass correlation 
coefficient between the model and the reference grader was 0.77 for GA area and 0.80 
for the square root of the GA area (n=100). The mean value of the differences between 
reference and model did not differ significantly from 0 on the basis of a 1-sample t 
test for either GA area (P=0.59) or square root GA area (P=0.54). Examples of automatic 
segmentation results on the AREDS set can be found in Figure S1 (available at www.
aaojournal.org).
Table 1. Dice Coefficients between Model and Consensus Grading and between Individual Graders.
N Dice coefficient
Model – Consensus 315 0.72 ± 0.26
Grader 1 – Grader 2 146 0.80 ± 0.27
Grader 1 – Grader 3 138 0.78 ± 0.27
Grader 1 – Grader 4 90 0.72 ± 0.26
Grader 2 – Grader 3 91 0.82 ± 0.21
Grader 2 – Grader 4 134 0.78 ± 0.22
Grader 3 – Grader 4 130 0.78 ± 0.19
Figure 2. Bland-Altman plot showing (A) geographic atrophy area an (B) square root GA area. Differences are 
calculated as the area or the square root area of the consensus grading minus he automatic segmentation. SD = 
standard deviation.
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Figure 3. Images showing examples of automatic geographic atrophy (GA) segmentation. The green area 
corresponds to either the consensus (left) or the model output (right). The top 3 rows show accurate segmentation 
results for various configurations of GA differing in area, shape and number of lesions and variable image quality 
and contrast. The bottom row shows examples of inaccurate model output.
Geographic Atrophy Growth Rate
After excluding visits at which the difference between left and right stereoscopic images 
in the automatically segmented area was more than 50%, 335 of the 376 eyes in the 
AREDS with at least 2 years of follow-up remained. Square root annual growth of GA for 
those eyes was 0.25 ± 0.40 mm/year. This value was significantly higher for eyes with 
small (<5 mm2) baseline GA area (0.31 ± 0.34mm/year; n=194), compared with eyes with 
large (≥ 5mm2) baseline GA area (0.16 ± 0.46mm/year; n=141; P<0.001). Table 2 shows 
differences in growth rate between groups. We observed that multifocal and extrafoveal 
lesions grow faster than unifocal or foveal lesions. Patients with bilateral GA showed 
faster progression than patients with unilateral GA, although this was not significant in 
our analysis (P=0.58). Growth rates between fellow eyes were correlated (r=0.58; P<0.001). 
Figure 4 highlights progression of GA for selected individual eyes.
Correlations between baseline lesion characteristic and square root annual growth are 
summarized in Table 3. Nine out of 11 features were significantly correlated with GA 
growth rate (after Bonferroni correction). Correlations for the subset with baseline lesions 
size smaller than 12 mm2 are analyzed in Table 4. Features included in the multivariate 
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model were area, circularity, convex area, eccentricity, foveal involvement and number 
of lesions. The coefficient of determination of this model was 0.18. A visualization that 
summarizes growth over time for all eyes with GA in the AREDS set can be found in 
Figure 5. The red dashed line in these graphs represent a quadratic model that best fitted 
the data for GA area of less than 12 mm2.
Figure 4. Graphs and images showing progression of geographic atrophy (GA) over time for 4 selected eyes. The 
graphs represent area measurements over time (2 points per timepoint for the left and right stereoscopic images). 
The blue line is a quadratic fit through the points. For the top 2 cases, an increment in growth rate can be observed: 
53834 left eye (LE) shows a more irregular shape than 51551 right eye (RE) and progressed faster. In the bottom 
2 cases, we observe that the growth decreased as the GA area increased. 
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Table 2. Square Root Annual Growth of the Geographic Atrophy Area.
Square root annual growth (mm/year)
All Small (<5mm2) Large (≥5mm2)
Overall 0.25 ± 0.40 (n=335) 0.31 ± 0.34 (n=194) 0.16 ± 0.46 (n=141)
Unifocal 0.22 ± 0.39 (n=251) 0.28 ± 0.33 (n=142) 0.14 ± 0.44 (n=109)
Multifocal 0.33 ± 0.43 (n=84) 0.39 ± 0.35 (n=52) 0.23 ± 0.52 (n=32)
P value 0.028 0.039 0.339
Foveal 0.21 ± 0.41 (n=258) 0.27 ± 0.31 (n=120) 0.16 ± 0.47 (n=138)
Extrafoveal 0.36 ± 0.36 (n=77) 0.37 ± 0.37 (n=74) 0.14 ± 0.17 (n=3)
P value 0.006 0.066 0.934
Unilateral 0.21 ± 0.32 (n=41) 0.23 ± 0.30 (n=29) 0.15 ± 0.36 (n=12)
Bilateral 0.25 ± 0.41 (n=128) 0.29 ± 0.34 (n=72) 0.19 ± 0.48 (n=56)
P value 0.58 0.446 0.76
Values represent mean ± standard deviation. P values are calculated using an unpaired t test.
Table 3. Correlations between Baseline Lesion Characteristics (Features) and Square Root Annual Growth Rate (in 
Millimeters per Year). 
Feature R2 Value Slope Intercept R Value P Value
Standard 
Error
Area 0.101 -0.015 0.351 -0.318 <0.001 0.002
Filled area 0.100 -0.015 0.351 -0.316 <0.001 0.002
Convex area 0.081 -0.012 0.347 -0.285 <0.001 0.002
Convex 
solidity
0.078 -0.743 0.849 -0.279 <0.001 0.140
Eccentricity 0.073 0.647 -0.167 0.271 <0.001 0.126
Roundness 0.073 -0.697 0.723 -0.270 <0.001 0.136
Foveal 
involvement
0.050 -2.950 0.370 -0.225 <0.001 0.701
Perimeter 0.029 -0.007 0.336 -0.170 0.002 0.002
Circularity 0.025 -0.282 0.384 -0.159 0.004 0.096
No. of lesions 0.024 0.078 0.130 0.154 0.005* 0.027
Filled solidity 0.001 0.646 -0.396 0.025 0.649* 1.419
Features are sorted in decreasing order of strength of association. A P value of less than 0.0045 (0.05, Bonferroni 
corrected) was considered significant. * Not significant
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Table 4. Correlations between Baseline Lesion Characteristics (Features) and Square Root Annual Growth Rate (in 
Millimeter per year) for Baseline Lesion Size less than 12mm2.
Feature R2 Value Slope Intercept R value P value Standard error
Convex solidity 0.076 -0.553 0.741 -0.276 <0.001 0.117
Circularity 0.066 -0.365 0.486 -0.258 <0.001 0.083
Roundness 0.060 -0.491 0.628 -0.245 <0.001 0.118
Eccentricity 0.055 0.446 0.005 0.234 <0.001 0.113
Foveal 
involvement
0.032 -1.858 0.368 -0.179 0.003 0.621
No. of lesions 0.031 0.076 0.188 0.175 0.004 0.026
Perimeter 0.007 0.005 0.252 0.086 0.156* 0.003
Area 0.001 -0.004 0.312 -0.034 0.574* 0.007
Filled area 0.001 -0.004 0.312 -0.034 0.580* 0.006
Convex area 0.001 0.002 0.289 0.026 0.671* 0.005
Filled solidity 0.000 0.091 0.209 0.004 0.948* 1.380
Features are sorted in decreasing order of strength of association. A P value of less than 0.0045 (0.05, Bonferroni 
corrected) was considered significant. * Not significant
Figure 5. Graphs showing geographic atrophy (GA) growth over time. A, Geographic atrophy growth rate (in 
square millimeters per year) as a function of GA area. The blue line represents growth rates estimated from the 
segmentations of the deep learning model. The shaded area represents the 95% confidence interval (estimated 
using bootstrapping). The dashed red line represents the growth rate of a quadratic model, as visualized in (B). B, 
Blue line represents the evolution of GA area over time, obtained by numerically integrating the estimated growth 
rates from (A) using a GA area of 0.5 mm2 at t=0. The red dashed line represents the best quadratic fit to the plot for 
GA area of less than 12 mm2. Above this area, the observed GA area diverges from the quadratic fit.




A deep-learning model for segmentation of GA in CFIs was developed and evaluated. 
We demonstrated how the automatically obtained segmentations of the model can 
be used to study growth rate of GA on an independent set and reproduced several 
previously reported associations with growth rate. The model can also be applied to 
datasets for which GA measurements are not yet available, providing a fast alternative 
to manual delineation. 
The performance of the deep learning model in terms of Dice coefficient on the BMES 
and RS set approached that of human experts. The model was able to identify GA 
even when image quality or contrast were relatively poor, as demonstrated in Figure 3. 
Nevertheless, some failure cases remained, which was the main reason for the lower 
average Dice coefficient. We suspect that more training data may solve this issue, 
because each of the models used only 60% of the data (approximately 245 images) for 
training, which may not be enough given the inherent difficulty of the problem and the 
variability in the data. For application to the AREDS set, this problem was circumvented 
partly by using an ensemble model, which indirectly made use of all training data.
Generalization ability of the model to the AREDS set was assessed on a subset of 50 CFIs. 
We separately analyzed the performance of the model for cases of pure GA and mixed 
late AMD, with co-occurring neovascular lesions (Table 5). Performance on the pure GA 
cases, in terms of Dice coefficient, was comparable with that on the BMES and RS set 
(0.71 ± 0.26 versus 0.72 ± 0.26). However, performance on mixed cases was significantly 
worse, as was agreement between graders. Hence, these cases were not included in the 
analysis of GA growth. We did not observe any bias in the automatic assessment of GA 
area or square root GA area. 
Table 5. Dice Coefficients on the 50 Images Selected from the Age-Related Eye Disease Study Dataset for the 
Model and 2 Graders Compared with the Reference Grader
All (n=50)
Pure Geographic 
Atrophy (n=30) Mix (n=20)
Model 0.66±0.27 0.71±0.26 0.59±0.27
Grader 2 0.73±0.24 0.78±0.22 0.64±0.25
Grader 3 0.73±0.27 0.81±0.21 0.61±0.31
The obtained mean square root annual growth rate on the AREDS set (0.25 ± 0.40 mm/
year) was slightly lower than previously reported values. For example, Domalpally et al.31 
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observed 0.30 mm/year, and Keenan et al.44 observed 0.28 mm/year. A reason for this 
may be the dependence of growth rate on baseline area. When we split the dataset on 
baseline lesion size, we observed that small lesions have larger square root growth rates 
(Table 2). This phenomenon was analyzed in more detail in Figure 5. A quadratic curve 
seemed to fit the observed GA progression very well up to an area of approximately 
12 mm2. For larger areas, the growth rate seemed to stabilize or even decrease, whereas 
the variability between patients also increased. Similar observations were made by 
Keenan et al.44, whose reported values are included in Figure 5 for comparison.
The importance of baseline area for assessing growth rate also became apparent in 
the regression analysis, where area, filled area, and convex area were correlated most 
strongly with square root annual growth rate. However, when we included only lesions 
with baseline area of less than 12mm2 in the regression analysis, no features related to 
lesion size were significantly associated with square root annual growth rate (Table 4). On 
an individual level, we also observed a quadratic growth of the area of GA in many cases 
in the AREDS set, some of them highlighted in Figure 4, in which we fitted a quadratic 
curve through the GA area over time. Again, the decrease in growth rate for larger lesions 
was visible (bottom 2 cases in Figure 4).
Of the features that are invariant to lesion size, convex solidity was associated most 
significantly with square root annual growth rate. Convex solidity is low for irregularly 
shaped lesions, but also for multifocal lesions. Hence, this feature captures multiple 
previously reported associations. Of note, the association of square root annual growth 
rate with circularity was much stronger in the subset of images with baseline area of 
less than 12mm². We observed that the average value for circularity of large lesions (≥ 
12mm²) was significantly lower: 0.40 ± 0.19, versus 0.51 ± 0.23 for small lesions (P < 0.001). 
For large lesions in particular, the model may have produced a segmentation with a very 
jagged border for lesions with indistinct borders of the atrophic area. This could have 
led to a relatively large perimeter and hence a lower value for circularity. In those cases, 
roundness will be a better representation of how well the lesion approaches a circular 
shape, because it represents the ratio of the area of an enclosing circle and the area of 
the lesion and hence is less sensitive to irregular borders.45 Indeed, contrary to circularity, 
roundness was significantly higher for large lesions (≥ 12mm2): 0.76 ± 0.10 versus 0.67 ± 
0.16 for small lesions (P< 0.001).
The multivariate model, which included 6 features related to the baseline shape and size 
of the GA area, was able to explain 18% of the variation in square root annual growth rate. 
It is unclear how much of the actual variation is explainable, because there may be factors 
influencing the growth rate that are not expressed in the image, such as genetics46, and 
possibly lifestyle or environmental factors. Moreover, inclusion of follow-up information 
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or lesion patterns around the border of the GA area may improve the model further, 
because those have been previously demonstrated to contain additional information 
and those are not captured by the presented multivariate model.12 The  model also 
does not take into account nonlinear interactions between features. Finally, errors in the 
automatically segmented GA may have resulted in inaccuracies, both in the estimation 
of the features and in the estimation of square root annual growth rate. Therefore, to 
be expected that in future work, building a model that captures more of the observed 
variation in growth rate will be achievable.
A limitation of our study is that the conversion from pixels to millimeters may have been 
inaccurate. This conversion was based on the average distance between fovea and optic 
disk in a subset of images. Although it is unlikely that this inaccuracy was a source for bias 
in reported associations with growth rate, reported values for area and growth rate may 
be slightly larger or smaller in reality.
Furthermore, direct application of the model in a setting where small errors are 
detrimental, such as clinical trials with GA area or progression rates as the end point, is 
currently beyond reach. The model may still fail in some cases, and additionally, color 
fundus imaging may not be the main method for assessment of GA in such a setting, 
where OCT and FAF are preferred. Nevertheless, the output of the model could still be 
valuable as a secondary measurement for identification of cases that may need further 
adjudication.13,26
In the future, we will extend the model to other methods, specifically FAF and OCT. This 
may give more accurate measurements of the atrophic area and hence more reliable 
assessment of growth rate. In this study, only morphologic features of the atrophic area 
were considered. A next step would be to include associations between growth rate and 
other lesions patterns, especially those visible on FAF or OCT. Finally, we are investigating 
the capabilities of deep learning models to predict directly areas where GA may develop. 
This will provide predictions of both the extent and location of future GA area.
In conclusion, we have presented and validated a robust segmentation model based on 
deep learning for GA on CFIs. The model was capable of reproducing known associations 
between current GA status and future growth. Moreover, we indicated novel structural 
biomarkers that are predictive for future growth rate, such as solidity, eccentricity or 
roundness of the lesion. We demonstrated how deep learning can help in the automation 
of grading, allowing for analysis of larger datasets and helping to understand progression 
of GA.
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Purpose: Genome-wide association studies and targeted sequencing studies of 
candidate genes have identified common and rare variants that are associated with age-
related macular degeneration (AMD). Whole-exome sequencing (WES) studies allow a 
more comprehensive analysis of rare coding variants across all genes of the genome 
and will contribute to a better understanding of the underlying disease mechanisms. 
To date, the number of WES studies in AMD case-control cohorts remains scarce and 
sample sizes are limited. To scrutinize the role of rare protein-altering variants in AMD 
cause, we performed the largest WES study in AMD to date in a large European cohort 
consisting of 1125 AMD patients and 1361 control participants. 
Design: Genome-wide case-control association study of WES data.
Participants: One thousand one hundred twenty-five AMD patients and 1361 control 
participants.
Method: A single variant association test of WES data was performed to detect variants 
that are associated individually with AMD. The cumulative effect of multiple rare variants 
with 1 gene was analyzed using a gene-based CMC burden test. Immunohistochemistry 
was performed to determine the localization of the Col8a1 protein in mouse eyes.
Main outcome measures: Genetic variants associated with AMD. 
Results: We detected significantly more rare protein-altering variants in the COL8A1 
gene in patients (22/2250 alleles [1.0%]) than in control participants (11/2722 alleles [0.4%]; 
P=7.07x10-5). The association of rare variants in the COL8A1 gene is independent of the 
common intergenic variant (rs140647181) near the COL8A1 gene, previously associated 
with AMD. We demonstrated that the Col8a1 protein localizes at Bruch’s membrane. 
Conclusions: This study supported a role for protein-altering variants in the COL8A1 gene 
in AMD pathogenesis. We demonstrated the presence of Col8a1 in Bruch’s membrane, 
further supporting the role of COL8A1 variants in AMD pathogenesis. Protein-altering 
variants in COL8A1 may alter the integrity of Bruch’s membrane, contributing to the 
accumulation of drusen and the development of AMD.




Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss 
among persons older than 50 years in the developed world1,2. The disease is characterized 
by progressive damage to the retinal pigment epithelium and photoreceptors in the 
macula, ultimately leading to visual impairment and blindness. In the early stages of AMD, 
a spectrum of changes occur, including hypopigmentations and hyperpigmentations of 
the retina and the formation of extracellular deposits (drusen) in Bruch’s membrane2. 
These drusen increase in size and number during the intermediate stages. Two types of 
AMD can develop in the end stage of the disease. Geographic atrophy (GA), also referred 
to as the dry form, is characterized by retinal pigment epithelium cell atrophy, causing 
photoreceptor cell death. Choroidal neovascularization (CNV), also called the wet form 
of AMD, is characterized by the formation of new blood vessels, leading to leakage, 
hemorrhages and sudden loss of vision.
Age-related macular degeneration is a multifactorial disease influenced by a variety 
of environmental factors, including age, smoking history, and sunlight exposure 
during working life3,4. There is a large genetic component to the cause of AMD, with 
an estimated heritability between 46% to 71%.5 Initially, genetic studies in AMD mainly 
focused on common variants in the population through genome-wide association studies 
(GWAS) using single nucleotide polymorphism (SNP) microarrays6–9. These studies 
identified genetic variants in or near genes belonging to 4 main pathways, including the 
complement system, lipoprotein metabolism, angiogenesis, and extracellular matrix 
remodeling. However, most common genetic variants identified by GWAS are located in 
noncoding or intergenic regions, and subsequently it is not always apparent which gene 
near the top-associated SNP is the causative gene.
Involvement of genes in a disease can be established further by identification of 
protein-altering variants in the coding regions, which are often rare in the population8. 
Thus, several studies focused on the discovery of rare variants by sequencing genes in 
AMD loci. In these studies, rare variants were identified in complement factor H (CFH), 
complement factor I (CFI), complement C3 (C3) and complement C9 (C9)10–14 that are 
associated individually with AMD. Recently, a GWAS performed by the International AMD 
Genomics Consortium using an exome array enriched with rare variants identified 52 
AMD-associated variants at 34 genomic loci. Of these 52 variants, 7 variants were rare 
and 45 variants were common8. 
Testing the association of individual rare variants can be challenging, because very large 
sample sizes are needed to obtain sufficient power15. Instead of testing each variant 
individually, gene-based burden tests can evaluate the cumulative effects of multiple 
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genetic variants within a gene, leading to an increased study power.16 Sequence analysis 
of the coding regions of 681 genes within AMD-associated loci in 1676 AMD patients 
and 745 control participants identified a higher burden of rare variants in CFI in patients 
(7.8%) than in control participants (2.3%)12,17,18. Furthermore, evaluation of the cumulative 
effect of rare protein-altering variants, using exome array data by the International AMD 
Genomics Consortium, identified a significant burden in 4 AMD-associated genes: CFH, 
CFI, tissue inhibitor of metalloproteinases 3 (TIMP3) and solute carrier family 16 member 
8 (SLC16A8)8. A limitation of these studies is that either rare variants in a limited set of 
genes12 or a limited number of rare variants across the genome8 were tested. 
Whole-exome sequencing (WES) studies allow a more comprehensive analysis of rare 
protein-altering variants across all genes of the genome19. To date, the number of WES 
studies in AMD case-control cohorts remain few and sample sizes are limited. Whole-
exome sequencing of 213 neovascular AMD patients and 1553 healthy control participants 
from East Asian populations showed association of a variant in ubiquitin protein ligase 
E3D (UBE3D) with AMD20. More recently, WES of 39 individuals with bilateral CNV with 
low genetic risk scores and 36 unaffected control participants with high genetic risk did 
not detect any genes that reached genome-wide significance21.
The main goal of the present study was the identification of rare protein-altering variants 
that are associated with AMD. To achieve this goal, we performed WES in a large 
European cohort consisting of 1125 patients and 1361 control participants to scrutinize the 
role of coding variants across the human genome in the cause of AMD.
METHODS
Study Population
A cohort of 2516 individuals of European ancestry (1493 women and 1023 men with a mean 
age of 79 years) was recruited from the European Genetic Database (www.eugenda.
org; n=799) and the Rotterdam Study (n=1717). From the European Genetic Database, 
667 AMD patients (488 patients with late AMD) and 132 healthy control participants 
were evaluated for this study. Inclusion of individuals took place between December 
2005 and June 2014. All participants underwent clinical evaluation by a retinal specialist 
and were graded for AMD according to the Cologne Image Reading Center protocol22. 
Fundus photographs and spectral-domain OCT images were used to classify AMD by 
the presence of pigmentary changes together with at least 10 small drusen (<63-µm 
diameter) or the presence of intermediate drusen (63-124-µm diameter) or large drusen 
(≥125-µm diameter) in the Early Treatment Diabetic Retinopathy Study grid. Furthermore, 
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late AMD was defined as either AMD with subfoveal GA or CNV in at least 1 eye. Control 
individuals were included in the study when they exhibited no signs of AMD in either 
eye and were at least 65 years of age at inclusion.
The design of the Rotterdam Study has been described previously in detail23,24. This 
prospective, population-based follow-up study started in 1990 and has follow-up visits 
every 5 years. For this analysis, we included a total of 466 AMD patients (74 patients with 
late AMD) and 1269 control participants from the Rotterdam Study I subcohort 55 years 
of age and older with WES data. All participants underwent fundus photography of the 
macula using a 35° film fundus camera (Topcon TRV-50VT; Topcon Global Gateway, 
Tokyo, Japan) after pupillary dilation. For the last 2 follow-up visits, a Topcon digital 35° 
color fundus camera (Topcon TRC 50EX; with a Sony DXC-950P 0.44 megapixel digital 
camera; Sony Corporation, Minato, Japan) was used. Fundus photographs were graded 
according to the Rotterdam Classification, which is based on the Wisconsin Age-Related 
Maculopathy Grading System25 and the modified International Classification System26. 
Patients were participants with early or late AMD, which is at least soft distinct drusen 
(≥63-µm diameter), in combination with hypopigmentary or hyperpigmentary changes or 
soft indistinct drusen (≥ 125-μm diameter) or reticular drusen. Control participants were 
those older than 65 years with no signs of AMD or those older than 75 years of age with 
hard or soft distinct drusen (≥63-µm diameter) or pigmentary abnormalities. 
In both cohorts, both eyes of all participants were graded separately by experienced 
graders (T.S.), who were under the supervision of senior retinal specialists (P.T.V.M.dJ., 
J.R.V., C.C.W.K, and S.F.). The worst affected eye was used to classify the individual. 
Written informed consent was obtained from all participants. The study was approved 
by the local ethics committees on research involving human subjects of the participating 
centers, and all procedures were conducted according to the tenets of the Declaration 
of Helsinki. The Rotterdam Study was approved by the Medical Ethics Committee of 
the Erasmus Medical Center and by the Ministry of Health, Welfare and Sport of the 
Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies 
Act: Rotterdam Study).
Whole-Exome Sequencing Capture and Variant Calling
Genomic DNA of all participants was isolated from blood samples according to standard 
procedures. DNA was fragmented into 200 to 400-bp fragments, and the exome library 
was prepared on a Caliper Sciclone NGS workstation (Caliper Life Science, Hopkinton, 
MA). The exome was captured with the Nimblegen SeqCap EZ Exome version 2.0 44-Mb 
kit (Roche Nimblegen, Inc., Madison, WI), covering 329 028 exons and 710 miRNAs. Paired-
end sequencing was performed on 2 Illumina HiSeq2000 sequencers using Illumina 
TruSeq V3 chemistry (Illumina, Inc., San Diego, CA). High-quality reads were mapped to 
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the UCSC hg19 reference genome using the Burrows-Wheeler alignment tool27. Variant 
calling was performed by Genome Analysis ToolKit (GATK) HaplotypeCaller, following 
the GATK best practice guidelines (available at https://software.broadinstitute.org/
gatk; accessed July 2016). Single nucleotide variants and indels were filtered separately 
using GATKs Variant-Quality Score Recalibration module. Variants with a variant quality 
score log-odds (VQSLOD) score lower than -7.2 were removed. Variant annotation was 
done using annotate variation (ANNOVAR)28 and an in-house pipeline developed by the 
Department of Human Genetics of the Radboud University Medical Center29. Functional 
effects of variants were predicted by 3 different prediction algorithms: Sorting Tolerant 
From Intolerant (SIFT)30, PolyPhen-231, and Combined Annotation Dependent Depletion 
(CADD)32 (threshold of deleteriousness for CADD, ≥ 20). In addition, conservation of 
candidate variants was estimated by PhyloP (threshold for deleteriousness, ≥2.7) and 
Grantham (threshold for deleteriousness, ≥ 80).
Data Quality Control
Stringent quality control steps were performed with PLINK version 1.0733 to exclude those 
positions that had high chances of being false positive results. Variants were removed 
according to the following criteria: (1) genotypes with a missing rate of more than 5% 
of individuals and (2) common variants (minor allele frequency, >0.05) that were not in 
Hardy-Weinberg equilibrium in control participants. After these quality control steps, a 
total of 744 022 variants were available for analysis. Subject-level quality control was 
carried out, excluding individuals with a call rate less than 95% or an extreme inbreeding 
coefficient (cutoff, ± 0.12)34. Pairwise identity by descent was calculated to confirm the 
lack of relatedness among all samples (PI-HAT, <0.25). A multi-dimensional scaling was 
performed with PLINK version 1.07 to obtain the principal components, which were used 
to confirm that all individuals were clustered as European samples and to correct for 
population stratification (Fig S1; available at www.aaojournal.org). After all quality controls, 
a cohort of 1125 AMD patients and 1361 control participants was selected for association 
analyses.
Statistical Analyses
A single variant association test was carried out with RAREMETALWORKER (available 
at http://genome.sph.umich.edu/wiki/RAREMETALWORKER; accessed January  2017) 
using a linear mixed model. This software performs a score statistics-based rare-
variant association analysis, providing single-variant results and a variance-covariance 
matrix. Linkage disequilibrium relationships between markers within 1 Mb are stored 
in the covariance matrix to perform the gene-level analyses. Analysis was performed 
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using an additive model controlling for age, gender, clinic, and the first 4 components. 
Genome-wide significance levels used for single-variant analysis were defined based on 
Bonferroni correction (P ≤ 5x10-8).
By definition, single-variant analyses have limited power to detect rare variant 
associations, especially for limited sample sizes. Association power was increased by 
evaluating the accumulated association of multiple rare exonic variants within each 
gene35. Gene-based burden tests were carried out by RAREMETAL36 using the summary 
statistics and linkage disequilibrium matrices generated in the single-variant analysis. 
Three different methods were used: the Combined Multivariate and Collapsing (CMC) 
counts and Variable Thresholds tests, which are burden tests that assume all alleles to 
influence the association in the same direction, and the sequence kernel association test 
(SKAT) test, which evaluates risk and protective alleles to maximize power. A subset of 
308 784 rare protein-altering variants (minor allele frequency <0.05) were used in the 
analysis, to avoid the major presence of non-protein-altering variants (n=435 238) diluting 
the burden because of deleterious variants. We selected rare variants that alter amino 
acid residues (nonsynonymous variants), truncate proteins (nonsense and stop-gain 
variants), or affect RNA splicing (variants affecting the invariate splice donor and splice 
acceptor sites). 
First, we focused on the 34 previously reported AMD loci and we applied a Bonferroni-
corrected significance threshold based on the 619 genes located within 500 kb of the 
top-associated SNP in each of the AMD loci (according to8) and carrying at least 1 rare 
protein-altering variant (P < 0.05/619 = 8.07x10-5). Haploview37 was used to reconstruct 
the region of interest to validate that the rare Collagen Type VIII Alpha 1 Chain (COL8A1) 
variants belong to different haplotype blocks than the common risk variant rs140647181 
identified in a previous single-variant test8. In a secondary analysis, we extended the 
search of rare variant burden to all genes across the genome, applying a Bonferroni-
corrected significance threshold of 0.05/17 596 = 2.84x10-6. Quantile-quantile plots of 
P values from single-variant analysis and gene-based tests were generated to discard 
any batch effect or population substructure.
Characterization of Phenotypic Features of COL8A1 Variant Carriers
Phenotypic characterization was performed including participants from the Rotterdam 
Study. Age-related macular degeneration features were based on the eye with the most 
severe phenotype. Glaucoma-related features were the mean of both eyes at the last 
visit during follow-up. Refraction was based on the mean spherical equivalent of both 
eyes at the last visit during follow-up, or the last visit before cataract extraction. Statistical 
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significance was tested with an independent sample t test for continuous variables, a 
chi-squared or Fisher exact test for dichotomous variables, and a Mann-Whitney U test 
for drusen area because of its nonnormal distribution. All tests performed were 2-sided. 
Mouse Retina Staining 
Eyes from P60 C57BL/6J wild-type mice were enucleated and embedded in Tissue-Tek 
O.C.T. Compound (4583, Sakura Finetek, Alphen aan den Rijn, the Netherlands). Seven-
micrometer sections were dried for 1 hour at room temperature. Using the hydrophobic 
PAP pen (Z377821-1EA, Sigma-Aldrich, St. Louis, MO), a circle was drawn surrounding 
the sections. Retinas were then incubated for 20 minutes in phosphate-buffered saline 
(PBS) 0.05% Tween (8.22184.0500, Merk millipore, Burlington, MA) and 0.05% Triton X-100 
(9002-93-1, Sigma Aldrich) at room temperature. After blocking in 0.1% ovo albumin 
(A4344,0250, AppliChem GmbH, Darmstadt, Germany), 0.5% fish gelatine (G7041-100G, 
Sigma-Aldrich) and 5% bovine serum albumin (A7906-100G, Sigma Aldrich) in PBS for 
30 minutes, primary antibodies were added and incubated overnight at 4°C. Primary 
antibodies used included rabbit polyclonal anticollagen type VIII a 1 (1:50; HPA053107, 
Sigma-Aldrich) and rat monoclonal Laminin β-1 (1:50; MA5-14657, ThermoFisher Scientific, 
Waltham, MA). Retinas were washed 4x5 minutes in PBS and incubated with the goat 
antirabbit Alexa 568 (1:500; A11006, Life technologies, Carlsbad, CA) and goat antirat 
Alexa 488 secondary antibody (1:500; A11006, Life technologies) for 45 minutes at room 
temperature (dilution 1:500 in blocking solution). Nuclei staining with 4,’6-diamidino-2-
phenylindole (1:8000, 0100-20, I.T.K. Diagnostics B.V., Uithoorn, the Netherlands) was 
combined with the secondary antibody incubation. Sections then were washed 4x5 
minutes in PBS, rinsed in MilliQ-purified water, and mounted in Prolong Gold anti-fade 
reagent (P36930, Life technologies). Imaging was performed using a Zeiss Z1 Imager. All 
images were obtained at the same intensity. An image with ZEN software was created to 
obtain TIFF or JPEG files.
RESULTS
Whole Exome Sequencing
We performed WES on 2516 unrelated individuals (1125 patients and 1361 control 
participants), obtaining an average of 2.8 billion bases per individual and a mean coverage 
of x63. After variant calling and recalibration, a total of 759 450 variants were identified, 
being 754 503 single nucleotide variants and 4947 insertions or deletions (indels). Of 
the complete set of variants, 7.6% (n=57 571) were common variants, and the remaining 
92.4% (n=701 879) were classified as rare variants with a minor allele frequency of less 
than 0.05. Genotype data obtained from WES were checked for concordance with the 
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genotype data of a customized Illumina exome array8, available for a subset of the study 
population (n=1330). Variants genotyped by both WES and exome array (n=80 779) had a 
concordance rate of more than 99%, demonstrating the high quality of our sequencing 
data and the high accuracy of our genotype calling.
Single Variant and Gene-Based Association Analyses
We first performed a genome-wide single-variant association analysis for individual 
common and rare variants using the WES data of 1125 AMD patients and 1361 control 
participants of European ancestry. Results confirmed association of variants in the CFH 
and Age-Related Maculopathy Susceptibility 2 (ARMS2) genes with AMD in this cohort8. 
Two common coding variants in CFH (rs1061170 [P=4.24x10-11] and rs1061147 [P=3.30x10-10]) 
and 1 common variant in ARMS2 (rs10490924 [P=1.89x10-9]) were associated with AMD 
above the threshold of genome-wide significance (P ≤ 5x10-8; see Figs S2 and S3, available 
at www.aaojournal.org). 
Subsequently, we evaluated the burden of rare protein-altering variants in genes at 
previously identified AMD loci using gene-based burden tests. For this analysis 619 
genes were selected that are within 500 kb of the top-associated SNP at 34 AMD loci 
identified in a recent GWAS8 (Table S1; available at www.aaojournal.org). A CMC burden 
test (applying genomic control λ = 0.940) showed a significant burden of rare variants in 
the COL8A1 gene (P=7.07x10-5; Fig 1).
We then expanded the burden analysis to protein-altering variants across the genome. 
The CMC burden test (applying genomic control λ = 1.057) showed a suggestive association 
in the KBTBD12 (P=3.50x10-6) and ZNF787 (P=2.89x10-5) genes, but these associations did 
not reach the genome-wide significance level (Fig 1). The signal at the KBTBD12 gene 
did reach the genome-wide significance threshold when the SKAT test was applied 
(P=4.45x10-7). In both tests, the association signal was mainly driven by the effect of 1 
rare variant (rs148151101; P=1.52x10-6). However, this particular variant in KBTBD12 was not 
associated with AMD in an exome array analysis in a cohort of 16 144 AMD patients and 
17 832 control participants of European ancestry by the International AMD Genomics 
Consortium (P=0.387)8.
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Figure 1. Gene-based burden test for rare variants using whole-exome sequencing data of 1125 AMD age-related 
macular degeneration (AMD) patients and 1361 control participants of European ancestry. The blue line indicates 
the significance threshold (P< 0.05/619 = 8.07x10-5) for testing 619 genes located in or near AMD-associated loci. 
The COL8A1 gene reaches the significance threshold, and is depicted in blue. The red line indicates the genome-
wide significant threshold (P< 0.05/17 596 = 2.84x10-6) for genes outside the AMD-associated loci. The KBTBD12 and 
ZNF787 genes do not reach genome-wide significance and are depicted in red. Bonferroni correction was applied 
to both significance thresholds.
Rare Variant Burden in the COL8A1 Gene
We next determined whether the rare variant burden in COL8A1 is independent of the 
previously identified AMD-associated common variant (rs140647181) near the COL8A1 
gene8. This common variant is intergenic, located 560 kb downstream of DCBLD2 and 
177 kb upstream of COL8A1. To evaluate the independence between the rare protein-
altering variants and the common intergenic variant rs140647181 , we reconstructed the 
haplotype block structure at the COL8A1 locus to visualize which regions of the gene 
are linked closely and are inherited together. Several recombination events between 
the rare protein-altering variants in the COL8A1 gene and rs140647181 were observed, 
meaning that the region containing the rare variants is not inherited together with the 
region containing the common intergenic variant (Fig 2). These results support that the 
rare variant burden observed in this study is independent of the common intergenic 
variant previously associated with AMD. 
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Figure 2. Haploblock structure of the genomic region encompassing the COL8A1 gene and the age-related 
macular degeneration-associated common intergenic variant rs140647181. A Haploview plot was generated based 
on common single nucleotide variants extracted from the 1000 Genomes phase 3 dataset. Red triangles marked 
with black lines represent genomic regions that are closely linked and are inherited together. This haplotype block 
distribution shows that the rare protein-altering variants identified in the COL8A1 gene (indicated with an asterisk) 
are not located in the same haplotype block as rs140647181, meaning that the rare variants are not inherited 
together with the common intergenic variant. This supports that the rare variant burden in COL8A1 is independent 
of the common intergenic variant rs140647181.
The COL8A1 burden is explained by 14 rare protein-altering variants spread across the 
protein (Fig 3), which are found more often in patients (22/2250 alleles [1.0%]) than in 
control participants (11/2722 alleles [0.4%]; Table 1; Table S2, available at www.aaojournal.
org). Six variants, including 1 nonsense variant (p.G414*) and 5 missense variants (p.M70T, 
p.A96V, p.E520K, p.G711E, p.M744I), were identified only in patients, but not in control 
participants, and 5 additional variants (p.R225Q, p.A250V, p.R362Q, p.G695D and p.L741F) 
were found at a higher frequency in patients than in control participants. The nonsense 
variant p.G414* is predicted to lead to a premature termination in the COL1 domain, or may 
cause nonsense-mediated decay of the COL8A1 mRNA. Two missense variants (p.G695D 
and p.G711E) are predicted to be deleterious with all conservation and pathogenicity 
tests used and have a CADD score of 20 or more, which classifies them among the top 
0.75% most deleterious mutations that are found in the human genome (Table 1). The 2 
missense variants p.G695D and p.G711E affect 2 highly conserved amino acid residues in 
the noncollagenous 1 domain (Fig 3).
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Figure 3. Location and conservation of protein-coding variants in COL8A1. A, Location of rare protein-altering 
variants identified in age-related macular degeneration (AMD) patients and control participants in the different 
COL8A1 domains: triple-helical region (COL1), noncollagenous domain 1 (NC1) and noncollagenous domain 2 (NC2). 
Variants detected only in control individuals are depicted in gray. B, Alignment of COL8A1 protein sequences 
of different species. Boxed missense variants identified in AMD patients, predicted to be deleterious in all 
conservation and pathogenicity tests (Table 1), affect highly conserved glycine residues in the NC1 domain. 
Phenotypic Features of COL8A1 Variant Carriers
We examined the effect of the COL8A1 variants on the AMD phenotype in participants 
from the Rotterdam Study only, because it is a population-based cohort study without 
prior selection on phenotype. This group consists of 16 AMD patients carrying a COL8A1 
variant, 11 individuals carrying a COL8A1 variant without AMD, and 450 AMD patients 
without a COL8A1 variant (Table 2). Features of early AMD were not significantly different 
between COL8A1 carriers and noncarriers with AMD, although COL8A1 carriers had a 
somewhat higher proportion of hyperpigmentary changes (P=0.062). No statistically 
significant differences were found for glaucoma-related features such as intraocular 
pressure and vertical cup-disc ratio. The groups differed significantly in spherical 
equivalent; with COL8A1 carriers being more myopic (P=0.005). However, there was no 
significant difference in the proportion of participants with mild and severe myopia. 
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Table 2. Comparison of Phenotypic Features between Carriers and Noncarriers of COL8A1 variants in the 
Rotterdam Study
Protein Change












Age at last visit (yrs) 79.6 (SD, 6.3) 82.5 (SD, 7.9) 80.0 (SD, 6.5)
Spherical equivalent -0.37 (SD, 1.86)* 1.14 (SD, 1.83) 1.26 (SD, 2.29)*
Mild myopia (-3 to -6D; %) 3/16 (19) 1/11 (9) 23/437 (5)
Severe myopia (≤-6D; %) 0/16 (0) 0/11 (0) 2/437 (0)
Corneal curvature (mm) 7.72 (SD, 0.32) 7.58 (SD, 0.26) 7.70 (SD, 0.26)
IOP (mmHg) 13.8 (SD, 3.0) 14.3 (SD, 2.8) 13.9 (SD, 3.3)
VCDR 0.36 (SD, 0.18) 0.37 (SD, 0.24) 0.32 (SD, 0.18)
Subtype of AMD (no.) 3 GA, 0 CNV, 0 
mixed†, 13 early
- 29 GA, 21 CNV, 21 
mixed†, 379 early
Drusen area >10% (%) 4/16 (25) 0/11 (0) 88/450 (20)
Presence of 
hyperpigmentation (%)
14/16 (88) 1/11 (9) 287/450 (64)
Presence of reticular 
drusen (%)
0/16 (0) 0/11 (0) 27/450 (6)
Presence of drusen 
outside grid (%)
10/16 (63) 7/11 (64) Not available
AMD = age-related macular degeneration; CNV = choroidal neovascularization (wet AMD); D = diopters; GA = 
geographic atrophy (dry AMD); IOP = intraocular pressure; SD = standard deviation; VCDR = vertical cup-to-disc ratio. 
*P=0.005 independent samples t test (2-tailed) between AMD patients carrying a COL8A1 variant (n=16) and AMD 
patients without variants in COL8A1 (n=437), t=2.81, degrees of freedom, 451. †Geographic atrophy and CNV.
Localization of COL8A1 to Bruch’s Membrane
Localization of COL8A1 in the retina has not yet been described in the literature. To 
assess whether COL8A1 is localized at Bruch’s membrane, the main AMD disease site, 
we performed immunohistochemistry on retinas of wild-type C57BL/6J adult mice. 
Mice were selected for these experiments because mouse and human retinas exhibit a 
common basic architecture38 and are often used to model human retinal disease, although 
mice lack a macula, and have a higher photoreceptor cell density and a relatively thicker 
Bruch’s membrane in the central retina39. Laminin β-1 was used as a marker for Bruch’s 
membrane40. The coimmunostaining of Laminin β-1 and Col8a1 robustly demonstrated 
that both proteins localize at Bruch’s membrane (Fig 4). In addition, Col8a1 showed some 
expression in the photoreceptor layer, being most evident at the outer plexiform layer, 
the synaptic region between the photoreceptor cells, and the inner nuclear layer cells. 
To exclude that the staining was the result of background staining derived from the use 
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of secondary antibodies, we performed the same procedure without adding primary 
antibody (Fig S4, available at www.aaojournal.org). This confirmed that the Col8a1 and 
Laminin β-1 staining observed at Bruch’s membrane is the result of the primary antibody.
Figure 4. Localization of Col8a1 in mouse retinas. A, The localization of Col8a1 (in red) was studied on P90 retinas 
derived from wild-type C57BL/6J mice. Laminin β-1 (Lamb1; green) was used as a Bruch’s membrane marker. 
Col8a1 colocalizes with Lamb1 at Bruch’s membrane. Col8a1 staining also showed a weaker signal in other 
layers of the retina. B, Magnifications of the outer region of the retina, where the colocalization between Lamb1 
and Col8a1 can be appreciated. DAPI (4’,6-diamidino-2-phenylindole) (blue) was used to stain cell nuclei. BM= 
Bruch’s membrane; GCL=ganglion cell layer; INL=inner nuclear layer, IPL=inner plexiform layer; IS=inner segment; 
ONL=outer nuclear layer; OPL=outer plexiform layer; OS=outer segment; RPE=retinal pigment epithelium




In this study, we aimed to scrutinize the role of rare protein-altering variants in the cause 
of AMD using WES. By focusing on rare protein-altering variants in the coding regions, 
we sought to determine the causality of genes in the disease. Because most top SNPs 
identified in GWAS studies for AMD are in noncoding or intergenic regions8, it is not always 
apparent which gene near the top-associated SNP is the causative gene. In this study, 
WES analysis in 1125 AMD patients and 1361 control participants revealed a significant 
burden of rare protein-altering variants in the COL8A1 gene in AMD. The COL8A1 burden 
is explained by 14 rare protein-altering variants spread across the protein, which are 
found more often in patients (22/2250 alleles [1.0%]) than in control participants (11/2722 
alleles [0.4%]). The association of rare variants in the COL8A1 gene is independent of the 
common AMD-associated intergenic variant rs140647181, located 560 kb downstream of 
DCBLD2 and 177 kb upstream of COL8A18. No rare-variant burden was observed in the 
DCBLD2 gene, nor in other genes at the same AMD locus. Taken together, these findings 
support that the previously observed association of the common intergenic variant 
rs140647181 is driven by effects on COL8A1 rather than by other genes at the locus. 
COL8A1 encodes 1 of the 2 a chains of collagen type VIII, which is a major component 
of ocular basement membranes41. Several studies have investigated the association 
between alterations in genes encoding the 2 subunits of collagen VIII (COL8A1 and 
COL8A2) and ocular abnormalities such as myopic CNV, anterior segment dysgenesis 
and thin corneal stroma42-45. Although several studies postulated a role for COL8A1 in 
ocular basement membranes, so far no published data confirmed the localization of 
COL8A1 in Bruch’s membrane. There are several lines of evidence to support that Bruch’s 
membrane plays a crucial role in AMD. Because of its location, Bruch’s membrane is 
involved intensively in the exchange of numerous biomolecules, nutrients and waste 
products between the retinal pigment epithelium and the choroidal capillary bed46. A 
disturbed integrity or stability of Bruch’s membrane can lead to accumulation of these 
products in drusen, or can weaken the physical barrier against the invasion of new blood 
vessels into the retina47. In this study, we demonstrate the presence of Col8a1 in Bruch’s 
membrane, further supporting the role of COL8A1 variants in AMD pathogenesis48. 
Protein-altering variants in COL8A1 may lead to structural alterations in Bruch’s membrane, 
which can be responsible for the development of AMD43. Interestingly, we describe 14 
rare protein-altering variants in COL8A1, including 1 nonsense variant (p.G414*), and 2 
deleterious missense variants (p.G695D and p.G711E) that affect highly conserved residues 
in the C-terminal noncollagenous 1 domain. The noncollagenous 1 domain mediates 
proper folding of the protein and the assembly of collagen VIII and X into polygonal 
lattices49-51. Therefore, these COL8A1 variants may lead to an aberrantly folded protein, 
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impairing transport of the protein to Bruch’s membrane or altering Bruch’s membrane 
integrity or stability. Consequently, this may contribute to the development of early AMD. 
In our study, we observed a higher, albeit nonsignificant, proportion of hyperpigmentary 
changes in AMD patients carrying COL8A1 variants. Larger patient populations are 
needed to validate this finding. Previous studies have implicated COL8A1 in retinal 
angiogenesis by mediating proliferation and migration of endothelial cells43, suggesting 
that COL8A1 variants could contribute to the development of neovascularization in late 
AMD. In the Rotterdam Study, we identified 3 COL8A1 carriers with GA, but no carriers 
who developed CNV (Table 2). However, in the European Genetic Database cohort, we 
identified 1 carrier with GA, 3 carriers with CNV, and 2 carriers with the mixed type of 
AMD with GA and CNV (data not shown). Therefore, we cannot conclude that there is an 
overrepresentation of CNV in carriers of COL8A1 variants. Interestingly, COL8A1 variants 
seem to contribute to refractive error, although the contribution to severe myopic errors 
was insignificant. In the Rotterdam Study the refractive error is, on average, emmetropic 
in AMD cases carrying COL8A1 variants. Therefore, it is unlikely that myopic thinning of 
Bruch’s membrane contributed to the development of AMD in these carriers.
The findings described herein need to be interpreted in light of several strengths and 
limitations. We demonstrated that WES with relatively large cohorts is an efficient 
strategy to detect rare variants in AMD-associated genes. Previous studies that detected 
rare variants in AMD were focused on predefined gene-sets using targeted sequencing12 
or predefined variant-sets using exome arrays8, whereas our study performed a 
comprehensive exome-wide search for rare variants using WES. The main advantage 
of performing WES is that it enables the identification of all rare variants present in 
coding regions across the genome, allowing a more comprehensive evaluation of rare 
variants than other approaches based on a limited set of genes or variants. A burden 
of rare variants has been described previously in CFH, CFI, TIMP3 and SLC16A88,12, but 
these findings were not confirmed in our study. This may be because although we had 
a relatively large cohort, our study may not have had sufficient power to detect these 
associations. In the study by Fritsche et al.8, a larger cohort was used, consisting of 16 
144 AMD patients and 17 832 control participants. However, most of the COL8A1 variants 
(11/14) identified by WES in our study were not present on the exome array that was 
used by Fritsche et al., which may explain why a burden of rare COL8A1 variants was not 
observed in that study8. In addition, differences in study designs and populations, case 
definition, geographical origin, statistical tests used, or correction for confounding factors 
may explain the different results observed among these studies. 
In conclusion, we performed an exome-wide sequence analysis of rare protein-altering 
variants in AMD and we detected a burden of rare variants in the COL8A1 gene. A 
common intergenic variant near this gene was associated previously with AMD risk7,8, but 
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no protein-altering variants within the gene have been described in AMD so far. This work 
supports a role for protein-altering variants in the COL8A1 gene in AMD pathogenesis 
and suggests that the previously observed association of the common intergenic variant 
is driven by effects on COL8A1. In this study, we demonstrate the presence of Col8a1 in 
Bruch’s membrane, further supporting the role of COL8A1 variants in AMD pathogenesis. 
Protein-altering variants in COL8A1 may alter the integrity of Bruch’s membrane, 
contributing to the accumulation of drusen and the development of AMD. This study 
showed that WES provides a fruitful approach for gene and variant identification in 
complex disorders such as AMD. Collaborative efforts among the scientific community 
are needed to perform even larger exome- or genome-wide sequencing studies52 that 
will increase our understanding of the genetic architecture and disease mechanisms of 
AMD further.
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Purpose: Age-related macular degeneration (AMD) is a common multifactorial disease 
in the elderly with a prominent genetic basis. Many risk variants have been identified, 
but the interpretation remains challenging. We investigated the genetic distribution of 
AMD-associated risk variants in a large European consortium, calculated attributable 
and pathway-specific genetic risks, and assessed the influence of lifestyle on genetic 
outcomes.
Design: Pooled analysis of cross-sectional data from the European Eye Epidemiology 
Consortium.
Participants: Seventeen thousand one hundred seventy-four individuals, 45 years of age 
or older participating in 6 population-based cohort studies, 2 clinic-based studies, and 1 
case-control study.
Methods: Age-related macular degeneration was diagnosed and graded based on 
fundus photographs. Data on genetics, lifestyle, and diet were harmonized. Minor allele 
frequencies and population attributable fraction (PAF) were calculated. A total genetic 
risk score (GRS) and pathway-specific risk scores (complement, lipid, extra-cellular 
matrix, other) were constructed based on the dosage of SNPs and conditional β values; 
a lifestyle score was constructed based on smoking and diet.
Main Outcome Measures: Intermediate and late AMD.
Results: The risk variants with the largest difference between late AMD patients and 
control participants and the highest PAFs were located in ARMS2 (rs3750846) and CHF 
(rs570618 and rs10922109). Combining all genetic variants, the total genetic risk score 
ranged from -3.50 to 4.63 and increased with AMD severity. Of the late AMD patients, 
1581 of 1777 (89%) showed a positive total GRS. The complement pathway and ARMS2 
were by far the most prominent genetic pathways contributing to late AMD (positive 
GRS, 90% of patients with late disease), but risk in 3 pathways was most frequent (35% 
of patients with late disease). Lifestyle was a strong determinant of the outcome in each 
genetic risk category; unfavorable lifestyle increased the risk of late AMD at least 2-fold.
Conclusions: Genetic risk variants contribute to late AMD in most patients. However, 
lifestyle factors have a strong influence on the outcome of genetic risk and should be 
a strong focus in patient management. Genetic risks in ARMS2 and the complement 
pathway are present in most late AMD patients but are mostly combined with risks in 
other pathways. 




Age-related macular degeneration (AMD) is a progressive degenerative disease of the 
retina and the most important cause of blindness in the Western world. Projections show 
that in up to 4.8 million Europeans and up to 18.6 million persons worldwide, a blinding 
stage of AMD will develop by 20401, 2. Age-related macular degeneration is classified into 
2 end stages: a more common wet form characterized by choroidal neovascularization 
(CNV) and a dry form characterized by geographic atrophy (GA) of the retinal pigment 
epithelium3. Only the wet form can be treated with anti-vascular endothelial growth 
factor agents, but visual decline remains inevitable in the long term4.
Age-related macular degeneration is a complex genetic disease influenced strongly by 
a combination of environmental and genetic factors. In particular, smoking and diet are 
known to increase the risk of AMD considerably. The genetic cause is well established: 
52 common, known AMD-associated variants and more than 100 rare variants have been 
reported5, 6. These variants explain most of the disease causes and helped to pinpoint 
several pathogenic pathways. Of these, the complement cascade seemed to be most 
important, but the first attempts to target this pathway in intervention trials have achieved 
limited success7, 8. This raises the question whether disease pathways are specific to 
groups of individuals. If this is the case, intervention trials may be more successful by 
stratifying patients based on the major disease pathway driving their disease. 
In this study, we aimed to investigate the contribution of genetic variants to AMD risk 
in Europe using data from the large European Eye Epidemiology (E3) Consortium. We 
aimed to determine the contribution of each disease pathway in AMD and investigated 
whether lifestyle changes can reduce the risk of late AMD, in particular in individuals with 
a high genetic risk of AMD. 
METHODS
Study Population:
The E3 Consortium is a European collaboration of studies with epidemiologic data on 
common eye disorders; a detailed description on the consortium can be found elsewhere9. 
All data on AMD were harmonized and collected in the EYE-RISK database (version 6.0). 
Nine studies from France, Germany, The Netherlands, and Portugal produced data on 
AMD genotype and phenotype available for analysis and were enrolled as a pooled 
dataset in the current study. The cohort descriptions of the included studies are listed 
in the Appendix (available at www.aaojournal.org). The Combined Ophthalmic Research 
Rotterdam Biobank (CORRBI), Muenster Aging and Retina Study (MARS), and the 
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European Genetic Database (EUGENDA) were clinic-based studies, and the remaining 
studies were population based (the Rotterdam Study I, II and III; Antioxidants, Essential 
Lipids, Nutrition and Ocular Diseases-three cities (Alienor-3C), Maculopathy Optic 
Nerve nuTRition neurovAsCular and HEarT diseases-three cities (Montrachet-3C); and 
the Coimbra Eye Study (CES)). Persons 45 years of age and older were included in the 
analyses; various analyses included only control participants 75 years of age or older. 
All studies were performed in accordance with the tenets of the Declaration of Helsinki 
for research involving human subjects and good epidemiologic practice guidelines, and 
written informed consent was obtained from all participants. 
Clinical Examination:
The phenotype of AMD was determined on fundus photographs centered on the macula; 
individuals received the diagnosis of the worst eye. Age-related macular degeneration 
features were graded locally by clinicians or experienced graders; classifications were 
grouped into 3 severity groups. Control participants did not display AMD, aside from 
only small drusen or only pigment irregularities; persons with early or intermediate AMD 
showed soft indistinct (large) drusen, reticular drusen, or both, with or without pigmentary 
irregularities, and further were considered to have intermediate AMD; persons with late 
AMD had GA or CNV; persons with both end stages were diagnosed as having CNV. 
Lifestyle factors including smoking and dietary habits were assessed by questionnaire. 
Genetic Analyses and Risk Scores
Age-related macular degeneration genetic risk variants were ascertained from the EYE-
RISK and E3 database5, 9. Studies had used various platforms to determine the 52 known 
risk variants, such as whole-exome sequencing, exome chip (Illumina HumanExome 
BeadChip), genomic single-nucleotide polymorphism (SNP) arrays (Illumina 550K [duo] 
chip or Illumina 610 quad), or TaqMan assays, and a custom-made AMD genotyping 
platform using single-molecule molecular inversion probes (smMIPs) with next-
generation sequencing; for the EYE-RISK genotype assay10, see cohort descriptions. If 
variants had been determined by multiple methods that included direct genotyping, we 
used data from the latter method. When no direct genotyping was available, genotypes 
were dosages derived from Haplotype Reference Consortium imputation or 1000G. 
Three (rs71507014, rs67538026, rs142450006) of the 52 known AMD risk variants could not 
be included in our analysis because genotypes were not available for multiple cohorts. 
Genetic risk scores (GRS) were calculated for the 17 174 individuals for whom the five 
major risk variants (CFH rs10922109, CFH rs570618, C2 rs429608, C3 rs2230199, and 
ARMS2 rs3750846) were available. Complete genotype data on minor risk alleles were 
available in 62.3% persons; 85.1% individuals had 47 of 49 variants. Genetic risk scores 
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were calculated by multiplying the conditional β value of the AMD risk variant5 with the 
allele dosage. Subsequently, all calculations were summed. Pathway-specific GRSs 
were constructed in the same manner. For the complement GRS, we included all risk 
variants in the CFH, CFI, C9, C2, TMEM97/VTN, and C3 genes. For the lipid GRS, variants 
in ABCA1, LIPC, CETP, and APOE were included. For the extracellular matrix (ECM) GRS, 
variants in COL4A3, ADAMTS9-AS2, COL8A1, VEGFA, and SYN3/TIMP3 were included. 
The remaining variants were included in ‘other’ GRS. The function of ARMS2 mostly 
was considered unsettled. However, because recent evidence suggests a role in the 
complement pathway11, we analyzed this gene as a stand-alone pathway GRS as well as 
part of the complement pathway GRS.
Lifestyle Score
Four well-established AMD lifestyle determinants (smoking status and servings of 
vegetables, fruit and fish per day) were assessed by questionnaire. Smoking status was 
categorized as no, former, or current smoker. Dietary intakes were analyzed in medium 
servings per day with a maximum of 1, that is, 120 g of vegetables per day, 120 g of fruit 
per day, and 100 g of fish per day. β coefficients for associations with late AMD were 
calculated by multivariate logistic regression, were multiplied by determinant values, 
and were summed to create a lifestyle risk score. Lifestyle risk scores were stratified into 
tertiles as an unfavorable, intermediate, or favorable lifestyle.
Statistical analysis
The population-attributable fraction (PAF) was calculated for each variant using the 
formula of Miettinen et al.12: PAF = Pc x ((OR−1)/OR), where OR is the odds ratio and Pc is the 
proportion of exposed patients among the patients. The pooled dataset formed the basis 
for all analysis. We calculated the discriminative accuracy between late AMD patients 
and control participants for our model of genetic factors using Saddle Point Signature 
software version 2.8.3 (Saddle Point Science, Ltd., Worcester Park, United Kingdom) in a 
batch multivariate regression analysis. Results were cross-validated by the leave-one-
out principle. Prediction performance at each iteration was quantified by counting errors 
of persons assigned to the wrong category (control participants or patients). The dataset 
was fully balanced between control participants and patients; the regression equations 
corresponded to a pseudo-dataset, in which the outcome classes were equal in size, 
but the other statistical features were identical to the true dataset. Missing values were 
not set to 0, but rather imputed to the mean. Covariates were selected based on error 
expectation minimization. 
Where appropriate, comparisons were made with Pearson chi-square test, Jonckheere-
Terpstra test for ordered alternatives, or independent-sample t test. Interaction of genetic 
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and lifestyle risk was assessed by a univariate analysis of variance. Graphical outputs 
were constructed with GraphPad Prism 5 version 7.00 for Windows software (GraphPad 
Software, La Jolla, CA). Histograms and a receiver operator characteristic curve were 
constructed with SPSS Statistics for Windows version 25.0 (IBM Corp). 
RESULTS 
We identified a total of 17 174 individuals 45 years of age and older with data on genetics 
and AMD: 13 324 persons without AMD, 2073 persons with intermediate AMD, and 1777 
persons with late AMD. Of the persons with late AMD, 309 demonstrated GA, and 1468 
demonstrated CNV. Age ranged from 45 to 101 years old with a mean of 68.7 years 
(standard deviation [SD], 10.4), the proportion of women was 58.5%, the proportion of 
current smokers was 16.8% (n=2888), and the proportion of former smokers was 39.5% 
(n=6786). For risk calculations, we aimed to ensure a true phenotype of no AMD and 
therefore included only control participants 75 years of age or older (n=3167) in these 
analyses. The proportion of women in this subset (control participants 75 years of age 
or older and patients with intermediate or late AMD) was 61.3%, the proportion of current 
smokers was 9% (n=630), and the proportion of former smokers was 36.2% (n=2541). 
Single Variants
First, we focused on frequency distributions of the 49 single risk variants in the 3 
phenotype groups and ranked variants according to frequency differences between late 
and no AMD (Fig 1A). Single-nucleotide polymorphisms from the complement pathway 
and ARMS2 showed the largest difference in frequency between patients and control 
participants (rs10922109, rs61818925 and rs570618 [CFH]; rs429608 [C2]; rs2230199 [C3]; 
and rs3750846 [ARMS2]). Among the first 10 variants, 5 variants showed a lower frequency 
among patients, corresponding to a protective effect on AMD. Next, we calculated the 
PAF for each single variant. The ARMS2 variant rs3750846 was associated with a large 
PAF (0.3) for late AMD, whereas variants in CFH exhibited both the largest PAF (0.33 for 
rs570618) and the largest inverse PAF (-0.37 for rs10922109; Fig 1B). A similar pattern with 
smaller PAFs was observed for intermediate AMD. Only variant rs11080055 in TMEM97/
VTN showed a higher PAF for intermediate (0.063) than for late (0.024) AMD. Only 4 late 
AMD patients (0.2% [4/1777]) did not carry any of the 5 major risk SNPs, compared with 33 
control participants (1% [33/3167]).
Genetic Risk Score for Age-Related Macular Degeneration
We subsequently combined all genetic variants in a GRS and assessed its distribution. In 
the population-based cohort studies (n= 13 194), the score ranged from -3.50 to 4.63 (mean, 
0.40; SD, 1.24) and showed a normal distribution (Fig 2A). With respect to the distribution 
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per phenotype, the GRS in control participants ranged from -3.03 to 3.94 (mean 0.26; SD, 
1.16), that in intermediate AMD patients ranged from -3.11 to 4.71 (mean, 0.83; SD, 1.33), 
and in late AMD patients ranged from -3.00 to 6.23 (mean, 1.64; SD, 1.32; Fig 2B). Although 
the lowest GRS value was similar for all phenotypes, the entire distribution showed a 
significant increase with increasing AMD severity (P<0.0001, Jonckheere-Terpstra test for 
ordered alternatives). When stratifying late AMD into GA and CNV, slightly higher scores 
were noted for CNV (Fig 2C) that for GA ranged from -2.72 to 4.87 (mean, 1.46; SD, 1.41) 
and that for CNV ranged from -3.00 to 6.23 (mean, 1.67; SD, 1.30; P=0.01, independent-
sample t test). We estimated the discriminative accuracy of a score based on the 49 
AMD-associated genetic variants (Figs S3 and S4, available at www.aaojournal.org) for 
identification of late AMD; the area under the receiver operating characteristic curve was 
0.838. We identified a minimal set of variants by using the leave-one-out principle and 
found an almost identical area under the receiver operating characteristic curve (0.837) 
when including 27 AMD-associated variants (score is available in the Supplemental 
Appendix, available at www.aaojournal.org).
Genetic Risk Scores per Pathway
Next, we constructed pathway-specific GRSs for the complement, lipids, ECM, ARMS2 
and ‘other’ pathways. The complement pathway score ranged from -3.15 to 3.64 in the 
population-based studies, and 55% of participants scored more than 0 for this pathway. 
The ARMS2 score ranged from 0 to 2.15 because only 1 risk variant determines this score. 
The lipid pathway showed a GRS ranging from -1.44 to 0.49, and the ECM pathway 
showed a GRS ranging from -0.92 to 1.46, and 36% and 33%, respectively, showed a 
score of more than 0. The pathway ‘other’ ranged from -1.06 to 1.45, and 61% showed a 
positive score. 
The distribution of all pathway GRSs in our total study population showed a positive 
shift with increasing AMD severity (P<0.0001, Jonckheere-Terpstra test for ordered 
alternatives; Table S1, available at www.aaojournal.org; Fig 5), but the complement and 
ARMS2 GRS demonstrated the largest increase for late AMD, especially when combined 
(shift of mean GRS from 0.39 to 1.59).
Frequency of positive Genetic Risk Score 
We studied the proportion of individuals with a positive (>0) GRS for each of the pathways, 
because this indicates more genetic risk than protection from that particular pathway. 
Positive GRSs for all pathways were most frequent in late AMD (Fig 6). Positive GRSs 
for the complement and ‘other’ pathways were most prevalent in all phenotypes. The 
largest increase per phenotype severity was found for the complement and ARMS2 
pathways; the proportion of persons with positive GRSs in the complement pathway rose 






Figure 2. A. Bar graph showing the distribution of the total age-related macular degeneration (AMD) genetic risk 
score (GRS) in the European population. B. Bar graph showing distributions of the total AMD GRS: (top panel) 
control participants (age, ≥75 years), (middle panel) intermediate AMD, and (bottom panel) late AMD. C. Bar graphs 
showing the distributions of the total AMD GRS: (left panel; light blue) frequency of geographic atrophy (GA) for 
each total AMD GRS and (right panel; green) frequency of choroidal neovascularization (CNV) for each total AMD 
GRS, both on a log scale. 
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from 51% in control participants to 77% (a 26% increase) in late AMD patients, and that for 
the ARMS2 pathway rose from 35% in control participants to 65% (30% increase) in late 






Figure 5. Bar graphs showing the distributions of the genetic risk scores for the complement (A), lipids (B), extra-
cellular matrix (C), ARMS2 (D) and 'other' pathway (E) and the complement with ARMS2 combined pathways (F) in 
control participants and late age-related macular degeneration (AMD) patients. 
Not one pathway GRS was more than 0 in all late AMD patients, but 90% showed a 
positive GRS for the combination of complement and ARMS2 pathways. On closer 
inspection of the remaining 10% (n=152), these late AMD patients did carry risk alleles 
in these 2 pathways but showed a high frequency of protective variants that resulted 
in a GRS of less than 0 (Table S2, available at www.aaojournal.org). Subsequently, we 
examined the risk SNPs in greater detail by investigating the proportion of persons with 
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at least 1 risk allele per pathway (Fig S7, available at www.aaojournal.org). Ninety-nine 
percent of persons with late AMD showed a risk SNP in either the complement or ‘other’ 
pathway, but this was also the case for control participants. For the ARMS2, lipid, and 

















































Figure 6. Bar graph showing the percentage of individuals with a positive genetic risk score for each of the pathways. 
Dark blue, control participants 75 years of age or older; light blue, intermediate age-related macular degeneration 
(AMD) patients; green, late AMD patients. The asterisk (*) indicated statistical differences in a Pearson chi-square 
test (2-sided) with P<0.0001; P<0.0028 with Bonferroni correction for multiple testing. ECM = extracellular matrix. 
The next question we addressed for each pathway was this: Can late AMD develop 
without a risk variant in this pathway? For some pathways, this was rare: 0.7% (12/1777) of 
late AMD patients for the complement pathway and 1.5% (26/1777) of late AMD patients 
for the ‘other’ pathway. For the ARMS2, lipids, and ECM pathways, these fractions were 
higher (34.8%, 6.1%, and 19.6%, respectively). When combining the complement and 
ARMS2 pathways, only 5 late AMD patients (0.3%) showed no risk allele in this pathway. 
Next, we calculated the distribution of pathways with a GRS of more than 0 (Fig 8). Most 
participants showed 2 to 4 pathways with a GRS of more than 0 (85%). A small proportion 
(7%) of individuals showed a GRS in only 1 pathway of more than 0, and an even smaller 
proportion (1% [n=23]) of individuals showed a GRS of 0 or less for all pathways. 
Combining Genetics with Lifestyle
Data on lifestyle factors were available for a subset of the study population (n=3525). 
In these participants, we investigated the AMD lifestyle factors of smoking and dietary 
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intake of vegetables, fruit, and fish. Patients more often were current smokers (OR, 1.39) 
and consumed fewer vegetables (OR, 0.40), less fruit (OR, 0.35), and less fish (OR, 0.17; 
P<0.0001 for all; Table S3, available at www.aaojournal.org). We composed a lifestyle score 
based on these variables and stratified the score into tertiles: favorable, intermediate, 
and unfavorable lifestyle. For each GRS category (also tertiles), we observed that the 
more unfavorable the lifestyle, the higher the risk of late AMD. Lifestyle increased the 
risk 2 to 2.3 times depending on the genetic risk. In the highest genetic risk group, the OR 
increased from 14.9 to 35.0 in individuals with an unfavorable lifestyle (Fig 9). 
DISCUSSION
This study provides a comprehensive interpretation of AMD genetic risk in the European 
population. The risk allele most discriminative between late AMD patients and control 
participants was located in ARMS2, closely followed by a risk-increasing and a protective 
allele in CFH. We observed a normal distribution of AMD-associated GRS, with variants 
increasing disease risk, but also a significant number offering protection against AMD. 
Patients with late AMD showed higher GRSs than control participants. Mathematically, 
we showed that the genetic contribution of the complement pathway and ARMS2 to late 
AMD was at least 90%. However, most patients carried genetic risk in multiple pathways, 
signifying the complex cause of AMD. All persons benefitted from a healthy lifestyle, but 
those with a high GRS showed the strongest risk reduction. This highlights the possibilities 
to counteracting predicted disease outcomes with lifestyle choices. 
Our results need to be seen in light of the strengths and limitations of this study. An 
important strength was the very large number of Europeans included in this study. From 
the E3 Consortium, we included 9 studies with genetic data, that is, population studies 
from The Netherlands, France, and Portugal, as well as case-control studies from The 
Netherlands and Germany. Data were harmonized and entered into a single database, 
which allowed us to perform in-depth analyses on combinations of phenotype, genotype, 
and lifestyle factors in the pooled dataset. Grouping genes into pathways and calculating 
pathway-specific genetic susceptibility enabled us to study molecular drivers and 
personalized risks. A limitation of our study was the incompleteness of data on several 
determinants in some studies. We focused on 49 genetic variants that were associated 
individually with AMD5, of which only few were rare. Hence, we cannot elaborate on risks 
provided by most of the currently known rare variants. The studies providing the greater 
part of patients were case-control studies without follow-up data, and therefore we were 
restricted to cross-sectional analyses. 
A positive GRS indicated more causative genetic risk than protection by genetic variants. 
Because this was present in 63% of the population (2546/4044), we conclude that genetic 
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susceptibility to AMD is highly prevalent. Among cases with late AMD, the proportion of 
a positive GRS rose to 89% (1581/1777). We investigated this in greater detail and found 
that the 5 major risk alleles were absent in only 66 persons (1%), indicating that 99% of 
the study population carried at least 1 major risk allele. By contrast, on average, 2.5 major 
risk alleles were present among late AMD patients and were absent in only 0.2% (4/1777). 
A set of 27 risk variants was enough to reach discriminative accuracy 0.84 for late AMD 
versus no AMD. Adding more variants did not improve this further, and the area under the 
receiver operating characteristic curve was in line with previous studies13, 14. It should be 
emphasized that such high discrimination based solely on genetic variants is exceptional 
for a complex disorder, although this is still challenging at mean GRS levels. 
Considering individual pathways, 19 of 52 common AMD risk variants are in the 
complement pathway5. Previous studies have reported already that common variants 
in the complement pathway explain 57% of the heritable risk of AMD15, and our study 
underscores the high attribution of this pathway to the overall GRS. Comparing the risk 
of the most important CFH SNP (rs570618 in high linkage disequilibrium (LD) 0.991 with 
rs1061170, Y402H) with an Asian population, we and others observed only a slightly higher 
OR of late AMD in Europeans (2.47 vs. 2.09)16 but very different allele frequencies (minor 
allele frequency, 0.34 vs. 0.049) 17. With respect to function, the complement pathway is 
part of the innate immune system, and numerous studies have shown that imbalance 
of this cascade at the protein level is important for AMD pathogenesis. Genetically, this 
system harbors strong causative as well as highly protective risk alleles (Fig 1), which 
mathematically can add up to a GRS of 0. Whether this also reflects a neutral risk at 
the tissue level is unclear, because persons with late AMD and a negative GRS for the 
complement pathway still carried risk-increasing alleles in this pathway. Nevertheless, 
the risk-reducing effect of these protective alleles are of high biological interest, and 
investigation into the functional consequences may provide leads for future therapy.
The rs3750846 (or its proxy, rs10490924, A69S) variant in the ARMS2 locus carried the 
highest risk of late AMD and the second highest attribution to overall AMD occurrence 
in our study (Fig 1). In East Asia, this allele is twice as common (minor allele frequency, 
0.40 in East Asians vs. 0.19 in Europeans), but the risk of late AMD for carriers seems 
comparable (OR, 2.94 in India vs. OR, 3.06 in Europe)18, 19. The function of ARMS2 is the 
subject of ongoing research. Recently, Micklisch et al. showed in vitro that ARMS2 
functions as a surface complement regulator by binding to the cell membrane of 
apoptotic and necrotic cells and that it subsequently binds properdin and activates 
complement11. This provides evidence that ARMS2 can be an initiator of complement. We 
considered 2 different scenarios for the pathway of ARMS2: a function in the complement 
pathway and an independent function. When regarded as a complement gene, the vast 
majority (90%) of late AMD patients showed an increased genetic risk in this pathway, 
150421-colijn-layout.indd   128 17/03/2021   17:41
129
GENETICS AND AMD
making complement the main driver of late AMD. As a stand-alone function, ARMS2 
also provided a significant contribution because it was present in two thirds of late AMD 
patients.
Variants in the lipid and ECM pathways showed smaller effects and attribution to overall 
late AMD. Variants in genes with other functions (the ‘other’ pathway) also showed 
smaller effects, but the 16 variants combined were rather frequent and predisposed 
considerably to late AMD. 
We further investigated the impact of the most important lifestyle factors, smoking and 
diet, in relationship to genetic risk. As expected, persons with AMD showed a lower 
intake of vegetables, fish, and fruit and higher rates of smoking (Table S3)20-26. Together, 
a more unfavorable lifestyle almost doubled the risk of late AMD. This occurred in all 
genetic risk strata, but the OR increase was most prominent in those at high genetic risk. 
These findings confirm previous reports from the Rotterdam Study27, 28 and Age-Related 
Eye Disease Study, which demonstrated interaction between single nutrients and CFH 
and ARMS and a protective role of diet in those with a high GRS29. The current study 
analyzed a more comprehensive set of risk variants and found that a healthy diet and not 
smoking also were beneficial in persons with low genetic risk. Oxidative stress is the most 
recognized molecular effect of smoking in the pathogenesis of AMD30, and antioxidants 
are the most important contribution to a healthy diet. Oxidative stress with abundant 
reactive oxygen species, peroxidation of lipids, proteins, RNA, and DNA in the retina 
can lead to cytotoxic effects and inflammation, enhancing the development of AMD31. 
Unfortunately, a healthy diet consisting of sufficient fruits, vegetables, and fatty fish is 
consumed by only a minority of the elderly28, and smoking is still twice as high among 
those with late AMD (Table S3). This asks for more rigorous measures for prevention, and 
training of doctors in behavioral change techniques may be part of this. 
In conclusion, this large European consortium showed that genetic risk of AMD is highly 
prevalent in the population at large and that risk variants in the complement pathway are 
by far the lead drivers of late AMD. Nevertheless, late AMD is mostly a result of multiple 
genetic pathways and lifestyle choices. The frequency and risk estimates provided by this 
study can lay the foundation for future intervention studies that are tailored to pathways.
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Purpose: Genetic and epidemiologic studies have shown that lipid genes and high 
density lipoproteins (HDLs) are implicated in age-related macular degeneration (AMD). 
We studied circulating lipid levels in relationship to AMD in a large European dataset.
Design: Pooled analysis of cross-sectional data.
Participants: Individuals (N=30 953) aged 50 years or older participating in the European 
Eye Epidemiology (E3) consortium and 1530 individuals from the Rotterdam Study with 
lipid subfraction data.
Methods: AMD features were graded per eye on fundus photographs using the Rotterdam 
classification. Routine blood lipid measurements, genetics, medication, and potential 
confounders were extracted from the E3 database. In a subgroup of the Rotterdam 
Study, lipid subfractions were identified by the Nightingale biomarker platform. Random-
intercepts mixed-effects models incorporating confounders and study site as a random-
effect were used to estimate associations.
Main Outcome Measures: AMD features and stage; lipid measurements. 
Results: HDL was associated with an increased risk of AMD (odds ratio [OR], 1.21 per 
1-mmol/l increase; 95% confidence interval [CI], 1.14-1.29), whereas triglycerides were 
associated with a decreased risk (OR, 0.94 per 1-mmol/l increase; 95%CI, 0.91-0.97). Both 
were associated with drusen size. Higher HDL raised the odds of larger drusen, whereas 
higher triglycerides decreases the odds. LDL cholesterol reached statistical significance 
only in the association with early AMD (P=0.045). Regarding lipid sub fractions, the 
concentration of extra-large HDL particles showed the most prominent association 
with AMD (OR, 1.24; 95%CI, 1.10-1.40). The cholesteryl ester transfer protein risk variant 
(rs17231506) for AMD was in line with increased HDL levels (P=7.7x10-7), but lipase C risk 
variants (rs2043085, rs2070895) were associated in an opposite way (P=1.0x10-6 and 
P=1.6x10-4). 
Conclusions: Our study suggested that HDL cholesterol is associated with increased 
risk of AMD and that triglycerides are negatively associated. Both show the strongest 
association with early AMD and drusen. Extra-large HDL subfractions seem to be drivers 
in the relationship with AMD, and variants in lipid genes play a more ambiguous role 
in this association. Whether systemic lipids directly influence AMD or represent lipid 
metabolism in the retina remains to be answered. 




Age-related macular degeneration (AMD) is a leading cause of blindness in the developed 
world, with 10.4 million persons diagnosed worldwide in 20151. It is a multifactorial disease 
affecting the elderly, which involves genetics and lifestyle factors. The diagnosis of 
AMD is based on imaging of the retina, with drusen as the hallmark of early disease. 
Chorioretinal neovascularization and atrophy of the retinal pigment epithelium (RPE) are 
indicative of late disease. The number of drusen and total drusen area are prominent 
predictors of progression of the early stages of AMD2, 3.
Drusen are lipid-rich, protein-containing deposits that accumulate between the RPE 
and Bruch’s membrane. The accumulation of drusen resembles the formation of 
atherosclerotic plaques4 seen in cardiovascular disease, with a similar composition 
of proteins and protein complexes, such as apolipoprotein E, cholesterol esters, and 
complement proteins.5, 6 The lipid load in drusen is as high as 40%7 and is thought to be 
derived partly from the systemic circulation. This triggered many studies evaluating the 
relationship between serum or plasma lipids and AMD.8-12 Some found associations with 
various serum or plasma lipid levels and drusen or AMD11-18, but results mainly were weak 
and inconsistent. Because a biological explanation is lacking, the relationship remains 
unsettled yet intriguing. 
Genetically, lipid metabolism also is involved in AMD. Genetic associations have 
been established for 4 genes encoding components of the high-density lipoprotein 
(HDL) metabolism: Adenosine triphosphate-binding cassette transporter A1 (ABCA1), 
cholesteryl ester transfer protein (CETP), apolipoprotein E (APOE), and lipase C, hepatic 
type (LIPC)19-25. ABCA1 encodes a cellular cholesterol efflux pump leading to formation 
of nascent HDL. Apolipoprotein E, encoded by the APOE gene, facilitates cholesterol 
uptake by HDL. CETP exchanges cholesteryl esters and triglycerides between HDL 
and other lipoproteins and thereby, influences HDL particle size.26 Finally, hepatic lipase 
encoded by the LIPC gene hydrolyzes triglycerides and phospholipids in lipoproteins27 
and thereby, partly converts very low-density lipoproteins (VLDLs) and intermediate 
density lipoproteins to low density lipoproteins (LDL)20 and plays a role in altering the 
HDL contents. 
The European Eye Epidemiology (E3) consortium within the European EYE-RISK 
project enabled us to investigate the relationships between systemic lipids levels, lipid 
genes, and AMD using a very large data set. With nuclear magnetic resonance (NMR) 
spectroscopy, we studied these relationships in greater detail to investigate which 
particles drive potential associations.





Routine Blood Lipid Measurements Fourteen studies from France, Germany, Italy, 
The Netherlands, Norway, Portugal and the United Kingdom participating in the E3 
consortium enrolled in the current study (Supplemental cohort descriptions, available 
at www.aaojournal.org). The E3 consists of European studies with epidemiologic data on 
common eye disorders; a detailed description on the studies included in the consortium 
has been published elsewhere.28 All studies with gradable macular fundus photographs 
(n=30 953 participants) 50 years of age and older contributed their data to the EYE-RISK 
database version 4.0. Studies were population-based cohort studies except for Creteil 
and the European Genetic Database (EUGENDA), which are clinic-based studies. Routine 
blood lipid measurements and AMD outcomes of the same visit were used for this 
analysis; for TwinsUK, the closest visit to capturing of the retinal fundus photographs 
was used. All studies were performed in accordance with the Declaration of Helsinki 
for research involving human subjects and the good epidemiologic practice guideline. 
All participants gave fully informed consent and the study was approved by all local 
institutional review boards of each study site. 
Detailed Lipid Analyses. The population-based Rotterdam Study (RS) I provided data on 
lipid subfractions that were determined at visit 4. Descriptive statistics of this cohort are 
shown in Table S1. (available at www.aaojournal.org). 
Clinical Examination:
Age-related macular degeneration features were graded per eye on fundus 
photographs by experienced graders or clinicians; the most severe AMD grade classified 
the AMD status of the person. When needed, photographs were regraded by expert 
graders from Moorfields Eye Hospital and the RS to harmonize the outcome. Age-
related macular degeneration status was determined for all included studies using the 
Rotterdam Classification as described previously.29 In brief, grade 0 or 1 are considered 
no AMD; grades 2 and 3 with soft indistinct drusen, reticular drusen or distinct drusen 
with pigmentary changes are considered as early AMD, and grade 4 with geographic 
atrophy or choroidal neovascularization as late AMD. The area of the Early Treatment 
Diabetic Retinopathy Study grid covered by drusen was estimated in RS I visit 4 per grid 
circle, and was calculated using previously defined harmonization criteria30. Medication 
use and lifestyle factors including smoking habits were assessed by questionnaire; 
lipid measurements and other clinical determinants such as hypertension, body mass 
index (BMI), and diabetes mellitus were examined at each individual research center 
(Supplement cohort descriptions available at www.aaojournal.org). Fasting blood draws 
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were taken in all studies except for the EUGENDA study, Muenster aging and retina study 
(MARS), and the Tromsø Eye Study, which drew blood samples in a nonfasting scenario. 
Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were measured in 
plasma (Pathologies Oculaires Liées à l'Age Study [POLA], Prevalence of Age-Related 
Macular Degeneration in Italy (PAMDI study), Montrachet-3 city (3C) study, and Creteil) or 
in serum (remaining studies) using standard operating procedures. When LDL was not 
measured and triglycerides were less than 4.52mmol/l, a proxy was calculated using 
the Friedewald formula31: LDL cholesterol = Total cholesterol – HDL cholesterol – (total 
triglyceride/2.19); only positive values entered the analysis. 
Nuclear Magnetic Resonance Metabolomics Analysis
Lipid subfractions were measured with the Nightingale’s NMR-based biomarker platform 
in fasting ethylenediaminetetraacetic acid plasma samples (Nightingale Ltd., Helsinki, 
Finland). These measurements cover multiple metabolic pathways, including lipoprotein 
lipids and subclasses, fatty acids, amino acids, and glycolysis-related metabolites. The 
NMR-based metabolic profiling has been described previously in detail32 and has been 
used in multiple large-scale epidemiologic and genetic studies33-36. 
Genetic Analyses 
The Alienor-3 city (3C) study and Montrachet-3 city (3C) study participants were genotyped 
with the Illumina Human 610-Quad BeadChip (Illumina, Inc., San Diego, CA) and imputed 
with the 1000 Genomes Phase I integrated variant set (March2012) using Shapeit software 
version 2.r727 (https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) 
for pre-phasing and Impute2 software version 2.3 (https://mathgen.stats.ox.ac.uk/
impute/impute_v2.html) for imputation. The RS I, II and III participants were genotyped 
using the Illumina 550K, 550k due/610K Illumina arrays (Illumina, Inc., San Diego, CA). The 
genotypes were imputed with the 1000 Genomes (phase 1 version 3) reference panel 
using the Markov chain haplotyping/minimac software37-39. The EUGENDA participants 
were genotyped with a custom-designed Illumina HumanCoreExome array (Illumina, 
Inc., San Diego, CA) within the International AMD Genetics Consortium. Details regarding 
the design of this array, as well as annotation, imputation, and quality control of the 
genotypic data, have been described previously 19. All cohorts applied similar quality 
control procedures to genotype data before analysis, and imputation quality was r2>0.3. 
A total AMD genetic risk score was calculated using 33 out of the 52 known AMD 
risk variants19 available in the EYE-RISK database version 4.0 (Table S19, available at 
www.aaojournal.org). Genetic allele dosage was annotated as 0 for noncarriers, 1  for 
heterozygotes, and 2 for homozygotes. The genetic risk score was composed by 
calculating the sum of the βs of independent risk variants. The score was standardized 
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and added as a covariate in a linear regression analysis with AMD as the dependent 
variable. The linear regression was corrected for age, sex, lipid lowering drugs, and study 
site. The effect of individual lipid-related single nucleotide polymorphisms on each lipid 
level or lipid subfraction was assessed in a mixed-effects regression correcting for age, 
gender, lipid lowering drug use, plasma or serum, and fasting state and using study 
site as a random effects term. The P value threshold for these analyses was 0.05/60 = 
0.00083 (8.3x10-4) after Bonferroni correction. 
Statistical Analysis 
The outcome variable was presence of early or late AMD versus no AMD. Differences 
in baseline characteristics were evaluated with a Wald test using a logistic regression 
analysis, adjusting for age, gender, and study site. Analyses were conducted on complete 
data. Odds ratios (ORs) for the routine blood lipid measurements were calculated using 
random-intercepts mixed-effects logistic regression models, including study site as a 
random effect term to allow for variability between study sites. The study site-specific 
fixed-effects estimates were transformed to their marginal counterparts as described by 
Heagerty and Zeger40. 
Association of HDL cholesterol with AMD characteristics (presence of various drusen 
sizes, hyperpigmentation, or hypopigmentation) was calculated in a univariate logistic 
regression analysis for the worse eye, defined as the eye with the most severe lesions of 
each AMD characteristic, correcting for age, gender, lipid-lowering drugs use and study 
site. The linear regression for HDL cholesterol and drusen area was calculated in the RS 
I visit 4 only. 
For the analysis on lipid subfractions, all subfractions were +1 log transformed and scaled 
to make comparable measurements. Association magnitudes were reported in units of 
standard deviation or OR change per 1-standard deviation increase in each metabolite, 
as previously suggested by others34, 35. To account for the correlation between lipid 
subfractions, the eigenvalues were calculated as proposed by Li and Ji41 on the SNPSpD 
online interface42. Bonferroni correction was applied to correct for multiple testing using 
the eigenvalues to calculate the P-value threshold (P=0.001087). To test for differences 
between AMD stage and the mean of the lipid subfractions, a Welch test was performed 
on the total of all age categories. The Welch test was chosen because homogeneity of 
variance was violated among the AMD severity classes. The post hoc Games-Howell test 
was used to investigate differences between the mean of the no-AMD and late-AMD 
groups.
Mixed-effects logistic regression models were performed with R package lme443, and 
mixed-effects regression models with nmle44 (R Core Team, Vienna, Austria); Welch-
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tests and genetic risk scores were carried out with SPSS software for Windows version 
24.0 (IBM Corp., Amonk, NY). Graphical outputs were constructed with GraphPad Prism 
for Windows version 7 (GraphPad Software, La Jolla, CA).
RESULTS
We identified a total of 4730 individuals with early AMD, 2441 with late AMD, and 23 782 
nonaffected persons. The baseline characteristics of these participants are summarized 
in Table 2. Age-related macular degeneration patients and controls differed in age, 
gender, BMI, lipid-lowering drug use, and smoking, in accordance with the known AMD 
risk profile. 
Table 3 shows the association between lipid levels and AMD adjusted for age, gender, 
lipid-lowering drug usage, BMI, smoking, plasma or serum, fasting state and study 
site in the E3 consortium. Analyses for late AMD were also corrected for diabetes. 
Total cholesterol was not associated with any of the AMD outcomes. Higher HDL 
cholesterol was associated with an increased risk of any AMD, and risk estimates were 
slightly higher for early AMD (OR, 1.34 per 1-mmol/l increase) than for late AMD (OR, 
1.12 per 1-mmol/l increase), but had overlapping confidence intervals (CIs). Low-density 
lipoprotein cholesterol and triglycerides were associated inversely with early AMD (OR, 
0.96 and 0.88 per 1-mmol/l increase, respectively) and any AMD (OR, 0.98 and 0.94 per 
1-mmol/l increase, respectively), but effect sizes were smaller than for HDL cholesterol. 
Sensitivity analysis on fasting and nonfasting sampling methods and gender showed no 
interaction, or it showed interaction but with similar point estimates of the ORs, which 
made sampling effect or confounding unlikely. However, a sensitivity analysis on plasma 
or serum sampling methods did show a change in direction of effect of triglycerides 
measured in plasma, although the change was not statistically significant (Tables S4-S10, 
available at www.aaojournal.org). To investigate whether observed associations were the 
result of the preferential survival of elderly persons without cardiovascular disease, we 
repeated the analyses in various age strata (Tables S11-S13, available at www.aaojournal.
org). Even in those aged 65 years of age or younger with AMD, HDL cholesterol was 
associated significantly with increased risk of AMD (OR, 1.19 per 1-mmol/l increase; 
P=0.02). Low-density lipoprotein cholesterol was associated inversely with AMD (OR, 0.93 
per 1-mmol/l; P=0.02); associations with triglycerides became insignificant.
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Gender (% female) Early 61.7 (n=2918) <0.0001 1.21 1.13 - 1.29
Late 59.4 (n=1449) 0.74 0.98 0.88 – 1.10
Any 57.5 (n=13680) 60.9 (n=4367) <0.0001 1.15 1.09 - 1.23
Age (yrs) Early 72.7 (SD, 8.4) <0.0001 1.06 1.06 – 1.06
Late 76.9 (SD, 8.1) <0.0001 1.12 1.11 – 1.13
Any 68.1 (SD, 8.7) 74.1 (SD, 8.5) <0.0001 1.08 1.07 - 1.08
BMI (kg/m2) Early 26.6 (SD, 4.2) 0.008 0.99 0.98 – 1.00
Late 26.4 (SD, 4.0) <0.0001 1.03 1.02 – 1.05





























Hypertension (%) Early 48.7 (n=2153) 0.30 1.04 0.97– 1.12
Late 45.3 (n=977) 0.84 1.01 0.90 – 1.14
Any 49.0 (n=11010) 47.6 (n=3130) 0.43 1.03 0.96 - 1.10
Diabetes (%) Early 9.7 (n=435) 0.35 0.95 0.84 – 1.06
Late 13.2 (n=284) 0.002 1.33 1.11 – 1.58
Any 10.7 (n=2408) 10.8 (n=719) 0.70 1.02 0.92 - 1.13
Lipid-lowering drugs (%) Early 24.7 (n=1084) 0.006 0.89 0.83 – 0.97
Late 22.5 (n=459) 0.86 0.99 0.85 – 1.14
Any 24.5 (n=5492) 24.0 (n=1543) 0.004 0.90 0.83 - 0.97
AMD = age-related macular degeneration; BMI= body mass index; SD = standard deviation. 
Odds ratios are corrected for age, gender, and study site. Numbers in bold indicate statistically significant values. 
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0.94 0.91-0.97 2.35 x10-5
Data are median (tenty-fifth-seventy-fifth percentile). Odds ratio estimates and 95% confidence intervals of lipid on 
early, late or any AMD after adjusting for age, gender, lipid-lowering drug usage, body mass index, smoking, plasma 
or serum, fasting state and study site. Late AMD was also corrected for diabetes. P=0.0042 is Bonferroni statistically 
significant. Numbers in boldface indicate statistically significant values. 
AMD = age-related macular degeneration; HDL = high-density lipoprotein; LDL = low-density lipoprotein. 
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Routine Blood Lipids Measurements and Early Age-Related Macular 
Degeneration Phenotype 
Because the association between HDL cholesterol and AMD was most pronounced in 
those with early AMD, we performed more detailed analyses using the various early AMD 
features as outcomes. Effects of HDL cholesterol and triglycerides became larger with 
increasing drusen size (Fig 1). Likewise, higher HDL levels were associated with greater 
drusen area (β, 0.014; P=0.001). Higher triglyceride levels were associated with smaller 
drusen area. Correcting for smoking did not change these results (data not shown). 
Lipids were not statistically significantly associated with pigmentary changes, and total 
cholesterol and LDL cholesterol were not associated with any early AMD characteristic 
(Tables S14 and S15, available at www.aaojournal.org). 
0.5 1.0 1.5 2.0
Large drusen 125




















Figure 1. Graph showing the association of high-density lipoprotein (HDL) cholesterol and triglycerides with age-
related macular degeneration characteristics.
Lipid Subfractions in the Rotterdam Study
To explore whether the association between HDL cholesterol, triglycerides, and AMD 
was driven by specific lipid subfractions, we examined lipid subfractions with NMR in RS I 
(Fig 2; Table S16, available at www.aaojournal.org). The concentration of extra-large HDL 
particles was associated most significantly with any AMD, particularly the subfractions of 
phospholipids and total lipids within extra-large HDL particles. These sub fractions are 
highly correlated (Pearson correlation, >0.97). Next, total cholesterol and free cholesterol 
in small VLDLs were associated significantly, as well as the ratio of apolipoprotein B-to-
apolipoprotein A1, with a Pearson correlation ranging between 0.93 and 0.87. No other 
metabolites were associated significantly with AMD. Correcting for smoking did not 
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change these significant results (data not shown). The apolipoprotein B-to-apolipoprotein 
A1 ratio is a surrogate for the LDL-to-HDL ratio with a small ratio suggesting a high level 


































































































































































































































































































































































































































Figure 2. Graph showing the association of metabolic variables and age-related macular degeneration (AMD). 
Each bar represents the association with AMD, the size of the bar is the odds ratio, the color refers to effect 
direction and significance. Dots indicate Bonferroni statistically significant metabolic variables corrected for 
age, gender, and lipid-lowering drugs. Labels describe the properties measured in each lipid subfraction: C= 
total cholesterol; CE = cholesterol esters; FC= free cholesterol; L=total lipids; P=concentration of particles; PL= 
phospholipids; and TG=triglycerides. List of abbreviations available in the Supplementary materials, available 
online at www.aaojournal.org 
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These associations show a dose-dependent relationship with AMD stages from the 
Rotterdam Classification (Fig 3). To test if the mean of the lipid subfractions per AMD 
stage differed statistically, we performed a Welch test, which was significant for each of 
the 6 subfractions. The subfractions related to HDL also showed a statistically significant 
difference in the Games-Howell post hoc test comparing the mean of those with no 
AMD to those with late AMD (P=0.01 for the concentration of extra-large HDL, P=0.02 for 
phospholipids in extra-large HDL, P=0.01 for total lipids in extra-large HDL). The Games-
Howell post-hoc test was not significant in the other 3 subfractions, likely because of 
the small group size and variance in late AMD. (Fig S4, available at www.aaojournal.org, 
shows dose dependency per age category).
We also performed the analyses stratified for lipid-lowering drug use, which was reported 
by fewer cases (17.0%) than controls (24.2%) in the RS (P=0.02). Significance was found 
only in those not taking lipid-lowering drugs, and point estimates were highly similar to 



































































No AMD Small drusen only Early AMD Late AMD
Welch test F(3,283)= 9.12, p-value= 9.0x10 -6 Welch test F(3,283)= 9.27, p-value= 7.0x10 -6 Welch test F(3,283)= 8.97, p-value= 1.1x10 -5
Welch test F(3,289)= 4.39, p-value= 0.005Welch test F(3,287)= 4.15, p-value= 0.007 Welch test F(3,292)= 5.24, p-value= 0.002
Figure 3. Box-and-whisker plots showing the stage-dependent relationship of the 6 associated lipid subfractions 
with age-related macular degeneration (AMD). Error bars indicate 95% confidence intervals of the mean. Apo= 
apolipoprotein; HDL= high-density lipoprotein; VLDL= very low-density lipoprotein.
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Lipid Genes, Lipid Subfractions, and Age-Related Macular Degeneration
Because genetic variants are an important cause of AMD, we investigated the relationship 
among genes, lipids, and AMD. First, we investigated whether a genetic risk score with 
33 single nucleotides polymorphisms covering all major AMD genes influenced lipid levels 
in the E3-consortium and found that with increasing genetic risk also came an increase 
of HDL cholesterol (P=0.03, Table S19 available at www.aaojournal.org). Subsequently, 
we focused on the individual AMD lipid genes. In E3, the CETP variant rs17231506 was 
associated positively with HDL cholesterol levels and associated negatively with LDL 
cholesterol, whereas both LIPC variants rs2043085 and rs2070895 were associated 
inversely with HDL cholesterol. In addition, the APOE variant rs429358 was associated 
with decreased levels of total cholesterol, triglycerides, and LDL cholesterol but with 
increased levels of HDL cholesterol. The APOE variant rs73036519 showed no significant 
effect on the routine lipid measurements or on the lipid subfractions. The ABCA1 variant 
rs2740488 influenced only total cholesterol and HDL cholesterol (Table 20). When 
restricting the analysis to lipid subfractions in the RS (Table 21), we found similar results 
for the CETP variant and the LIPC variants with all extra-large HDL subfractions. 

































































0.01 (P=0.67) 0.04 (P=0.01)
Triglycerides -0.025 
(P=0.04)




0.03 (P=0.03) 0.004 
(P=0.78)
HDL= high-density lipoprotein; LDL = low density lipoprotein. 
βs are corrected for age, gender, lipid-lowering drugs, plasma or serum, fasting state, and study site. βs indicate 
the effect of the risk allele versus the reference allele. Bonferroni: 0.05/60 = 0.00083 (8.3x10-4). Numbers in boldface 
indicate statistically significant values.
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-0.09 (P=0.003) -0.09 (P=0.003) -0.08 (P=0.02) -0.05 (P=0.294) -0.02 (P=0.631) 0.08 (P=0.027)
Ratio ApoB-to-
ApoA1
-0.10 (P=0.002) 0.004 (P=0.897) -0.003 
(P=0.936)
-0.09 (P=0.037) -0.04 (P=0.250) 0.02 (P=0.521)








-0.08 (P=0.056) 0.04 (P=0.213) 0.05 (P=0.138)
Free cholesterol 
in small VLDL
-0.08 (P=0.01) -0.08 (P=0.005) -0.09 (P=0.009) 0.01 (P=0.784) -0.03 (P=0.434) 0.07 (P=0.058)
Apo= apolipoprotein; HDL= high-density lipoprotein; LDL= low-density lipoprotein; VLDL=very low-density lipoprotein.
βs are corrected for age, gender, and lipid-lowering drug use; subfractions are log+1 and standardized. βs indicate 
the effect of the risk allele versus the reference allele. Numbers in boldface indicate statistically significant values.
DISCUSSION
Based on pooled data of 30 953 participants from Western Europe, we have showed 
that high circulating HDL cholesterol levels and low triglyceride levels are associated 
significantly with AMD. The magnitude of the effect was higher for early than for late AMD, 
and associations were related to drusen size and area. By focusing on lipid subfractions, 
we revealed that extra-large HDL particles, small VLDL particles, and the apolipoprotein 
B-to-apolipoprotein A1 ratio, a surrogate for the LDL-to-HDL ratio, were dose-dependent 
drivers of this association. Age-related macular degeneration risk variants in lipid genes 
did not provide a clear explanation; in particular, the variants in LIPC that increase the risk 
of AMD decreased HDL cholesterol in the systemic circulation.
Our results should be interpreted in light of the strengths and limitations of the study. The 
combined efforts of 2 European consortia enabled us to create a very large database 
providing the statistical power to resolve conflicting findings from previous studies. The 
detailed NMR lipid analysis in a subset created the opportunity to find the metabolic 
profile behind the lipid associations. A weakness of the consortia was the use of different 
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protocols for blood sampling, definition of confounders, and AMD phenotyping. We 
addressed this issue by performing a stratified analysis on sampling methods and found 
that only the associations for triglycerides changed direction of effect for plasma, albeit 
nonsignificantly. We harmonized all confounders as well as the criteria for early and late 
AMD, and corrected for study site in the mixed-effect models. 
Many previous studies did not find a statistically significant association between lipids 
and AMD, but studies with the larger sample sizes often found a positive association with 
HDL cholesterol and an inverse association with triglycerides13. The current pooled study 
showed that the levels of these lipids were within physiologic range in both cases and 
controls and that absolute differences were small in millimoles per liter. However, our 
data suggest that an increase of HDL from the twenty-fifth percentile to the seventy-fifth 
percentile coincides with an AMD risk increase of approximately 20%. Selective survival 
does not seem to explain our findings because the association was present already in the 
youngest age group (≤ 65 years). The exact clinical interpretation remains to be defined. 
Nevertheless, the findings contribute to the understanding of AMD pathogenesis. 
Animal research has provided some key insights in retinal lipid metabolism. Studies in 
rodents show that most lipids in the retina are synthesized locally and up to a quarter 
are derived from the systemic circulation45. Another study in mice shows that a high-fat 
diet increases cholesterol in the retina but not as much as in the circulation. These results 
suggest that transport from the systemic circulation to the retina does take place, albeit 
modestly. Although LDLs deliver cholesterol most efficiently from the systemic circulation 
to the retina, HDL cholesterol, with apolipoprotein A-I as its major lipid component46, 
does this as well via scavenger receptors26, 47, 48. The RPE processes the internalized lipids 
and subsequently secretes them again on the apical side via ABCA1 transporters into the 
interphotoreceptor matrix. Thereafter, lecithin-cholesterol acyltransferase, located at the 
surface of nascent HDL49, converts free cholesterol into esterified cholesterol,50 which 
is present in nascent HDL. In this way, lecithin-cholesterol acyltransferase transforms 
nascent HDL into larger, mature HDL, while LIPC hydrolyzes phospholipids in the HDL 
lipoprotein23, 51. As suggested by Tserentsoodol et al.26, because of the absence of LDL in 
the retina, it is possible that CETP has a role in transferring esterified cholesterol between 
lipoproteins or photoreceptor membranes. In the interphotoreceptor matrix, HDL 
functions as a transport vehicle between the RPE and the photoreceptors supporting 
the high synthesis and degradation of the lipid-rich photoreceptor discs26. The RPE 
maintains the lipid balance by transporting lipoproteins back to Bruchs membrane52. The 
lipid contents of these lipoproteins resemble those of LDL lipoproteins rather than of 
HDL, because it has a high abundance of esterified cholesterol and both apolipoprotein 
A and B53. It has been proposed that this large amount of esterified cholesterol acts as 
a barrier for lipid transport through an aging retina, thereby facilitating the formation of 
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deposits54. Another mechanism proposed to form deposits is through the impairment of 
ABCA1 transporter of macrophages, which impairs the efflux of free cholesterol out of 
the macrophage. This results in senescent macrophages with high levels of cholesterol 
in the retina of mice55. 
Interestingly, lipoproteins seem to be related closely to the complement system, the 
major pathway in AMD pathogenesis. Proteomic studies have shown that HDL lipoproteins 
can contain essential complement components, such as C1, C2, C3, C5 and factor B56-58. 
One study showed that complement factor H (CFH) and lipoproteins have competitive 
binding in the sub-RPE extracellular matrix, and when CFH is low, lipoproteins can 
accumulate under the RPE59. By contrast, HDL also can carry complement regulators 
such as FH1, CFHR4 and CFHR560, 61. Apolipoprotein A-I attached to HDL can bind 
clusterin, a complement lysis inhibitor that stops the complement cascade just before 
the C5b-9 complex is inserted into the target62. These findings suggest that HDL is 
involved in proinflammatory as well as complement-inhibitory tasks. Higher HDL levels 
may cause imbalance of the physiologic homeostasis8, 63. Taken together, this plethora of 
biological leads supports the contention that HDL may play a role in the initiation of AMD. 
More comprehensive research into lipid metabolism in the retina is warranted. 
In our study, we found elevated levels of HDL cholesterol in the circulation and decreased 
levels of triglycerides in persons with AMD. In more detailed analysis, we observed a 
higher concentration of extra-large HDL particles with higher total lipid and phospholipid 
contents, which are under genetic control of CETP and LIPC. The high phospholipid 
content of extra-large HDL very likely is related to the larger particle size, because 
phospholipids comprise the outer shell of the lipoprotein. CETP may exert its effect 
on AMD partly through systemic HDL, in line with previous Mendelian randomization 
studies24, 66. The opposing effects that we found for LIPC are less easily explained, but 
have been observed by others23, 24. This finding suggests that systemic HDL may be a 
biomarker rather than directly causally related to AMD. In a larger study, Kettunen et al.33 
found more genetic effects on lipid subfractions; variants in CETP and APOE also had a 
decreasing effect on the small VLDL subfractions, whereas a variant in ABCA1 increased 
extra-large HDL. Our smaller sample size hampered the replication of these findings. 
Where do these lipid associations fit in the chronology of AMD development? The more 
pronounced risk for early AMD and increasing ORs of HDL cholesterol for the larger 
size drusen suggest that lipids play an important role at the early phase of disease. 
Hypothetically, intervention at this phase would be most promising in preventing 
blindness. We did not find statistical significance for any lipid subfraction in only those 
using lipid-lowering drugs, possibly because there is no effect, but probably due to the 
lower power in this subgroup. Evidence from other studies indicates that statins increase 
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HDL levels slightly67 but reduce extra-large HDL68 and that HDL protein composition 
may change as well69. Most epidemiologic studies do not find any effect of lipid lowering 
drugs on AMD8, 70-72; however, one study observed a slower progression of AMD in 
persons with a certain CFH risk variant73. Large randomized controlled trials with long 
term follow-up are needed to clarify the relation between lipid-lowering drugs and AMD. 
In conclusion, this study showed that HDL cholesterol and triglycerides levels are 
particularly associated with early AMD, mostly through the association with drusen. Extra-
large HDL subfractions seem to be drivers of this association. Whether systemic lipids 
directly influence lipid metabolism in the retina or whether these lipids mirror pathologic 
features in the retina is a question that remains to be answered.
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Purpose: To investigate associations of adherence to the Mediterranean diet (MeDi) with 
incidence of advanced age-related macular degeneration (AMD; the symptomatic form 
of AMD) in 2 European population-based prospective cohorts. 
Design Prospective cohort study of the Rotterdam study I (RS-I) and the Antioxydants, 
Lipides Essentiels, Nutrition et Maladies Oculaires (Alienor) Study populations.
Participants: Four thousand four hundred forty-six participants 55 years of age or older 
from the RS-I (The Netherlands) and 550 French adults 73 years of age or older from 
the Alienor Study with complete ophthalmologic and dietary data were included in the 
present study. 
Methods: Examinations were performed approximately every 5 years over a 21-year 
period (1990-2011) in RS-I and every 2 years over a 4-year period (2006-2012) in the 
Alienor Study. Adherence to the MeDi was evaluated using a 9-component score based 
on intake of vegetables, fruits, legumes, cereals, fish, meat, dairy products, alcohol and 
the monounsaturated-to-saturated fatty acids ratio. Associations of incidence of AMD 
with MeDi were estimated using multivariate Cox proportional hazard models. 
Main Outcomes Measures: Incidence of advanced AMD based on retinal fundus 
photographs.
Results: Among the 4996 included participants, 155 demonstrated advanced incident 
AMD (117 from the RS-I and 38 from the Alienor Study). The mean follow-up time was 
9.9 years (range, 0.6-21.7 years) in the RS-I and 4.1 years (range, 2.5-5.0 years) in the 
Alienor Study. Pooling data for both the RS-I and Alienor Study, participants with a high 
(range, 6-9) MeDi score showed a significantly reduced risk for incident advanced AMD 
compared with participants with a low (range, 0-3) MeDi score in the fully adjusted Cox 
model (hazard ratio, 0.59; 95% confidence interval, 0.37-0.95; P=0.04 for trend). 
Conclusions: Pooling data from the RS-I and Alienor Study, higher adherence to the 
MeDi was associated with a 41% reduced risk of incident advanced AMD. These findings 
support the role of a diet rich in healthful nutrient-rich foods such as fruits, vegetables, 
legumes and fish in the prevention of AMD. 




Age-related macular degeneration (AMD) is the leading cause of blindness in 
industrialized countries1. This degenerative disease affects the central part of the retina, 
which is crucial for daily living tasks such as reading, driving, and recognition of faces. 
Worldwide, 196 million people will be affected by AMD in 2020, increasing to 288 million 
in 20402. Advanced forms of the disease (neovascular or atrophic AMD) associated 
with a deep visual impairment generally are preceded by asymptomatic early stages. 
Although no treatment currently is available for atrophic AMD, effective treatments are 
available for the neovascular form3, 4. These treatments also incur major costs to society, 
with an estimated $2.3 billion of Medicare claims in 20135. The risk of AMD developing 
is determined jointly by age, individual genetic background, and lifestyle1, 6. Prevention 
strategies based on the modifiable risk factors of AMD may help to decrease the major 
medical and social burden associated with AMD.
Epidemiological studies have observed a reduced risk of AMD associated with high 
consumption of antioxidants (lutein and zeaxanthin7-12, fruits and vegetables rich in these 
nutrients) and omega 3 polyunsaturated fatty acids,8,9, 13-15 provided by fish and nuts13, 14, 16, 17. 
However, a single nutrient or food approach cannot capture the synergistic effects of 
food and nutrients consumed in combination in the diet. The Mediterranean diet (MeDi) is 
characterized by high consumption of plant foods and fish, low consumption of meat and 
dairy products, olive oil as the primary fat source, and a moderate consumption of wine18. 
Adherence to the MeDi has been linked to lower rates of mortality,19 chronic diseases, 
stroke,20 cognitive decline,21 and recently diabetic retinopathy.22 Regarding AMD, very few 
studies are available to date.23-27 In 3 population-based studies, the MeDi was associated 
with a lower prevalence of early AMD,23 neovascular AMD,25 and any AMD26, 27, although 
dietary modifications resulting from AMD cannot be excluded in these cross-sectional 
studies. In a post hoc analysis of a randomized clinical trial, the MeDi was associated with 
a lower incidence of advanced AMD,24 but the selected nature of the sample limits its 
generalizability. We therefore investigated the associations between MeDi and incidence 
of advanced AMD in a large sample from 2 population-based prospective studies.
METHODS
Study Population
The EYE-RISK project (http://www.eyerisk.eu/ ) aims to identify risk factors, molecular 
mechanisms, and therapeutic approaches for AMD. It uses epidemiologic data 
describing clinical phenotype, molecular genetics, lifestyle, nutrition and in-depth retinal 
imaging derived from existing European epidemiologic cohorts to provide major insights 
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needed for prevention and therapy of AMD. Within the EYE-RISK consortium, a unique 
harmonized database of individual data from 16 European epidemiologic studies was 
constructed28. Two prospective studies with appropriate data for the present analyses 
were available: the Rotterdam Study I (RS-I)29 and the Antioxydants, Lipides Essentiels, 
Nutrition et maladies Oculaires (Alienor) Study.30 For both studies, all participants provided 
written informed consent in accordance with the Declaration of Helsinki to participate in 
the study. 
The Rotterdam Study I
At baseline, 7983 eligible persons 55 years of age or older were interviewed and examined. 
Ophthalmologic examinations were carried out and fundus photographs were obtained 
at each round starting from 1990 through 1993. Follow-up rounds were completed from 
1993 through 1995, from 1997 through 1999, from 2002 through 2004, and from 2009 
through 2011. After pharmacologic mydriasis, 35° stereoscopic color fundus photographs 
of the macula (Topcon TRV-50VT; Topcon Optical Co., Tokyo, Japan) were obtained in 
each of the first 3 visits, and 35° digital images (Topcon TRC 50EX) were obtained for the 
fourth and fifth visits31.
The Rotterdam Study was approved by the Medical Ethics Committee of the Erasmus 
Medical Center (registration number MEC 02.1015) and by the Dutch Ministry of Health, 
Welfare and Sport (Population Screening Act WBO; license number, 1071272-159521-
PG). The Rotterdam Study has been entered into the Netherlands National Trial Register 
(www.trialregister.nl) and into the World Health Organization International Clinical Trials 
Registry Platform (www.who.int/ictrp/network/primary/en/) under shared catalogue 
number NTR6831. 
The Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires Study
At baseline (2006-2008), 963 participants 73 years of age or older were interviewed and 
underwent an ophthalmological examination30. Of these, 624 and 614 were re-examined at 
the second (2009-2010) and third (2011-2012) visits, respectively. The study was approved 
by the Ethical Committee of Bordeaux (Comité de Protection des Personnes Sud-Ouest 
et Outre-Mer III) in May 2006 (http://www.alienor-study.com/langue-english-1.html).
The eye examinations took place in the Department of Ophthalmology of the University 
Hospital of Bordeaux. Two 45° nonmydriatic color retinal photographs were obtained 
using a high-resolution digital nonmydriatic retinograph (Topcon TRC-NW6S)30. At the 
third visit (2011-2012), for participants who were not able to come to the hospital, the 
eye examination took place at home and 40° retinal photographs were obtained using a 
digital nonmydriatic portable retinograph (Smartscope, Optomed, Oulu, Finland). 
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Age-Related Macular Degeneration Classification
Retinal photographs of both eyes were graded by trained graders of each study and 
were interpreted according to a modification of the Wisconsin Age-Related Maculopathy 
Grading System32 for RS-I and according to the International Classification33 for the Alienor 
Study. All advanced AMD cases were adjudicated and confirmed by retina specialists of 
the corresponding study. Phenotype harmonization was performed within the EYE RISK 
Consortium28.
Incidence
At each visit, each participant was classified according to the worst eye into one of the 
following exclusive groups: no AMD, early AMD, or advanced AMD. Advanced AMD was 
defined by the presence of neovascular or atrophic AMD. Neovascular AMD included 
serous or hemorrhagic detachment of the retinal pigment epithelium or sensory retina, 
subretinal, or sub-retinal pigment epithelium hemorrhages, and fibrous scar tissue. 
Geographic atrophy was defined as a discrete area of retinal depigmentation 175µm in 
diameter or larger characterized by a sharp border and the presence of visible choroidal 
vessels. Early AMD (in the absence of advanced AMD) was defined by the presence of (1) 
soft indistinct (≥125µm, decreasing density from the center outward and fuzzy edges) or 
reticular drusen only or soft distinct drusen (≥63µm, with uniform density and sharp edges) 
and pigmentary abnormalities, or by (2) soft indistinct large drusen (≥125µm, decreasing 
density from the center outward and fuzzy edges) or reticular drusen and pigmentary 
abnormalities (corresponding to grades 2 and 3 of the Rotterdam Classification). No AMD 
was defined by the absence of early AMD and advanced AMD. 
Incidence of advanced AMD was defined as the participant progressing from no or early 
AMD at baseline to advanced AMD (either neovascular or atrophic AMD) at any point 
during the study period. The date of occurrence of advanced AMD was calculated as the 
midpoint of the interval between the last visit without advanced AMD and the first visit 
with advanced AMD. Follow-up ended at the date of occurrence of advanced AMD, or 
the date of the last gradable photograph. Participants with advanced AMD or no gradable 
eyes at baseline were excluded from the analysis.
For the purpose of AMD subtype analysis, neovascular AMD comprised all participants 
demonstrating some neovascular lesions, with or without coexisting atrophy. Atrophic 
AMD was defined as pure geographic atrophy (in the absence of neovascular AMD).
Dietary Assessment
In RS-I, participants completed a checklist at home and underwent a face-to-face 
interview conducted by a trained dietician at the research center using a 170-item 
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validated semiquantitative food frequency questionnaire (FFQ)34. The food items were 
converted into quantities consumed daily (grams per day). By using the computerized 
Dutch Food Composition Table, these dietary data were converted to total energy intake 
(TEI; in kilocalories per day) and nutrient intakes (in grams per day)34.
In the Alienor Study, participants were visited at home by a specifically trained dietician 
who administered a 40-item validated FFQ and a 24-hour dietary recall35, 36. The food 
items were converted into number of servings per day. The 24-hour recall was used 
to estimate nutrient intake (in grams per day) and TEI (in kilocalories per day) and to 
compute the monounsaturated fatty acids (MUFAs)-to-saturated fatty acids (SFAs) ratio.
Adherence to the MeDi was assessed using the MeDi score developed by Trichopoulou 
et al.37. This score included 9 components; vegetables, fruits, legumes, cereals, fish, meat, 
dairy products, alcohol and the MUFAs-to-SFAs ratio. The MeDi score was applied to 
both studies. The daily intake of each food or beverage group was calculated as quantity 
in grams per day in the RS-I and as the number of servings per day in the Alienor Study. 
Participants with unreliable TEI were excluded (valid TEI range: women, 600–3200 kcal; 
men, 600–4200 kcal). For each component hypothesized to benefit health (vegetables, 
fruits, legumes, cereals, fish, and MUFAs-to-SFAs ratio), 1 point was given if intake 
was higher than the gender-specific median values and 0 otherwise. For components 
presumed to be detrimental to health (meat and dairy products), 1 point was given if 
intake was less than the gender-specific median values and 0 otherwise. For alcohol, 
1 point was given for moderate consumption and 0 otherwise (moderate consumption: 
women, 1-10 g/day; men, 5-15 g/day). Gender-specific medians were calculated 
separately for each study. The total MeDi score was computed by adding the scores (0 
or 1 point) for each component per participant. Scores ranged from 0 (nonadherence) to 
9 (perfect adherence). Participants were classified according to 3 categories of the MeDi 
score: low (0–3), medium (4–5), or high (6–9).
Covariates
Age (years), gender, education (primary, secondary, higher), smoking (never smoker, 
smoker <20 pack-years, smoker ≥20 pack-years; pack-year = packs [20 cigarettes] smoked 
per day for number of years of smoking), and multivitamin and mineral supplement use 
(yes or no) were measured using self-reported questionnaires at baseline30, 38 for each 
study. Vascular risk factors included body mass index (weight in kilograms per height [in 
square meters]), diabetes (treated or self-reported), hypertension (blood diastolic blood 
pressure ≥90mmHg or systolic blood pressure ≥140 mmHg, treated, or self-reported), 
and hypercholesterolemia (treated or self-reported). Complement Factor H (CFH) Y402H 
(rs1061170) and Age-Related Maculopathy Susceptibly 2 (ARMS2) A69S (rs10490924), the 
2 main AMD-related single nucleotide polymorphisms, were assessed in each study39, 40.




Participants excluded from analyses were compared with those included using a logistic 
regression model adjusted for age and gender for each characteristic separately. The 
same method was used to compare characteristics of participants included between the 
2 cohorts. 
The associations of MeDi score with incidence of advanced AMD were analyzed using 
Cox proportional hazards models with delayed entry and age as a time scale, which 
allows for a better adjustment for age than the classical Cox models based on time 
from entry in the study41. Model I was unadjusted and model 2 was adjusted for gender, 
AMD grade at baseline (no or early AMD), TEI (continuous), education, body mass index, 
smoking, multivitamin or mineral supplement use, diabetes, and hypercholesterolemia. 
Variables retained in model 2 were factors associated incidence of AMD, with MeDi score, 
or both after adjustment for age and gender (P<0.10). For the pooled analysis, including 
data from both studies, models were adjusted further for the study (fixed study effect).
Low MeDi score was designated as the reference group. The P value for trend was 
calculated by using the median value of the MeDi score for each category. In all Cox 
models, the proportional hazard assumptions were tested.
Participants from the RS-I and Alienor Study were different regarding some characteristics. 
To estimate the potential effect of these differences, interactions between study and 
each covariate were assessed and none were significant. Thus, because the proportional 
hazard assumptions were satisfied and there were no interactions, to account for 
differences between the 2 studies, all models combining both studies were adjusted for 
a fixed effect. 
Secondary Analyses
We also assessed whether associations of MeDi score with incident advanced AMD may 
be the result of individual dietary components by examining associations between the 
individual components of the MeDi score and advanced AMD. Each component was 
introduced independently into model 2. In secondary analyses, CFH Y402H and ARMS2 
A69S polymorphisms were added to model 2. Interactions between CFH Y402H and 
ARMS2 A69S polymorphisms and MeDi score also were analyzed. Interaction terms for 
the number of risk alleles and MeDi score were assessed separately for each genetic 
variant using model 2. All P values representing a 2-tailed test of significance with a of 
0.05 and SAS software version 9.4 (SAS Institute Inc. Cary, NC) were used for all analyses.




Of the 7146 participants at risk of demonstrating advanced AMD, 1337 had no follow-
up data for both eyes. In addition, 813 were excluded because of missing or unreliable 
dietary data (Fig 1). Overall 4996 participants (4446 from RS-I and 550 from Alienor Study) 
free of advanced AMD at baseline with complete and reliable dietary data together 
with follow-up information were included in our analyses. Among the 4996 included 
participants, 155 demonstrated advanced incident AMD (117 from RS-I and 38 from the 
Alienor Study). The mean follow-up time was 9.9 years (range, 0.6-21.7 years) in RS-I and 
4.1 years (range, 2.5-5.0 years) in the Alienor Study.
In both studies, participants included in the analyses tended to be younger than those 
excluded (Table 1). In RS-I, after adjustment for age and gender, included participants 
tended to be women, to have a higher education, to have a history of smoking and 
diabetes, to have a lower TEI, to have a higher MeDi score, and less often to carry a 
CFH Y402H CC genotype than excluded participants. In the Alienor Study, included 
participants were more likely to have a higher education than excluded participants. 
Figure 1. Flowchart showing selection of participants for analyses. AMD = age-related macular degeneration; 
Alienor = Antioxydants, Lipids Essentiels, Nutrition at Maladies Oculaires; RS-I = Rotterdam Study I; TEI = total 
energy intake.
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Participants from the RS-I, tented to be younger, to have a lower education, to have 
a history of smoking, to have less hypertension, to have less hypercholesterolemia, to 
have a higher TEI, to have a lower adherence to the MeDi score, and to have less early 
AMD than participants from the Alienor Study. Also, the presence of the CFH Y402H 
polymorphism differed slightly between the 2 studies. 
Participants from the Alienor Study tented to have a higher median of consumption of 
vegetables, cereals and fish, whereas participants from the RS-I tended to have a higher 
median of consumption of dairy products. Consumption of fruits, legumes, meat and the 
MUFAs-to-SFAs ratio were similar (Table S1, available at www.aaojournal.org).
For both studies, the incidence of advanced AMD was lower among participants who 
showed a high adherence to the MeDi score (Fig 2). The effect of MeDi is more notable 
among older people (85 years of age or older) at higher risk of AMD, but because the 
proportional hazard assumption is respected, associations are considered similar among 
the different age groups.
In the unadjusted model, similar estimations were obtained in both studies, with a 
hazard ratio (HR) of 0.56 (95% confidence interval [CI], 0.33-0.96) in the RS-I and an HR 
of 0.48 (95% CI, 0.18-1.26) in the Alienor Study for participants with a high MeDi score, by 
comparison with those with a low MeDi score (Table 2). When pooling both studies, a 
high MeDi score was associated significantly with a lower risk for incident advanced AMD 
(HR, 0.53; 95% CI, 0.33-0.84; P = 0.009 for trend). These associations remained similar and 
significant after further adjustment for gender, TEI, AMD grade at baseline, education, 
body mass index, smoking, supplement use of multivitamins or minerals, diabetes, and 
hypercholesterolemia (HR, 0.59; 95% CI, 0.37-0.95; P=0.04 for trend). 







































































Figure 2. Graphs showing the incidence of advanced age-related macular degeneration (AMD) according to 
adherence to Mediterranean diet (MeDi) score. Alienor = Antioydants, Lipides Essentiels, Nutrition et Maladies 
Oculaires.
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Table 2. Association between Mediterranean Diet Score and Incidence of Advanced Age-Related Macular 
Degeneration













Rotterdam I 4446 117
HR (95% CI)↕ Reference 0.69 (0.46-1.03) 0.56 (0.33-0.96) 0.036
Alienor 550 38
HR (95% CI)↕ Reference 0.80 (0.39-1.63) 0.48 (0.18-1.26) 0.16
Overall 4996 155
HR (95% CI)§ Reference 0.71 (0.50-1.00) 0.53 (0.33-0.84) 0.009
Model 2II
Rotterdam I 4104 108
HR (95% CI)↕ Reference 0.70 (0.46-1.06) 0.69 (0.40-1.20) 0.19
Alienor 539 38
HR (95% CI)↕ Reference 0.83 (0.38-1.80) 0.52 (0.19-1.40) 0.23
Overall 4643 146
HR (95% CI)§ Reference 0.70 (0.49-1.01) 0.59 (0.37-0.95) 0.04
Alienor = Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires; CI = confidence interval; HR = hazard ratio. 
* P value for trend calculated using the median value for each Mediterranean diet score category.
† Model 1, unadjusted model.
↕ Estimated using Cox proportional hazard model.
§ Estimated using Cox proportional hazard model with additional adjustment for study.
II Model 2, adjusted for gender, total energy intake, age-related macular degeneration grade at baseline, 
education, body mass index, smoking, supplement use of multivitamins or minerals, and presence of diabetes and 
hypercholesterolemia
In secondary analyses, we further adjusted for CFH Y402H and ARMS2 genes and the HR 
remained unchanged (data not shown). Interaction terms between MeDi and CFH Y402H 
and ARMS2 genes were not statistically significant (P=0.89 and P=0.18 for interaction, 
respectively; data not shown). 
Adherence to MeDi score was not associated significantly with the risk for incident 
neovascular AMD in the RS-I, in the Alienor Study, or in the pooled analysis (Table 3). It 
was associated significantly with the risk for incident atrophic AMD in the RS-I (HR, 0.41; 
P=0.046 for trend), but the association did not reach significance in the Alienor Study (HR, 
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0.52; P=0.52 for trend). In the pooled data analysis, a higher MeDi score was associated 
significantly with a reduced risk for incident atrophic AMD (HR, 0.42; 95% CI, 0.20-0.90; 
P=0.04 for trend).
We assessed whether the benefit of high adherence to the MeDi score was the result of 
a specific component. Using the gender specific median as cutoffs, no component was 
associated significantly with incidence of advanced AMD (Table S2, available at www.
aaojournal.org). 
Table 3. Association between Mediterranean Diet Score and Incidence of Advanced Neovascular and Atrophic 
Age-Related Macular Degeneration






Mediterranean Diet Score categories





Rotterdam I 4104 68
HR (95% CI)† Reference 0.87 (0.51-1.51) 1.03 (0.53-1.99) 0.91
Alienor 538 18
HR (95% CI) † Reference 0.80 (0.25-2.63) 0.75 (0.20-2.91) 0.65
Overall 4642 86
HR (95% CI)↕ Reference 0.78 (0.48-1.27) 0.88 (0.49-1.57) 0.64
Atrophic AMD
Rotterdam I 4104 52
HR (95% CI) † Reference 0.61 (0.34-1.10) 0.41 (0.16-1.03) 0.046
Alienor 538 21
HR (95% CI) † Reference 1.08 (0.38-3.06) 0.52 (0.13-2.12) 0.52
Overall 4642 73
HR (95% CI)↕ Reference 0.70 (0.42-1.15) 0.42 (0.20-0.90) 0.04
Alienor = Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires; AMD = age-related macular degeneration; 
CI = confidence interval; HR = hazard ratio.
* P value for trend is calculated using the median value for each Mediterranean diet score category.
† Cox proportional hazard model adjusted for gender, total energy intake, AMD grade at baseline, education, body 
mass index, smoking, supplement use of multivitamins or minerals, diabetes and hypercholesterolemia.
↕ Cox proportional hazard adjusted for gender, total energy intake, AMD grade at baseline, study, education, body 
mass index, smoking, supplement use of multivitamins or minerals, diabetes and hypercholesterolemia.




High adherence to the MeDi was associated with a 41% reduced risk of incident advanced 
AMD in the pooled analysis. None of the 9 components, including vegetable, fruit, 
legume, cereal, fish, meat, dairy products, and alcohol consumption and MUFAs-to-
SFAs ratio were associated significantly with incidence of advanced AMD, highlighting 
the importance of assessing dietary patterns rather than single components. In our 
studies, a high adherence to the MeDi was associated significantly with a reduced risk of 
incident atrophic AMD. A similar association was observed for neovascular AMD but did 
not reach statistical significance. 
By evaluating the individual and the pooled associations of the adherence to the MeDi 
and incidence of advanced AMD in 2 well-established and harmonized European 
population-based prospective cohorts, this study expands on prior studies, mainly cross-
sectional, case-control, and clinical trials on this topic. Visual impairment resulting from 
AMD could influence dietary practices; prospective studies, by assessing diet prior the 
onset of the disease, limit reverse causation. Thus, a prospective design is more accurate 
and less biased than a cross-sectional or case-control design to evaluate the association 
between diet and AMD. In addition, although using a prospective design, clinical trials are 
limited by the selected nature of the sample. Results from population-based studies are 
more generalizable. 
Our results are partially consistent with previous cross-sectional studies: the Carotenoids 
in Age-Related Eye Disease Study (CAREDS) reported a lower prevalence of early AMD in 
American women with high adherence to the MeDi23, the Coimbra Study demonstrated a 
lower prevalence of any AMD in Portuguese participants who showed a high adherence 
to the MeDi26, 27, and the European Eye Study showed a lower prevalence of neovascular 
AMD in participants with a high MeDi score, whereas atrophic AMD was not associated 
with MeDi score25. Our findings confirm the post hoc analyses of the Age-Related Eye 
Disease Study (AREDS) clinical trial. In this sample of American participants 55 to 80 
years of age, a high MeDi score was associated with a 26% lower risk of progression to 
advanced AMD24. The AREDS study also showed the fish and vegetable components 
were associated with a lower risk of progression to advanced AMD24. Our study were in 
the same direction, but did not reach the statistical significance when gender-specific 
median cutoffs were used. No significant interactions were observed between MeDi 
score and CFH Y402H and ARMS2 genes. Our findings report a significant association with 
advanced AMD. Regarding subtypes, only atrophic AMD was associated significantly with 
MeDi score. For neovascular AMD, even if the association was not statistically significant, 
the HRs were similar to those for atrophic AMD. These differences could be explained 
by a low number of incident cases. In the European Eye Study, the only study to show 
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separate results for the 2 advanced forms of AMD, the association was significant with 
neovascular AMD. Although in our studies this association with neovascular AMD was not 
statistically significant, HRs were similar to those for the European Eye Study. 
Our results thus support public health efforts to emphasize adherence to the MeDi 
for everyone. The biological basis for the potential benefits of the MeDi is associated 
with a decrease in oxidative stress and inflammation, which are also involved in the 
pathophysiology of AMD42, 43.
The Prevención con Dieta Mediterránea (PREDIMED) study, a clinical trial among persons 
at high cardiovascular risk, showed that adhering to a MeDi reduced the incidence of 
major cardiovascular events20. Median consumptions were similar to the goals suggested 
by PREDIMED for vegetables (≥2 servings/day), fish (≥3 servings/week), and meat (<1 
serving/day) in the Alienor Study and for meat in the RS-I. For both studies, the medians 
of fruit and legume consumption were less than the goals of PREDIMED (≤3 serving/
day) as well as the medians of vegetable and fish consumption in the RS-I. Although 
the medians in our study were lower for consumption of vegetables and fruits, the 
association with the MeDi score was significant, suggesting the importance of a global 
approach to prevent the development of AMD. 
By showing a prospective association between AMD and MeDi, an energy-unrestricted 
diet mainly composed of nutrient-rich food, our study confirmed the importance of 
dietary quality focused on healthful foods and dietary patterns rather than single nutrients 
or low-energy diet for AMD.
In observational studies, residual confounding is always a concern. In the present study, 
results were similar in the basic model (unadjusted model) and the fully-adjusted model 
(adjusted for gender, TEI, AMD grade at baseline, cardiovascular risk factors, educational 
level, and dietary supplement use), suggesting that our results are not highly confounded. 
In the fully adjusted model, the association between MeDi and incidence of AMD seems 
to be weaker in the RS-I. This could be explained by a lower statistical power resulting 
from a low incidence of participants demonstrating advanced AMD combined with 
the increasing number of covariates compared with the unadjusted model. In addition, 
our findings are based on prospective follow-up, thereby limiting reverse causation. 
However, only randomized clinical trials can prove the causal nature of the associations. 
Such randomized clinical trial testing dietary interventions have proven to be efficient in 
the prevention of stroke20 or diabetes44, for instance, but none are available in the field 
of AMD.
Selection bias cannot be dismissed completely, because participants included in this 
analysis were different from nonparticipants in both the RS-I and Alienor Study. Moreover, 
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participants included from the RS-I were different from those from the Alienor Study 
regarding some socio-demographic and medical characteristics as well as follow-up 
duration and frequency. Incidence rates of AMD also were higher in the Alienor Study than 
in the RS-I. These differences may be explained by the older age at baseline and a closer 
follow-up (every 2 years instead of every 5 years in the RS-I, with home examinations 
for participants unable to come to the hospital in the Alienor Study, but not in every RS-I 
follow-up visit), or by different incidence rates in France and The Netherlands. 
The MeDi score uses cutoffs based on each study population and results can be 
generalizable only to similar populations. To calculate the MeDi score, we used validated 
FFQs for both studies, adapted to the specific dietary habits of each population (France 
and The Netherlands). Because the FFQ in the Alienor Study was a 40-item FFQ, we 
used the 24-hour recall to calculate the MUFAs-to-SFAs ratio and the TEI to increase the 
exactitude of their ascertainment, as published previously21. The distribution of the MeDi 
score was different between the 2 studies, and participants from RS-I were less adherent. 
This result was expected in a Northern European population. 
Despite these major differences in populations (different countries, different periods, 
different generations, and different dietary habits) and methods (different follow-up time 
and frequency and different dietary assessment methods), the association between 
MeDi and incidence of advanced AMD was similar in both cohorts. This association thus 
seems to be robust. 
To strengthen our analyses, we excluded participants with unusually high or low TEI and 
adjusted for several factors know to be related to MeDi and AMD. We used a well-known 
and validated score to assess diet and probable synergistic effects between nutrients 
and food groups. Our MeDi score was developed by using gender-specific thresholds 
according to each study to account better for differences between men and women 
and between studies. Other strengths include a large sample from 2 well-documented 
and data-harmonized population-based prospective cohorts in the framework of the 
European EYE-RISK project.
In conclusion, combined results from our 2 observational studies suggest that adopting 
an energy-unrestricted diet rich in healthful nutrient-rich foods such as fruits, vegetables, 
legumes and fish and reducing the unhealthful foods such as red and processed meats 
and savory and salty industrialized products may contribute to the prevention of AMD.
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Age-related macular degeneration (AMD) is one of the leading causes of blindness in 
the Western world, and the pathophysiology of this complex disease remains poorly 
understood. The overall aims of this thesis were to investigate the prevalence and 
progression of AMD, determine how genetics plays a role in the disease, and determine 
how lipids and nutrition affect the development of the disease. In this general discussion, 
we will review the findings of this thesis, discuss our current view regarding AMD, and 
consider the main findings of this thesis in the context of our current knowledge by 
discussing the clinical relevance and directions for future research.
The effects of aging 
AMD is a disease that affects the elderly. As we age, our physiology changes, leading 
to loss of function and increasing our vulnerability to a wide range of diseases and 
conditions1. With increasing age, various biological and physiological processes occur, 
including shortening of our telomeres with each cell division, an accumulation of cellular 
damage, and cumulative metabolic damage, all of which are regulated by genes 
involved in repair and conservation2. 
Aging also affects our eyes. At the tissue level, the retina undergoes reorganization, 
with a loss of rod cells compensated by larger rod inner segments3,4. In addition, the 
so-called on bipolar cells become elongated and extend into the outer nuclear layer at 
the periphery of the retina, possibly compensating for reduced signal transduction in the 
aging retina5. 
Importantly, the retinal pigment epithelium (RPE) is also affected by aging; this retinal 
layer is particularly vulnerable to metabolic waste, as it is composed of terminally 
differentiated cells and—unlike actively dividing cells—cannot dilute this waste2. The 
fovea contains the highest density of RPE cells and is mainly hexagonal in shape, but 
changes in later life to other polygonal shapes without changing the number of cells6. In 
addition, as we age the number of desmosomes, which maintain the blood-retina barrier, 
decreases. Moreover, Bruch’s membrane, located below the RPE, becomes thicker with 
each passing year, doubling or even tripling in thickness at the macula; in contrast, the 
complex formed between Bruch’s membrane and the RPE becomes thinner with each 
passing year7. The increased thickness of Bruch’s membrane reduces the bi-directional 
transport of particles between the RPE and the choroid8. 
Some aging-related changes in the retina are due to changes in cellular metabolism, as 
the retina has the highest consumption of oxygen per gram tissue, even higher than the 
brain9. Due to this high level of metabolism, molecular damage due to reactive oxygen 
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species (ROS) is inevitable, and oxidative stress damages both proteins and DNA10. High 
levels of ROS also cause the peroxidation of polyunsaturated fatty acids, which are 
present in high levels in the cell membranes of photoreceptors and RPE cells, leading to 
the loss of these cells11. 
Together, these aging-related changes in our physiology create an ideal environment for 
the development of AMD. 
Bruch’s membrane
Bruch’s membrane forms the basal layer of the RPE and acts as a structural support for 
the choriocapillaris, consisting of an elastic layer and two collagen layers12. Aging effects 
the structural integrity13 of Bruch’s membrane, resulting in an increase in thickness. 
To maintain its function, enzymes known as matrix metalloproteinases (MMPs) break 
down the extracellular matrix; these enzymes are regulated by tissue inhibitors of 
metalloproteinases (TIMPs), and the activity of TIMP-3 increases in Bruch’s membrane 
with aging14. In contrast, MMP-2 and MMP-9 are more frequently found in Bruch’s 
membrane in the elderly compared to younger individuals, but are more often inactive 
with aging15. In addition, genetic variations in the MMP9 and TIMP3 genes have been 
associated with AMD and may contribute to the thickening of Bruch’s membrane11. Other 
genetic variants have also been associated with AMD and include genes involved in the 
extracellular matrix16, including the COL8A1 gene, which encodes an alpha chain in type 
VIII collagen.17 A common gene variant associated with an increased risk of AMD was 
previously identified16; however, using gene-based analyses we found that rare protein-
altering variants are more prevalent in patients with AMD compared to controls. This 
finding underscores both the importance of the COL8A1 gene in the pathogenesis of 
AMD and the key role of Bruch’s membrane in this process (Chapter 4.1). The structural 
changes, including thickening of Bruch’s membrane, may affect the transport of nutrients 
and waste products through the membrane, which can lead to the buildup of deposits 
and waste products in the membrane as we age, as discussed below. 
Drusen 
Beginning in the second decade of life, debris becomes deposited in the collagen 
layers of Bruch’s membrane18. Over time, focal deposits known as drusen are formed19, 
containing lipids, minerals, and a wide variety of proteins20,21. Drusen are typically the first 
sign of AMD and are often used to distinguish between AMD and other retinal diseases. 
A high percentage of the general population has small drusen22,23; thus, this finding is 
considered to be associated with the normal aging process, rather than indicative of 
AMD. When these small drusen increase in number and/or size, however, the risk of 
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pathology increases24. The lipids and proteins contained in drusen are derived from 
both the systemic circulation and the retina itself; in the retina, lipid metabolism plays an 
important role in this process25-27.
The role of circulating lipids and lipoproteins in AMD has been studied extensively26. 
The RPE expresses receptors that allow it to take up both low-density lipoproteins (LDL) 
and high-density lipoproteins (HDL) from the systemic circulation into the retina28,29. 
Interestingly, studies regarding lipids and AMD have yielded conflicting results30. In 
Chapter 5.1, we report our findings in a large European study showing that patients with 
AMD have higher levels of circulating HDL-cholesterol and lower levels of triglycerides 
compared to controls, with the highest increase in the largest subclass of HDL31. We also 
found that high HDL-cholesterol and low triglyceride levels are associated with large 
drusen (Chapter 5.1) and an increased risk of AMD. Moreover, we found that genetic 
variations are associated with changes in lipid levels (Chapter 5.1). A novel finding is, 
using Mendelian randomization analyses, that these genetic variants act on AMD by 
changing lipid levels and lipid subclasses32,33. Mendelian randomization analysis uses 
variations in genes in a randomized controlled trial to examine the putative effects of 
modifiable factors on a disease. This analysis is possible because genes are passed 
randomly from the parents to their children, and the genotype is not related to possible 
confounding factors. In addition, the disease does not affect the genetic variation, so 
reverse causation—which can play a major role in observational studies—is not possible. 
The large subclass of HDL in AMD might affect their transport. One of the principal 
functions of HDL-cholesterol is to carry complement factors such as C2, C3, C4B, C5, 
and complement factor B, as well as subcomponents of complement 1 and many other 
proteins34,35. Large HDL subclasses are significantly associated with systemic activation 
of the complement system31, whereas smaller HDL subclasses reduce complement 
activation. This finding has led to the hypothesis that the size of HDL particles—a reflection 
of their composition and function—drives the pathology. For example, large subclasses 
of HDL molecules are likely to contribute to the formation of drusen by inducing a pro-
inflammatory state. 
In the eye, the RPE and photoreceptors also produce cholesterol36 and package 
cholesterol particles into HDL-cholesterol for bi-directional transport between the RPE 
and photoreceptors, a process facilitated in part by the enzyme CETP (cholesteryl ester 
transfer protein)29,37. Cholesterol from photoreceptors is re-processed in the RPE by 
autophagosomes and lysosomes. In AMD, the processing of internalized photoreceptor 
outer segment disks can be reduced by impaired function of autophagosomes, leading 
to a disruption in cholesterol metabolism in the RPE38,39. To prevent the accumulation 
of cholesterol in the RPE, cholesterol is secreted into the choriocapillaris in lipoprotein-
150421-colijn-layout.indd   183 17/03/2021   17:41
184
CHAPTER 6
like particles by the phospholipid-transporting ATPase ABCA1(refs. 29,40,41). With aging, 
this secretion can contribute to the accumulation of debris in Bruch’s membrane. Any 
disruption in cholesterol metabolism in the retina can affect the risk of developing 
drusen; moreover, oxidation of these lipids can cause the molecules to form crosslinks, 
thus driving the development of drusen. Finally, the cellular response to the developing 
drusen and activation of the complement system can cause the disease to progress to 
the next stage. 
Genetics
Genetics has long been known to play a major role in the pathogenesis of AMD, as 
was shown in twin studies and family aggregation studies42-44. Recently, genome-wide 
association studies (GWAS) and next-generation sequencing techniques have enabled 
researchers to investigate genetic variations in even more depth. For example, a large 
GWAS found a set of 52 independent genetic variants associated with AMD16, to which 
12 novel loci and 20 novel genes were subsequently added by the largest, most recent 
GWAS45. Other studies using different sequencing techniques, as well as family studies, 
identified more than 100 rare AMD-associated variants in at least 13 genes, the majority 
of which encode complement-related proteins46. Although the functional role of the 
majority of these variants with respect to AMD is currently unknown, they provide new 
insights into the pathogenesis of AMD. For example, studying the proteins encoded 
by these genes has revealed several functional pathways, including the complement 
system, lipid metabolism, and the extracellular matrix (Chapter 4.2). 
The complement pathway is an important component of the innate immune system, 
and activation of this pathway initiates a signaling cascade that ultimately leads to cell 
lysis. Both causal and protective genetic variants in this cascade have been associated 
with AMD16, and our population-based studies revealed that the causal variants are 
more prevalent in late AMD than in newly identified patients (Chapter 4.2). It has long 
been known that the complement system plays an important role in the pathogenesis 
of AMD47, and our study described in Chapter 4.2 revealed significantly higher genetic 
pathway risk scores in patients with late AMD compared to controls. Importantly, drusen 
contain complement components34, and patients with AMD have elevated serum levels 
of activated complement48,49, suggesting that the pro-inflammatory component of AMD 
is not specific to the eye but is likely systemic. 
The protein ARMS2 (age-related maculopathy susceptibility 2) plays a major role in the 
pathogenesis of AMD. Although its function is not fully known, recent studies suggest 
that it may be part of the complement pathway, serving as a complement regulator 
expressed at the cell surface. ARMS2 binds to apoptotic and necrotic cells, mobilizing the 
protein properdin, which activates the complement system50. Other, non-complement-
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related genes include genes involved in the extracellular matrix, which likely play a 
role in maintaining Bruch’s membrane, and lipid-related genes, which likely play a role 
in the formation of drusen as described above. We found that for the vast majority of 
the general population, several genetic pathways contribute to the risk of developing 
AMD (Chapter 4.2). Generally speaking, individuals who have more AMD-associated risk 
variants are more susceptible to developing AMD. In addition to the common variants, 
rare variants also contribute to the risk of developing AMD, as discussed previously for 
the COL8A1 gene (Chapter 4.1)46. 
Many of the genetic variants associated with AMD are common variants. As a 
consequence, the vast majority of the general population has a genetic risk of AMD, 
even among individuals who also carry genetic variants that protect against AMD 
(Chapter 4.2). When separating early AMD from late AMD with geographic atrophy (GA) 
and/or choroidal neovascularization (CNV), we found that the complement pathway 
is nearly always linked genetically to the development of late AMD (Chapter 4.2). 
Interestingly, risk variants in complement genes are related to a pro-inflammatory state 
that can protect younger individuals, but can cause degeneration over time when this 
state is perpetually active51,52. In the elderly, the presence of drusen may exacerbate the 
adverse effects of complement activation, including tissue damage, an influx of immune 
cells, fibrosis formation, and a burst of ROS. Thus, antioxidants and lifestyle changes can 
help reduce the formation and effects of ROS, reducing tissue damage. 
Lifestyle
In addition to genetic factors, behavior and lifestyle can also affect the risk of developing 
AMD. Given the high heritability of AMD and the current lack of a cure, research has 
focused primarily on identifying factors that can be modified in order to affect the 
development of AMD, including behavior and lifestyle. One such modifiable factor is 
smoking, which has consistently been associated with a more than twofold increase 
in the risk of developing AMD53,54. Smoking is believed to induce oxidative stress via 
free radicals, causing lipid peroxidation and inflammation55,56, thus contributing to the 
pathophysiology of AMD. A variety of other factors have also been investigated for their 
possible role in AMD, ranging from iris color57 and sunlight58 to cardiovascular-related 
factors59, body-mass index60, and waist-to-hip ratio61,62; however, none of these factors 
has been consistently associated with AMD61,63-65.
In addition, many studies have investigated the role of nutrition in AMD. Initial studies 
focused on carotenoids and vitamins66, but later studies also included vitamin C, vitamin 
E, lutein, zeaxanthin, and zinc.67,68 Consuming foods rich in omega-3 fatty acids such as 
nuts and fatty fish has been associated with a reduced risk of developing late AMD69. 
It is generally believed that these nutrients and compounds protect against AMD by 
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reducing the pro-inflammatory state and reducing free radicals70. In addition, studies 
have found that consuming food items containing these nutrients, including fruit, fish, 
and vegetables, can have a protective effect against late AMD71,72. Indeed, studies of 
dietary behavior have found that individuals who adhere to a Mediterranean diet rich in 
antioxidants and omega-3 fatty acids can reduce their risk of developing late AMD by 
41% (Chapter 5.2)73-75. Thus, diet can play a major role in reducing the risk of developing 
AMD. Conversely, an unfavorable lifestyle can increase the risk of developing AMD, 
independent of genetics, for example as shown in a twin study in which differences in 
lifestyle were associated with different rates of disease progression76. These findings are 
supported by our population-based studies in which a healthy lifestyle that includes not 
smoking and eating plenty of fruit, fish, and vegetables reduces the risk of developing 
AMD, regardless of the genetic risk profile (Chapter 4.2). Thus, living a healthy lifestyle 
can reduce the risk of developing AMD, even in individuals who have a low risk based 
on genetics. 
Disease progression
When a patient is initially diagnosed with AMD, a major clinical goal is to determine the 
patient’s prognosis with respect to the course of the disease. For patients with early signs 
of pathology such as drusen, preventive interventions may be indicated. Even though a 
relatively large percentage of elderly individuals develop drusen at some point, a small 
subgroup progresses to early AMD, and an even smaller subgroup will develop late 
AMD (Chapter 2.1)77. Specifically, only 0.4% of individuals with small drusen develop 
late AMD within 5 years78. Whether a patient progresses to a more severe or higher 
pathological stage of AMD depends on a variety of factors, including genetics79, aging, 
and lifestyle, which together contribute to structural changes combined with a low-
grade inflammatory state (Figure 1). 
Compared to the early stages of disease, various phenotypic features in AMD have been 
associated with disease progression. Both drusen area and the presence of large drusen 
are risk factors for developing late AMD59,80,81. Presence of a specific type of drusen known 
as calcified drusen appears to be associated with an increased risk of developing GA82, 
although calcified drusen can also lead to CNV82. However, these results are based on 
a single study involving 138 patients with one year of follow-up; thus, further research is 
clearly needed. Another type of drusen, reticular pseudodrusen, present with drusenoid 
deposits between the RPE and the photoreceptor outer segments and increase the risk 
of developing late AMD, particularly GA83,84, as well as more rapid growth of the GA lesion 
toward the drusen85. Pigmentary changes have also been associated with progression to 
late AMD78,86. In addition, we found that both pigmentary changes and drusen area are 
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associated with the progression of unilateral to bilateral disease and/or the progression 
from early AMD to late AMD (Chapter 2.2); importantly, this association appears to be 
independent of genetic risk factors and smoking, consistent with previous reports17,86. 
In addition, even late AMD can progress further. For example, the development of 
CNV has been associated with a genetic variant in the MMP9 gene16. However, a major 
challenge is quantifying disease progression in this stage. The development of GA is 
associated with the shape—but not the size—of the baseline lesion87,88. For example, we 
found that estimating the roundness of a lesion can be used to predict the rate of GA 
growth (Chapter 3.2). Furthermore, extrafoveal GA lesions tend to grow more rapidly 
than foveal GA lesions89, and lesion growth toward the periphery is more rapid than 
growth toward the fovea90. Moreover, our results confirm91,92 that GA growth in one eye 
is correlated with the severity of AMD in the other eye, and bilateral GA growth is closely 
correlated, with a correlation coefficient of 0.87 (Chapter 3.1). However, we also found 
wide variation with respect to lesion growth; therefore, further research is needed in 
order to reliably predict lesion growth in individual patients, particularly individuals who 
are at risk of rapid progression.
Prevalence and prediction
Our population-based studies revealed that the prevalence of late AMD among Europeans 
ranges from 0.1% among 55-59-year-olds to 9.8% among individuals 85 years of age and 
older (Chapter 2.1), providing the first such overview within the European population. 
Interestingly, we found that the prevalence decreased over the past decade, and this is 
likely due to our improved lifestyle and reduced numbers of smokers93. Unfortunately, 
however, even in the context of this downward trend the number of individuals with AMD 
is expected to increase in the next twenty years due to our aging population (Chapter 2.1); 
thus, ophthalmologists are encouraged to reorganize the healthcare system, and new 
therapies are urgently needed. Aging provides the foundation for developing AMD, while 
genetics and environmental factors drive the development and progression of AMD 
(Figure 1). Nevertheless, changes in lifestyle can reduce the risk and/or severity of AMD.
The risk of developing AMD can be predicted at multiple levels. The first level is to 
predict individuals who are susceptible to developing AMD. Many studies have focused 
on distinguishing between high-risk individuals and those with an average or low risk of 
AMD. Given the disease’s high heritability, the large effect of the complement pathway, 
and the large number of low-risk genes identified to date, one can estimate with 
high accuracy the AMD risk of an individual and discriminate between risk categories 
(Chapter 4.2). Thus, in principle the risk of developing AMD can be estimated at birth. 
However, although screening for genetic factors can provide an extremely powerful tool 
for estimating the life-long cumulative risk of developing AMD, they are a rather poor 
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predictor of when the disease will likely develop. The age at onset is a key factor for high-
risk individuals, but is also relevant for optimizing the start of preventive measures. The 
model can be improved by incorporating environmental and phenotypic factors based 




Changes in Bruch’s membrane
Progression
Figure 1. Flow chart summarizing the clinical development of AMD. 
Several models have been developed in order to differentiate between patients with late 
AMD and controls, as well as to predict who will likely develop late AMD over time based 
on genetics, lifestyle, and/or phenotypic factors. These models have yielded a predictive 
value ranging from 0.67 in an early study95 to as high as 0.96(ref. 96), with varying levels 
of validity97,98. Achieving such a high prediction level suggests that it might be possible 
to screen for high-risk individuals. Given that changing one’s lifestyle can significantly 
reduce the risk of developing AMD, these models can be used to identify high-risk 
individuals as early as possible and begin steering them toward living a healthier lifestyle. 
In addition, major progress has been made with respect to predicting the rate of 
progression from early AMD to late AMD, as well as the rate of lesion growth in GA. This 
information will be essential for designing robust clinical trials and intervention studies. 
Risk factors associated with rapid disease progression include bilateral AMD lesions, 
genetic susceptibility, smoking, and infrequent consumption of fish99. With respect to GA, 
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the shape and location of the lesion can predict the rate of lesion growth (Chapter 3.2). 
Obtaining an accurate prognosis can help researchers investigate the effects of new 
interventions for GA in clinical trials. Given the high importance of preventing the 
progression of GA, software designed to analyze multimodal ocular imaging data, as 
well as clinical tools to identify high-risk individuals, are needed in order to facilitate 
patient follow-up and provide efficient healthcare options. 
Methodological considerations
Each chapter in this thesis addressed the respective methodological considerations; 
here, we discuss some of the more general considerations. Each chapter used datasets 
obtained from several studies; in some cases these datasets were combined to increase 
the sample size. To facilitate the use of several studies and combine datasets, data 
harmonization is required, which can result in loss of data. In addition, heterogeneity can 
be introduced due to differences in the study protocols and/or the study location. In 
our analysis, we addressed heterogeneity either by correcting for it or by repeating the 
analyses separately for each study site. 
The long-term follow-up of population-based studies provides added value, but such 
studies often involve intervals of five years or longer. The use of follow-up data comes at 
a price of reduced accuracy with respect to time-estimated outcomes, as the pathology 
can change in less than five years, and mortality—which can be high in studies involving 
elderly participants—can limit the ability to examine the participants. Thus, our results 
provide a rough estimate and will need to be refined in future studies using other designs. 
During the follow-up period of the studies included in this thesis, imaging techniques 
have improved, and the system for grading AMD was refined. This may have affected the 
results over time, as some diagnoses are now easier to make. Although this may have 
affected our follow-up data, excluding data obtained using new technologies would 
likely have compromised our analysis. Advances in medicine and technology are always 
occurring and are inevitable when conducting longitudinal research, and this must be 
considered when interpreting the results. 
The use of deep learning algorithms is rapidly growing in the fields of image interpretation 
and disease grading100,101. The translation from data to clinical care and prevention is far 
from clear and differs from classic translation using clinical epidemiological outcomes 
such as relative risk. Although machine learning–based interpretation is progressing 
rapidly, the images must still be reviewed manually in order to achieve the highest 
accuracy. 




Due to changes in our global demographics, the number of individuals who develop 
AMD is only going to increase in the coming 20 years, placing considerable pressure 
on efforts to ensure sustainable healthcare. For example, referrals to ophthalmologists 
will increase, as will the number of anti-VEGF injections administered and the number 
of OCT scans performed. In addition, the costs associated with treating and educating 
the visually impaired will increase. Last, but certainly not least, the growing number of 
patients with late-onset disorders such as AMD will result in a loss of productivity, due 
in part to the high burden placed on family members and society with respect to caring 
for these patients. 
Adopting a healthier lifestyle can significantly reduce the risk of developing certain 
diseases, but it may not necessarily prevent the disease altogether, particularly in 
the case of AMD, which is driven largely by genetic susceptibility. This underscores 
the importance of not only focusing on prevention, but also investing in developing 
new interventions that can slow or even stop the disease progression. Importantly, a 
therapeutic window exists during the development from unilateral AMD to bilateral 
AMD, as well as during the progression of GA. Ideally, specific interventions should be 
developed and then administered at the first signs of late AMD; however, the ultimate 
therapeutic goal is to develop a cure that will halt the pathology.
Preventing blindness due to AMD requires three key steps. First, the general public must 
be better educated regarding AMD, particularly given the current lack of awareness102. 
This education should include the potential implications of AMD, as well as the possibility 
of preventing the disease by adopting a healthy lifestyle. In this respect, we can draw 
lessons from existing awareness campaigns103 in other parts of the world, including 
Australia104, Singapore105, Ireland, and France106,107. These awareness campaigns are 
designed to inform the public regarding AMD, which symptoms to watch for, when to 
visit an ophthalmologist, and how to live a healthy lifestyle104. In addition, relatives of 
patients must be made aware of the heritability of AMD and must have easy access to 
ophthalmic checkups starting at the age of 60. The second step involves a shift in focus 
from anti-VEGF treatment for neovascularization and checkups for GA toward prevention 
in high-risk individuals who have a family history of AMD and/or a high-risk genetic 
profile. This approach could include genetic testing and personalized advice based on 
algorithms designed to predict one’s likelihood of developing AMD, as shown recently94, 
and guiding individuals toward living a healthier lifestyle108. Lastly, well-designed clinical 
trials that focus on genetics and/or pathology and have sufficient follow-up duration 
are needed. These trials can be improved by using deep learning algorithms to predict 
the development and progression of GA, identify specific patient groups based on 
the intervention, and follow the disease progression or the effect of treatment more 
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accurately, as these algorithms can detect relatively small changes in disease status 
with high accuracy. Importantly, improving patient selection and increasing the ability 
to detect small changes in disease status will reduce the number of patients needed to 
effectively measure the effect size of the intervention and will shorten the study duration, 
thereby reducing study costs and accelerating the discovery process. 
Future perspectives
Developing new interventions and therapies for AMD requires additional research that 
builds upon existing knowledge, as well as new fields of study. With respect to genetic 
risk, an interesting question is whether combinations of genetic variants occur more 
often in patient subgroups, for example a risk variant in a complement gene together 
with a risk variant in an extracellular matrix gene, which when combined increase the risk 
of developing AMD more than expected based on each separate variant. Thus, linking 
genetics to the phenotype and disease progression could provide further insight into the 
pathology of AMD, as shown previously by linking variants in MMP9 to CNV and variants 
in PRMT6 and LSS to the progression of GA16,109. 
In addition, the role of lifestyle on the risk of AMD should be studied further by 
investigating the association between epigenetic changes and AMD. For example, in 
addition to increased oxidative stress, smokers develop a specific DNA methylation 
profile that can revert back to the previous profile—at least to a certain extent—when 
they quit smoking110. Moreover, the odds ratio (i.e., relative risk) for AMD is lower among 
former smokers compared to current smokers111; an interesting question is how much 
of that difference can be attributed to smoking-induced epigenetic changes. Similarly, 
the benefits of changing to a healthier diet rich in fruit, fish, and vegetables could be 
investigated. 
An emerging field driven by hypothesis-free research focuses on proteomics and 
metabolomics, giving valuable insights into the pathophysiology of AMD and revealing 
potential disease biomarkers. Ideally, these biomarkers could be used to detect preclinical 
disease or indicate whether a specific treatment is likely to be more beneficial than 
another. Proteomics-based studies have been performed using aqueous humor obtained 
from patients with GA or CNV, revealing for example proteins related to inflammation 
and the extracellular matrix112,113. Additional studies have also been performed focusing 
on the RPE and blood samples, showing promising results with respect to putative 
biomarkers such as proteins and metabolites related to the complement pathway, lipids, 
and oxidative stress30. Imaging biomarkers are also being investigated and could serve as 
a valuable addition for detecting preclinical disease and/or disease progression. 
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Recent studies have examined the role of the gut microbiome in AMD, as this 
microbiome facilitates the uptake of nutrients from food and can affect metabolism and 
inflammation114,115. Thus, altering the gut microbiome in patients with AMD or in high-risk 
individuals by consuming prebiotics and probiotics can be explored as a potential new 
therapeutic strategy.
The ability to detect AMD will likely be facilitated by advances in automated grading of 
retinal imaging data. Although developments in this field are rapidly emerging, the results 
are currently not sufficiently accurate to become fully independent without the need 
for human involvement. Further advances in artificial intelligence–based solutions will 
facilitate the diagnosis of early AMD, thereby helping to prevent or delay the progression 
to late AMD. Thus, these technological breakthroughs should be embraced by the clinical 
community and advanced using the growing knowledge base of ophthalmologists. 
Ultimately, treating AMD will require an interdisciplinary approach using the latest 
technologies to detect the disease in its earliest stages. Mathematicians and 
epidemiologists should work together to develop and optimize algorithms that predict 
the risk of AMD, and healthcare professionals should work to educate the general public 
regarding the benefits of living a healthy lifestyle, quitting smoking (or never starting). 
Finally, scientists and clinicians should work together to develop and administer new 
therapies for AMD.




1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 
2013;153(6):1194-1217.
2. Kirkwood TB. Understanding the odd science of aging. Cell. 2005;120(4):437-447.
3. Curcio CA, Millican CL, Allen KA, Kalina RE. Aging of the human photoreceptor mosaic: evidence 
for selective vulnerability of rods in central retina. Invest Ophthalmol Vis Sci. 1993;34(12):3278-
3296.
4. Gao H, Hollyfield JG. Aging of the human retina. Differential loss of neurons and retinal pigment 
epithelial cells. Invest Ophthalmol Vis Sci. 1992;33(1):1-17.
5. Eliasieh K, Liets LC, Chalupa LM. Cellular reorganization in the human retina during normal 
aging. Invest Ophthalmol Vis Sci. 2007;48(6):2824-2830.
6. Ach T, Huisingh C, McGwin G, Jr., et al. Quantitative autofluorescence and cell density maps of 
the human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2014;55(8):4832-4841.
7. Ko F, Foster PJ, Strouthidis NG, et al. Associations with Retinal Pigment Epithelium Thickness 
Measures in a Large Cohort: Results from the UK Biobank. Ophthalmology. 2017;124(1):105-117.
8. Moore DJ, Hussain AA, Marshall J. Age-related variation in the hydraulic conductivity of Bruch's 
membrane. Invest Ophthalmol Vis Sci. 1995;36(7):1290-1297.
9. Anderson B, Jr., Saltzman HA. Retinal Oxygen Utilization Measured by Hyperbaric Blackout. 
Arch Ophthalmol. 1964;72:792-795.
10. Eells JT. Mitochondrial Dysfunction in the Aging Retina. Biology (Basel). 2019;8(2).
11. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch 
Ophthalmol. 2004;122(4):598-614.
12. Curcio CA JM. Structure, Function, and Pathology of Bruch's Membrane. Vol Vol. 1: Elsevier Inc; 
2012.
13. Keenan TD, Pickford CE, Holley RJ, et al. Age-dependent changes in heparan sulfate in human 
Bruch's membrane: implications for age-related macular degeneration. Invest Ophthalmol Vis 
Sci. 2014;55(8):5370-5379.
14. Macgregor AM, Eberhart CG, Fraig M, Lu J, Halushka MK. Tissue inhibitor of matrix 
metalloproteinase-3 levels in the extracellular matrix of lung, kidney, and eye increase with 
age. J Histochem Cytochem. 2009;57(3):207-213.
15. Guo L, Hussain AA, Limb GA, Marshall J. Age-dependent variation in metalloproteinase activity 
of isolated human Bruch's membrane and choroid. Invest Ophthalmol Vis Sci. 1999;40(11):2676-
2682.
16. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related 
macular degeneration highlights contributions of rare and common variants. Nat Genet. 
2016;48(2):134-143.
17. Joachim ND, Mitchell P, Kifley A, Wang JJ. Incidence, Progression, and Associated Risk Factors 
of Medium Drusen in Age-Related Macular Degeneration: Findings From the 15-Year Follow-
up of an Australian Cohort. JAMA Ophthalmol. 2015;133(6):698-705.
18. Newsome DA, Huh W, Green WR. Bruch's membrane age-related changes vary by region. 
Curr Eye Res. 1987;6(10):1211-1221.
19. Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early age-related 
maculopathy. Arch Ophthalmol. 1999;117(3):329-339.
150421-colijn-layout.indd   193 17/03/2021   17:41
194
CHAPTER 6
20. Curcio CA, Millican CL, Bailey T, Kruth HS. Accumulation of cholesterol with age in human 
Bruch's membrane. Invest Ophthalmol Vis Sci. 2001;42(1):265-274.
21. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-
related macular degeneration. Proc Natl Acad Sci U S A. 2002;99(23):14682-14687.
22. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye 
Study. Ophthalmology. 1992;99(6):933-943.
23. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the 
Rotterdam Study. Ophthalmology. 1995;102(2):205-210.
24. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system 
for age-related maculopathy and age-related macular degeneration. The International ARM 
Epidemiological Study Group. Surv Ophthalmol. 1995;39(5):367-374.
25. Kishan AU, Modjtahedi BS, Martins EN, Modjtahedi SP, Morse LS. Lipids and age-related 
macular degeneration. Surv Ophthalmol. 2011;56(3):195-213.
26. van Leeuwen EM, Emri E, Merle BMJ, et al. A new perspective on lipid research in age-related 
macular degeneration. Prog Retin Eye Res. 2018;67:56-86.
27. Giusto NM, Pasquare SJ, Salvador GA, Castagnet PI, Roque ME, Ilincheta de Boschero MG. 
Lipid metabolism in vertebrate retinal rod outer segments. Prog Lipid Res. 2000;39(4):315-391.
28. Tserentsoodol N, Sztein J, Campos M, et al. Uptake of cholesterol by the retina occurs primarily 
via a low density lipoprotein receptor-mediated process. Mol Vis. 2006;12:1306-1318.
29. Tserentsoodol N, Gordiyenko NV, Pascual I, Lee JW, Fliesler SJ, Rodriguez IR. Intraretinal 
lipid transport is dependent on high density lipoprotein-like particles and class B scavenger 
receptors. Mol Vis. 2006;12:1319-1333.
30. Kersten E, Paun CC, Schellevis RL, et al. Systemic and ocular fluid compounds as potential 
biomarkers in age-related macular degeneration. Surv Ophthalmol. 2018;63(1):9-39.
31. Acar IE dML, Colijn JM, Meester MA, Verzijden T, Cougnard-Grégoire A, Ajana S, Merle BMJ, 
de Breuk A, Heesterbeek TJ, van den Akker E, Daha MR, Claes B, Pauleikhoff D, Hense H, EYE-
RISK Consortium, van Duijn CM, Fauser S, Hoyng CB, Delcourt C, Klaver CCW, Galesloot TE, 
den Hollander AI. Integrating metabolomics, genomics and disease pathways in age-related 
macular degeneration. Submitted. 2020.
32. Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors from high-throughput 
experiments using multivariable Mendelian randomization. Nat Commun. 2020;11(1):29.
33. Burgess S, Davey Smith G. Mendelian Randomization Implicates High-Density Lipoprotein 
Cholesterol-Associated Mechanisms in Etiology of Age-Related Macular Degeneration. 
Ophthalmology. 2017;124(8):1165-1174.
34. Gordon SM, Deng J, Lu LJ, Davidson WS. Proteomic characterization of human plasma 
high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res. 
2010;9(10):5239-5249.
35. Bergen AA, Arya S, Koster C, et al. On the origin of proteins in human drusen: The meet, greet 
and stick hypothesis. Prog Retin Eye Res. 2019;70:55-84.
36. Fliesler SJ, Bretillon L. The ins and outs of cholesterol in the vertebrate retina. J Lipid Res. 
2010;51(12):3399-3413.
37. Small DM. Mechanisms of reversed cholesterol transport. Agents Actions Suppl. 1988;26:135-
146.
150421-colijn-layout.indd   194 17/03/2021   17:41
195
DISCUSSION AND SUMMARY
38. Wang S, Wang X, Cheng Y, et al. Autophagy Dysfunction, Cellular Senescence, and Abnormal 
Immune-Inflammatory Responses in AMD: From Mechanisms to Therapeutic Potential. Oxid 
Med Cell Longev. 2019;2019:3632169.
39. Mitter SK, Rao HV, Qi X, et al. Autophagy in the retina: a potential role in age-related macular 
degeneration. Adv Exp Med Biol. 2012;723:83-90.
40. Fitzgerald ML, Okuhira K, Short GF, 3rd, Manning JJ, Bell SA, Freeman MW. ATP-binding 
cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its 
cholesterol efflux and ApoA-I binding activities. J Biol Chem. 2004;279(46):48477-48485.
41. Yokoyama S. Assembly of high density lipoprotein by the ABCA1/apolipoprotein pathway. 
Curr Opin Lipidol. 2005;16(3):269-279.
42. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US twin study of age-related macular 
degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol. 
2005;123(3):321-327.
43. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J 
Ophthalmol. 1997;123(2):199-206.
44. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-
related maculopathy. Population-based familial aggregation study. Arch Ophthalmol. 
1998;116(12):1646-1651.
45. Han X, Gharahkhani P, Mitchell P, Liew G, Hewitt AW, MacGregor S. Genome-wide meta-
analysis identifies novel loci associated with age-related macular degeneration. J Hum Genet. 
2020.
46. Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular 
degeneration: A review of rare genetic variants and implications for personalized treatment. 
Mol Immunol. 2017;84:65-76.
47. Clark SJ, Bishop PN. The eye as a complement dysregulation hotspot. Semin Immunopathol. 
2018;40(1):65-74.
48. Heesterbeek TJ, Lechanteur YTE, Lores-Motta L, et al. Complement Activation Levels Are 
Related to Disease Stage in AMD. Invest Ophthalmol Vis Sci. 2020;61(3):18.
49. Saksens NT, Lechanteur YT, Verbakel SK, et al. Analysis of Risk Alleles and Complement 
Activation Levels in Familial and Non-Familial Age-Related Macular Degeneration. PLoS One. 
2016;11(6):e0144367.
50. Micklisch S, Lin Y, Jacob S, et al. Age-related macular degeneration associated polymorphism 
rs10490924 in ARMS2 results in deficiency of a complement activator. J Neuroinflammation. 
2017;14(1):4.
51. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production 
and fatal meningococcal disease. Lancet. 1997;349(9046):170-173.
52. Van Bodegom D, May L, Meij HJ, Westendorp RG. Regulation of human life histories: the role 
of the inflammatory host response. Ann N Y Acad Sci. 2007;1100:84-97.
53. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular 
degeneration: pooled findings from 3 continents. Ophthalmology. 2004;111(7):1280-1287.
54. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related 
maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol. 2002;120(10):1357-1363.
55. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis 
of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115-134.
150421-colijn-layout.indd   195 17/03/2021   17:41
196
CHAPTER 6
56. Cai J, Nelson KC, Wu M, Sternberg P, Jr., Jones DP. Oxidative damage and protection of the 
RPE. Prog Retin Eye Res. 2000;19(2):205-221.
57. Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity, and age-related maculopathy. The 
Blue Mountains Eye Study. Ophthalmology. 1998;105(8):1359-1363.
58. Schick T, Ersoy L, Lechanteur YT, et al. History of Sunlight Exposure Is a Risk Factor for Age-
Related Macular Degeneration. Retina. 2016;36(4):787-790.
59. Shim SH, Kim SG, Bae JH, Yu HG, Song SJ. Risk Factors for Progression of Early Age-Related 
Macular Degeneration in Koreans. Ophthalmic Epidemiol. 2016;23(2):80-87.
60. Jonasson F, Fisher DE, Eiriksdottir G, et al. Five-year incidence, progression, and risk factors 
for age-related macular degeneration: the age, gene/environment susceptibility study. 
Ophthalmology. 2014;121(9):1766-1772.
61. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular 
degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.
62. Howard KP, Klein BE, Lee KE, Klein R. Measures of body shape and adiposity as related to 
incidence of age-related eye diseases: observations from the Beaver Dam Eye Study. Invest 
Ophthalmol Vis Sci. 2014;55(4):2592-2598.
63. Zhou H, Zhang H, Yu A, Xie J. Association between sunlight exposure and risk of age-related 
macular degeneration: a meta-analysis. BMC Ophthalmol. 2018;18(1):331.
64. Erke MG, Bertelsen G, Peto T, Sjolie AK, Lindekleiv H, Njolstad I. Cardiovascular risk factors 
associated with age-related macular degeneration: the Tromso Study. Acta Ophthalmol. 
2014;92(7):662-669.
65. Munch IC, Linneberg A, Larsen M. Precursors of age-related macular degeneration: associations 
with physical activity, obesity, and serum lipids in the inter99 eye study. Invest Ophthalmol Vis 
Sci. 2013;54(6):3932-3940.
66. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and 
advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA. 
1994;272(18):1413-1420.
67. Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial 
of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related 
macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-
1436.
68. Moeller SM, Parekh N, Tinker L, et al. Associations between intermediate age-related macular 
degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study 
(CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol. 2006;124(8):1151-
1162.
69. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association 
with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol. 2003;121(12):1728-
1737.
70. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in 
health and disease of the retina. Prog Retin Eye Res. 2005;24(1):87-138.
71. Ho L, van Leeuwen R, Witteman JC, et al. Reducing the genetic risk of age-related macular 
degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam study. 
Arch Ophthalmol. 2011;129(6):758-766.
72. de Koning-Backus APM, Buitendijk GHS, Kiefte-de Jong JC, et al. Intake of Vegetables, Fruit, 
and Fish is Beneficial for Age-Related Macular Degeneration. Am J Ophthalmol. 2019;198:70-79.
150421-colijn-layout.indd   196 17/03/2021   17:41
197
DISCUSSION AND SUMMARY
73. Raimundo M, Mira F, Cachulo MDL, et al. Adherence to a Mediterranean diet, lifestyle and 
age-related macular degeneration: the Coimbra Eye Study - report 3. Acta Ophthalmol. 
2018;96(8):e926-e932.
74. Nunes S, Alves D, Barreto P, et al. Adherence to a Mediterranean diet and its association with 
age-related macular degeneration. The Coimbra Eye Study-Report 4. Nutrition. 2018;51-52:6-
12.
75. Merle BM, Silver RE, Rosner B, Seddon JM. Adherence to a Mediterranean diet, genetic 
susceptibility, and progression to advanced macular degeneration: a prospective cohort study. 
Am J Clin Nutr. 2015;102(5):1196-1206.
76. Seddon JM, Reynolds R, Shah HR, Rosner B. Smoking, dietary betaine, methionine, and 
vitamin D in monozygotic twins with discordant macular degeneration: epigenetic implications. 
Ophthalmology. 2011;118(7):1386-1394.
77. Tikellis G, Robman LD, Dimitrov P, Nicolas C, McCarty CA, Guymer RH. Characteristics of 
progression of early age-related macular degeneration: the cardiovascular health and age-
related maculopathy study. Eye (Lond). 2007;21(2):169-176.
78. Ferris FL, 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular 
degeneration. Ophthalmology. 2013;120(4):844-851.
79. Yan Q, Ding Y, Liu Y, et al. Genome-wide analysis of disease progression in age-related 
macular degeneration. Hum Mol Genet. 2018;27(5):929-940.
80. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course 
of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 
2003;121(4):519-526.
81. Chew EY, Clemons TE, Agron E, et al. Ten-year follow-up of age-related macular degeneration 
in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol. 2014;132(3):272-
277.
82. Tan ACS, Pilgrim MG, Fearn S, et al. Calcified nodules in retinal drusen are associated with 
disease progression in age-related macular degeneration. Sci Transl Med. 2018;10(466).
83. Joachim N, Mitchell P, Kifley A, Rochtchina E, Hong T, Wang JJ. Incidence and progression 
of geographic atrophy: observations from a population-based cohort. Ophthalmology. 
2013;120(10):2042-2050.
84. Finger RP, Wu Z, Luu CD, et al. Reticular pseudodrusen: a risk factor for geographic atrophy 
in fellow eyes of individuals with unilateral choroidal neovascularization. Ophthalmology. 
2014;121(6):1252-1256.
85. Marsiglia M, Boddu S, Bearelly S, et al. Association between geographic atrophy progression 
and reticular pseudodrusen in eyes with dry age-related macular degeneration. Invest 
Ophthalmol Vis Sci. 2013;54(12):7362-7369.
86. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related 
maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001;42(10):2237-2241.
87. Feuer WJ, Yehoshua Z, Gregori G, et al. Square root transformation of geographic atrophy area 
measurements to eliminate dependence of growth rates on baseline lesion measurements: a 
reanalysis of age-related eye disease study report no. 26. JAMA Ophthalmol. 2013;131(1):110-111.
88. Yehoshua Z, Rosenfeld PJ, Gregori G, et al. Progression of geographic atrophy in age-
related macular degeneration imaged with spectral domain optical coherence tomography. 
Ophthalmology. 2011;118(4):679-686.
150421-colijn-layout.indd   197 17/03/2021   17:41
198
CHAPTER 6
89. Keenan TD, Agron E, Domalpally A, et al. Progression of Geographic Atrophy in Age-related 
Macular Degeneration: AREDS2 Report Number 16. Ophthalmology. 2018;125(12):1913-1928.
90. Lindner M, Boker A, Mauschitz MM, et al. Directional Kinetics of Geographic Atrophy Progression 
in Age-Related Macular Degeneration with Foveal Sparing. Ophthalmology. 2015;122(7):1356-
1365.
91. Sunness JS, Margalit E, Srikumaran D, et al. The long-term natural history of geographic 
atrophy from age-related macular degeneration: enlargement of atrophy and implications for 
interventional clinical trials. Ophthalmology. 2007;114(2):271-277.
92. Lindblad AS, Lloyd PC, Clemons TE, et al. Change in area of geographic atrophy in the Age-
Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009;127(9):1168-1174.
93. Cruickshanks KJ, Nondahl DM, Johnson LJ, et al. Generational Differences in the 5-Year 
Incidence of Age-Related Macular Degeneration. JAMA Ophthalmol. 2017;135(12):1417-1423.
94. Ajana S. C-GA, Colijn JM, Merle B, Verzijden T, de Jong PTVM, Hofman A, Vingerling JR, 
Hejblum BP, Korobelnik J, Meester-Smoor MA, Jacqmin-Gadda H, Klaver CCW, Delcourt C, 
and on behalf of the EYE-RISK Consortium. Development of a prediction model for advanced 
age-related macular degeneration using a machine learning approach. 2020.
95. Sardell RJ, Persad PJ, Pan SS, et al. Progression Rate From Intermediate to Advanced Age-
Related Macular Degeneration Is Correlated With the Number of Risk Alleles at the CFH Locus. 
Invest Ophthalmol Vis Sci. 2016;57(14):6107-6115.
96. Perlee LT, Bansal AT, Gehrs K, et al. Inclusion of genotype with fundus phenotype improves 
accuracy of predicting choroidal neovascularization and geographic atrophy. Ophthalmology. 
2013;120(9):1880-1892.
97. Heesterbeek TJ, Lores-Motta L, Hoyng CB, Lechanteur YTE, den Hollander AI. Risk factors for 
progression of age-related macular degeneration. Ophthalmic Physiol Opt. 2020;40(2):140-170.
98. Zhang M, Baird PN. A decade of age-related macular degeneration risk models: What have we 
learned from them and where are we going? Ophthalmic Genet. 2017;38(4):301-307.
99. Joachim N, Kifley A, Colijn JM, et al. Joint Contribution of Genetic Susceptibility and Modifiable 
Factors to the Progression of Age-Related Macular Degeneration over 10 Years: The Three 
Continent AMD Consortium Report. Ophthalmol Retina. 2018;2(7):684-693.
100. Ting DSW, Pasquale LR, Peng L, et al. Artificial intelligence and deep learning in ophthalmology. 
Br J Ophthalmol. 2019;103(2):167-175.
101. Balyen L, Peto T. Promising Artificial Intelligence-Machine Learning-Deep Learning Algorithms 
in Ophthalmology. Asia Pac J Ophthalmol (Phila). 2019;8(3):264-272.
102. Association AM. Surveys show lack of awareness macular disease. 2019; https://ama.com.au/
ausmed/surveys-show-lack-awareness-re-macular-disease. Accessed 6-4-2020, 2020.
103. Zealand MdN. Annual report 2018/2019. Auckand2019.
104. Heraghty J, Cummins R. A layered approach to raising public awareness of macular 
degeneration in Australia. Am J Public Health. 2012;102(9):1655-1659.
105. Wagle AM, How Sau Har, A., Maheshwar, B., Gopal, L. A vision for the nation. Singapore: Spring 
Publishing Pte Ltd; 2014.
106. Association of optometrists Ireland Fb, Irish college of ophthalmologists, NCBI. Information on 
age related macular degeneration. 2019; https://www.amd.ie/2019-campaign/. Accessed 25-
4-2020, 2020.
107. Healthcare B. La DMLA et moi. 2015; https://www.ladmlaetmoi.fr/. Accessed 25-4-2020, 2020.
150421-colijn-layout.indd   198 17/03/2021   17:41
199
DISCUSSION AND SUMMARY
108. Schmidhuber J, Traill WB. The changing structure of diets in the European Union in relation to 
healthy eating guidelines. Public Health Nutr. 2006;9(5):584-595.
109. Grassmann F, Harsch S, Brandl C, et al. Assessment of Novel Genome-Wide Significant 
Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular 
Degeneration. JAMA Ophthalmol. 2019.
110. McCartney DL, Stevenson AJ, Hillary RF, et al. Epigenetic signatures of starting and stopping 
smoking. EBioMedicine. 2018;37:214-220.
111. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the 
number of pack years of cigarette smoking is a major determinant of risk for both geographic 
atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006;90(1):75-80.
112. Nobl M, Reich M, Dacheva I, et al. Proteomics of vitreous in neovascular age-related macular 
degeneration. Exp Eye Res. 2016;146:107-117.
113. Qu SC, Xu D, Li TT, Zhang JF, Liu F. iTRAQ-based proteomics analysis of aqueous humor in 
patients with dry age-related macular degeneration. Int J Ophthalmol. 2019;12(11):1758-1766.
114. Zinkernagel MS, Zysset-Burri DC, Keller I, et al. Association of the Intestinal Microbiome with 
the Development of Neovascular Age-Related Macular Degeneration. Sci Rep. 2017;7:40826.
115. Rowan S, Jiang S, Korem T, et al. Involvement of a gut-retina axis in protection against 
dietary glycemia-induced age-related macular degeneration. Proc Natl Acad Sci U S A. 
2017;114(22):E4472-E4481.
150421-colijn-layout.indd   199 17/03/2021   17:41




Age-related macular degeneration (AMD) is a common disease in elderly leading to visual 
impairment and blindness. It is a multifactorial disease driven by aging, genetics, and 
environmental factors. On clinical examination, the early stage of AMD is characterized 
by drusen and pigmentary alterations in the macular area of the retina. The late stages 
of the disease are choroidal neovascularization (CNV) and geographic atrophy (GA); the 
first can be treated with anti-VEGF injections, but not cured. The aim of this thesis was 
to answer questions related to the genetics and epidemiology of AMD. The general 
introduction and the outline of this thesis are described in Chapter 1.
Prevalence
Chapter 2.1 discusses the prevalence of AMD in Europe by using fourteen population 
based studies from the E3 Consortium. We show that the prevalence of early AMD 
increases steeply from 3.5% at 55-59 years old to 17.6% in those aged 85 years and older. 
Late AMD increased up to 9.8% in people aged 85 years and over. Improved visual acuity 
was observed after the introduction of anti-VEGF therapy in cases with CNV. In addition, 
we noticed a decreasing age-specific prevalence over time, possibly due to healthier 
lifestyles. Even with decreasing age-specific prevalences, the number of AMD patients 
is going to increase in the next twenty years due to the aging population. 
Progression
In Chapter 2.2 we show that a 27 to 68% of the people with unilateral late AMD become 
bilateral within five years. For any AMD, these numbers are smaller; one fifth to one 
quarter progresses from any unilateral AMD to bilateral any AMD. We also show that the 
risk factors for progression are similar to developing the disease; genetic predisposition, 
smoking and large drusen area with pigmentary changes. The progression of GA is 
discussed in Chapter 3.1 in which we show that GA lesions grow on average 0.97mm2/
year, with a very wide variety in the speed of growth, but bilateral growth is highly 
correlated. 60.4% of the extra foveal GA reaches the fovea within five years. This affects 
visual acuity and inevitably self-sustainability of these patients such as the ability to drive 
a car. Half of the people with bilateral GA die visually impaired. In Chapter 3.2 the growth 
of GA is predicted using deep learning software. We show that the shape of the lesion is 
predictive of its growth, factors related to a round shape seem to grow slower. Bilateral 
growth is not associated with faster growth. We show that computer algorithms are a fast 
and accurate way to asses and predict growth, a tool that can be used for clinical trials 
and predictive estimates. 




The importance of rare protein altering genetic variants not only in families but also in 
the population is shown in Chapter 4.1. Whole exome sequencing data was analyzed 
in almost 3,000 participants from the Rotterdam Study I and EUGENDA. We observed 
protein altering variants in COL8A1 more often in AMD cases (1.0%) than in controls (0.4%), 
independent from the previously found variant in this gene. We showed that the protein 
of this gene is located in the Bruchs membrane. As part of the extra-cellular matrix, 
alterations can affect the integrity of the membrane. 
We explored the genetic risk for AMD in the population in Chapter 4.2. We showed that 
the biggest differences in minor allele frequencies and population attributable risks are 
in ARMS2 and variants of the complement pathway. When constructing a genetic risk 
score (GRS) as a measure of total genetic load for AMD, the score increases with the 
severity of AMD. Constructing GRS per pathway showed that the complement pathway 
together with ARMS2 contributed to genetic susceptibility in 90% of the late AMD cases, 
suggesting that the vast majority of AMD has complement as a molecular driver. 
Lipids and lifestyle
In Chapter 5.1 we investigated the association of lipids with AMD in almost 31,000 
Europeans. We showed that a high HDL-cholesterol level and a low triglycerides level 
were associated with AMD. A high HDL-cholesterol level was associated with large 
drusen. In a subgroup of the Rotterdam Study I we explored the associations with 
lipid subfractions and observed that extra-large HDL subfractions were associated 
with AMD. Genetic variants in the lipid pathway, previously associated with AMD, also 
showed association with systemic lipids. The CETP variant rs17231506 and APOE variant 
rs429358 were both positively associated with HDL-cholesterol, while both LIPC variants 
(rs2043085 and rs2070895) were negatively associated. 
Chapter 5.2 focusses on the effect of diet on the development of AMD in two population 
based cohort studies (Rotterdam Study I and Alienor-3C). A score was constructed to 
investigate the adherence to a Mediterranean diet. This showed that participants with 
high adherence to this diet reduced their risk of incident late AMD with 41%. This finding 
was further underlined in Chapter 4.2, where a lifestyle score was constructed based 
on smoking and a diet rich in fish, fruits, and vegetables. Those with the most favorable 
lifestyle had almost half the risk of late AMD in all genetic risk groups. This points out the 
enormous impact of lifestyle on the outcome of AMD genes.
Finally in Chapter 6 the main findings are placed in the context of my view on the 
pathophysiology of AMD or on AMD related matters such as prevalence, progression 
and prediction. This chapter also considers ideas for future research and implications. 




Leeftijdsgebonden macula degeneratie (LMD) is een veel voorkomende ziekte onder 
ouderen die zorgt voor slechtziendheid en blindheid. Het is een multi-factoriele 
ziekte die veroorzaakt wordt door veroudering, genetica en omgevingsfactoren. Bij 
funduscopie wordt het vroege stadium van LMD gekarakteriseerd door drusen en 
pigmentveranderingen in de macula. De late stadia van de ziekte zijn choroidale 
neovascularisaties (CNV) en geografische atrofie (GA); de eerste kan behandeld worden 
met anti-VEGF injecties maar niet worden genezen. Het doel van dit proefschrift was 
om vragen te beantwoorden die gerelateerd zijn aan de genetica en epidemiologie 
van LMD. De algemene introductie en de opzet van het proefschrift zijn beschreven in 
Hoofdstuk 1. 
Prevalentie 
Hoofdstuk 2.1 beschrijft de prevalentie van LMD in Europa op basis van veertien populatie 
studies uit het E3 Consortium. Wij laten hierin zien dat de prevalentie van vroege LMD 
sterk toeneemt met de leeftijd; van 3.5% op 55-59 jarige leeftijd tot 17.6% in mensen van 
85 jaar en ouder. De prevalentie van late LMD stijgt tot 9.8% in mensen van 85 jaar en 
ouder. In de mensen met CNV zagen wij een verbeterde visus na de introductie van anti-
VEGF. Daarnaast zagen we dat, over de tijd, de leeftijdsgebonden prevalentie afnam. 
Mogelijk door een toename in gezondere levensgewoontes. Zelfs met de afnemende 
leeftijdsspecifieke prevalenties gaat het absolute aantal mensen met LMD toenemen in 
de komende twintig jaar door de vergrijzende populatie. 
Progressie
In Hoofdstuk 2.2 laten we zien dat 27 tot 68% van de mensen met unilaterale late LMD 
binnen 5 jaar ook het tweede oog late LMD krijgt. Voor alle vormen van LMD samen 
is dit aantal wat kleiner; een vijfde tot een kwart krijgt een bilaterale vorm van LMD 
binnen 5 jaar. We laten ook zien dat de risico factoren voor progressie gelijk zijn aan 
de risicofactoren voor het krijgen van de ziekte; namelijk genetische predispositie, 
roken, grote drusen oppervlakte, en pigment veranderingen. De progressie van GA 
wordt beschreven in Hoofdstuk 3.1, waarin we laten zien dat GA laesies gemiddeld met 
0.97mm2/jaar toenemen. Er is een grote spreiding in de groeisnelheid, maar de groei van 
GA in bilateraal aangedane patiënten is sterk gecorreleerd. Een groot deel (60.4%) van 
de laesies die buiten de fovea zit, groeien binnen 5 jaar in de fovea. Dit heeft effect op 
het zicht en op de zelfredzaamheid van deze patiënten, bijvoorbeeld of ze nog kunnen 
autorijden. De helft van de mensen met bilaterale GA is slechtziend als ze overlijden. In 
Hoofdstuk 3.2 wordt de groei van GA voorspeld middels deep learning software. We 
tonen aan dat de vorm van de laesie de groeisnelheid voorspelt. Factoren gerelateerd 
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aan hoe rond de laesie is, zijn gerelateerd aan een langzamere groei. Bilaterale GA zorgt 
niet voor snellere groei. We laten zien dat computer algoritmes snel en precies de groei 
van een laesie kunnen inschatten, dit kan gebruikt worden voor klinische studies en om 
een prognose te geven voor de patiënt. 
Genetica 
Zeldzame eiwit veranderende genetische varianten zijn niet alleen belangrijk in families 
met LMD maar ook in de populatie, dat laten we zien in Hoofdstuk 4.1. Hiervoor 
analyseerden wij de sequenties van alle exonen uit het genoom van bijna 3000 deelnemers 
uit de Rotterdam Studie I en EUGENDA. Wij vonden dat eiwit coderende varianten in het 
COL8A1 gen vaker voorkomen in mensen met LMD (1.0%) dan in controles (0.4%). Deze 
bevinding is onafhankelijk van de eerder gevonden variant in dit gen dat geassocieerd 
is met LMD. Wij toonden aan dat het COL8A1 eiwit in het Bruchs membraan zit. Omdat 
het een onderdeel is van de extra-cellulaire matrix kunnen veranderingen in het eiwit de 
integriteit van het membraan aantasten. 
Ook onderzochten wij het genetische risico voor LMD in de populatie, Hoofdstuk 4.2. 
We lieten zien dat ARMS2 en varianten gerelateerd aan complement activiteit het meest 
voorkomen in patiënten met LMD. Ook het populatie risico op LMD kan voornamelijk 
toegeschreven worden aan deze varianten. Wij maakten een genetische risico score op 
basis van alle varianten uit het tot dan toe grootste genome wide association study. Deze 
score nam toe met elk stadium van LMD. Daarnaast hebben wij ook genetische scores 
gemaakt per “pathway”, dit liet zien dat in 90% van de late LDM patiënten de complement 
“pathway” samen met ARMS2 bijdraagt aan de genetische aanleg om LMD te krijgen. Dit 
suggereert dat de meerderheid van de patiënten met late LMD complement heeft als 
een moleculaire stimulans. 
Lipiden en leefstijl
In Hoofdstuk 5.1 hebben wij de associatie van lipiden met LMD onderzocht in bijna 
31.000 Europeanen. We lieten zien dat een hoog HDL-cholesterol in het bloed en een 
laag triglyceriden niveau geassocieerd waren met LMD. Een hoog HDL-cholesterol 
was ook geassocieerd met grote drusen. In een subgroep van de Rotterdam Study I 
onderzochten wij de associaties met lipiden subfracties en zagen wij dat de extra grote 
HDL-subfracties geassocieerd waren met LMD. Genetische varianten in de lipiden 
“pathway” die eerder al geassocieerd waren met LMD, lieten ook een associatie met 
de lipiden in het bloed zien. De CETP variant rs17231506 en APOE variant rs429358 
waren beiden positief geassocieerd met HDL-cholesterol, terwijl beide LIPC varianten 
(rs2043085 en rs2070895) negatief waren geassocieerd. 
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Hoofdstuk 5.2 focust op het effect van dieet op de ontwikkeling van LMD in twee 
populatie cohorten (Rotterdam Study I en Alienor-3C). Een dieet score werd gemaakt om 
vast te kunnen stellen in hoeverre iemand een Mediterraans dieet volgt. Dit toonde aan 
dat deelnemers die het Mediterraanse dieet goed volgden het risico op het ontwikkelen 
van late LMD verkleinden met 41%. Deze bevinding werd verder ondersteund door 
Hoofdstuk 4.2 waar een score voor levensstijl werd gemaakt op basis van roken en het 
eten van groente, fruit en vis. De personen die de meest gunstige levensstijl hadden 
reduceerden het risico op late LMD met ongeveer de helft, ongeacht de genetische 
belasting voor LMD. Dit laat zien wat de enorme impact van de levensstijl is op de 
uitkomst van LMD geassocieerde genen. 
Tenslotte, in Hoofdstuk 6 worden de bevindingen uit dit proefschrift besproken in de 
context van mijn kijk op de pathofysiologie van LMD of LMD gerelateerde zaken zoals 
de prevalentie, progressie van de ziekte en predictie. Ook worden de implicaties en de 
overwegingen voor toekomstig onderzoek besproken. 
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